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Abstract
Expression of p53 was studied immunohistochemically in a consecutive
series of resected human colorectal tumours using monoclonal antibody
PAb1801. Expression was detected in 41 of 87 carcinomas (47%) but in only
4 of 46 sporadic adenomas (8.7%) indicating that p53 expression is
associated with malignant transition in colorectal tumourigenesis.
Immunoblots of total protein extracted from immunohistochemically positive
and negative carcinomas confirmed that the immunostaining was indeed
marking p53 in these tissues. Immunohistochemistry of a subset of 45
carcinomas using monoclonal antibody PAb240 (mutant p53 specific)
showed positivity in 22 (48.9%) and a highly significant correlation with
PAb1801 immunostaining suggesting that the p53 expression identified with
PAb1801 is due to p53 mutation possibly via protein stabilisation. Expression
of p53 did not correlate with Dukes' stage or histopathological markers of
poor prognosis but did correlate with the presence of DNA aneuploidy and in
particular the presence of multiple divergent clones defined by flow
cytometry. This finding agrees with the hypothesis that wild-type p53 has a
role in genomic surveillance and loss of this function may result in cell
replication in the presence of DNA sequence abnormalities leading to
aneuploidy and clonal divergence. DNA aneuploidy is a marker of poor
prognosis and p53 expression may therefore mark more aggressive
tumours.
Fine mapping of the deletion on chromosome 17p using 4 polymorphisms
indicated allele loss in 46 of 79 cases (58%) and that this usually included
the p53 gene locus. Loss of any 17p allele and loss of markers adjacent to or
within the p53 gene correlated with p53 expression and thus mutation. There
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was also a correlation between 17p allele loss and the presence of DNA
aneuploidy. These data indicate that 17p allele loss and p53 expression
(indicating mutation) are linked suggesting inactivation of both copies of p53
is important in colorectal carcinogenesis. This appears to occur at the phase
of malignant transition, possibly by permitting replication of sequence
abnormalities and the development of aneuploidy. Analysis of p53 gene
sequence in 12 cases defined for 17p allele loss and p53 expression
indicated that p53 mutation results in positive p53 immunostaining. Further
analysis suggested that not all p53 mutations have the same phenotype
some perhaps not requiring deletion of the remaining wild-type gene for
expression of the "p53 null" phenotype.
Loss of a marker on chromosome 17q was seen in 13 of 64 (20%) of
colorectal cancers. This is a higher frequency than detected previously and
correlated in this series with the presence of lymph node metastasis
suggesting the presence of a tumour metastasis suppressor gene at this
locus.
To investigate the role of germ-line p53 mutation in tumourigenesis, a partial
p53 gene containing a single point mutation was inserted into the genomic
p53 of pluripotent mouse embryonal stem cells by homologous
recombination. Selection for reversion leaving such a mutation in an
otherwise unaltered p53 gene is under way. In addition, inactivation of p53
by homologous recombination was achieved and successfully passed into
the germ-line. Mice deficient in one (p53+/-) or both (p53-/-) gene alleles
were developmentally normal but developed malignant tumours of lymphoid
tissue and mesenchyme at high frequency. Homozygous (p53-/-) mice
succumbed to malignancy more quickly than heterozygous (p53+/-) litter
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mates.
These results indicate a central role for p53 inactivation in human colorectal
tumourigenesis probably at the critical phase of malignant transition, possibly
by permitting premature replication or replication in the presence of DNA
sequence abnormalities and the development of aneuploidy. Although not
necessary for normal development in mice, p53 is vital in the prevention of
carcinogenesis and p53 deficient mice will permit further study of cancer
prevention and therapy. Finally, a possible tumour metastasis suppressor





Neoplasia can be defined as the proliferation of cells within a tissue outwith
the normal growth controls operating in that tissue. Malignant forms of
neoplasia (cancer) are distinguished from benign by their ability to invade
locally into surrounding normal tissue and to spread widely (metastasise) to
distant sites within the body.
As a disease, cancer is an important cause of mortality and morbidity world¬
wide with 253,000 new diagnoses each year in the UK alone accounting for
162,000 deaths annually. The commonest malignancy in males in the UK is
carcinoma of the lung, followed by skin cancers and then carcinoma of the
colorectum giving 13,370 new cases each year. In females, colorectal cancer
is second only to breast cancer accounting for 13,870 new cases per year
(Cancer Research Campaign, 1990). Colorectal cancer causes the deaths of
significant numbers of people in the UK and the Western World as a whole
despite being potentially curable if diagnosed early. However the incidence
of colorectal cancer has not altered materially in the last two decades, nor
has the the 37% overall five year survival (Cancer Research Campaign,
1990). Research into the pathogenesis and natural history of this disease is
therefore necessary to define the critical events in its development. This
knowledge will permit preventative measures to be employed, allow its
earlier detection and enable a more rational approach to its treatment to be
followed.
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Colorectal carcinogenesis is a multi-stage process requiring some or all of a
number of specific genetic events of which several have now been described
(section 1.5). Some of these events can be inherited as germ-line mutations
as in the case of Adenomatous Polyposis Coli gene mutations in Familial
Adenomatous Polyposis and Gardner's Syndrome but thus far the genes
responsible for Hereditary Non-Polyposis Colorectal Cancer and the familial
clustering of "sporadic" colorectal cancer have not been elucidated (section
1.3). Some of the environmental factors associated with colorectal
carcinogenesis have been described (section 1.2) but until the critical events
are characterized it will not be possible to dissect out the relevant causative
factors and remove them from the environment. Some of the critical events
are now being identified (section 1.5) and amongst them, p53 abnormalities
appear to be the commonest and to act at the critical phase of transition from
benign to malignant neoplasm (chapter 2).
This thesis is concerned with the role of p53 in colorectal carcinogenesis. To
help understand this role in the context of a complex disease such as
colorectal cancer with its multifactorial pathogenesis, the putative
environmental and genetic factors will be reviewed initially and the numerous
abnormalities of histopathology, karyotype, DNA ploidy and genetic material
will be discussed.
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1.2 The Role of Environmental Factors in Colorectal Carcinogenesis
1.2.1 Introduction
External factors involved in carcinogenesis fall into 3 categories: oncogenic
viruses; electro-magnetic radiation; and chemical carcinogens. Thus far no
viruses have been associated with adenocarcinoma of the colorectum.
Survivors of the atomic bombs at Hiroshima and Nagasaki in 1945 show an
excess of colon cancers (although not rectal cancers) when compared to an
unexposed control population after 30 years of follow-up (Kohn et al., 1984).
However, the effect is small and unlikely to be important outwith this
population. Most external carcinogens affecting the colon and rectum are
thus likely to be chemicals.
The epithelium of the colorectum can be exposed to chemical carcinogens
via the blood stream or directly by the bowel contents. Most research has
focused on the bowel contents: dietary elements, bile, secretions from the
gastrointestinal tract and pancreas and their metabolites. Unfortunately,
much of the evidence in this field is circumstantial and contradictory.
Information of interest comes, however, from epidemiological studies of
cancer incidence, case-control studies which suggest some possible dietary
factors and more specific studies of dietary fibre, meat, bile acids,
faecapentaenes, and calcium. Each of these will be discussed in turn.
1.2.2 Epidemiology
Armstrong and Doll (1975) investigated the correlation of cancer incidence
and mortality for individual countries with per capita consumption of various
16
commodities. A positive correlation between colorectal cancer mortality rates
and animal protein and fat consumption was demonstrated along with a
negative correlation for cereal consumption. A similar study (Liu et al., 1979)
again showed a positive correlation of per capita consumption of saturated
fat and cholesterol with colorectal cancer and a negative correlation with
dietary fibre intake. Further analysis revealed cholesterol consumption as
having the most significant correlation with colorectal cancer mortality.
Studies of native Japanese emigrating to the USA demonstrated that their
relatively low levels of colorectal cancer mortality when living in Japan had,
within one generation, risen to equal that of the indigenous white population
(Haenszel & Kurihara, 1968). This alteration in colorectal cancer mortality
suggests that environmental differences between Japanese and Western
life-style and diet rather than genetic differences account for the different
incidences in the 2 countries. Furthermore, in Japan itself, since 1945 there
has been a dramatic rise in colorectal cancer incidence (Lee et al., 1976)
accompanied by increases in fat consumption (Hirayami et al., 1975).
1.2.3 Case-control studies
Population studies assume a uniform consumption across a population and a
uniform cancer incidence, ignoring what may be important regional
differences. Case control studies of dietary intake in Canada (Jain et al.,
1980) and Puerto Rico (Martinez et al., 1979) comparing patients with
colorectal cancer to carefully matched controls demonstrated a strong
correlation with fat and cholesterol intake (being particularly strong for
saturated fat). However, similar studies from the USA (Graham et al., 1978)
and Israel (Modan et al., 1975) have failed to show any such correlation.
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Further studies in Greece (Manousos et al., 1983) and Australia (Potter &
McMichael, 1986) showed that meat intake (which may simply reflect a large
source of saturated fat) was strongly related to colorectal cancer risk, a trend
enhanced by low dietary fibre. One other notably positive association is with
total energy intake (Jain et al., 1980; Potter & McMichael, 1986; Lyon et al.,
1987) which may account for some of the discrepancies between studies as
dietary fat is a very rich source of energy and not all studies control for total
energy intake when assessing dietary fat. Despite this association, obesity
does not appear to be a risk factor (Jain et al., 1980).
1.2.4 Dietary fibre
Following a study of rural Africans, Burkitt (1971) proposed that a high intake
of unrefined fibre was associated with a lower incidence of colorectal cancer.
The high fibre diet of the Africans was associated with a high stool bulk and
a more rapid intestinal transit time which Burkitt interpreted as responsible
for the lower incidence of colorectal cancer in this population. It was
proposed that these factors acted by diluting carcinogens, reducing the time
they had to act on the mucosa and preventing bile salt degradation. Further
studies have demonstrated a similar correlation in the USA (Graham et al.,
1978), Greece (Manousos et al., 1975) and Israel (Modan et al., 1975)
although a negative correlation has also been reported (Martinez et al.,
1979). A possible cause of this discrepancy is the difference in the protective
effects of different varieties of fibre. Consumption of fruit and vegetable fibre
is higher in healthy controls than in colorectal cancer patients (Haenszel et
al., 1980; Potter & McMichael, 1986; Macquart-Moulin, 1986; La Vecchia et
al., 1988) whereas cereal fibre intake is unrelated or positively related to
colorectal cancer in the same studies.
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Burkitt (1971) proposed that dietary fibre reduced the incidence of colorectal
cancer by diluting carcinogens and reducing their time to act on the colonic
mucosa. The data showing that fruit and vegetable fibre are protective and
cereal fibre is not suggest that this is an over-simplification. It is more likely
that certain, undefined, factors consumed along with vegetable fibre are
exerting an influence on colorectal cancer risk. Animal studies have
suggested that oral fibre can reduce excreted bile acids, especially
secondary bile acids (Reddy, 1981) and inhibit the epithelial injury and
resulting proliferation induced by fat ingestion (Caderni et al., 1987). Colonic
tumours in rats induced by azoxymethane are also significantly reduced in
animals fed citrus fibre or wheat bran (Reddy et al., 1981). Dietary fibre can
be protective against colorectal cancer but its mechanism of action is far
from clear as yet.
In summary, although there are inevitable inconsistencies in the data
from these epidemiological and case control studies, it seems that
high consumption of saturated fat, cholesterol and meat (whether this
is simply a source of fat and cholesterol is not yet clear) along with low
intake of unrefined dietary fibre correlate with higher incidence of
colorectal cancer. These particular dietary factors are characteristic of
the diet found in the Western world and thus laboratory studies are
necessary to establish whether they are causative and not simply
coincident and to discover their mechanism of action.
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1.2.5 Meat consumption
Mice fed a variety of food products including cooked meats have a
significantly elevated frequency of nuclear aberration in their colonic mucosa
(Bird & Bruce, 1983). Although the particular chemicals have not been
isolated, certain carcinogens and mutagens (protein and amino acid
pyrolysates) known to be present in cooked meats, mostly heterocyclic
amines and polycyclic aromatic hydrocarbons (Felton et al., 1984; Sugimura,
1986) can result in an increase in nuclear aberration frequencies in the
colons of laboratory animals (Bird & Bruce, 1984). Further studies have also
demonstrated that certain of these products (isolated from ordinarily cooked
food) when fed to rats induce colon tumours (Sugimura, 1986). Activation of
the ras and raf oncogenes (presumably by mutation) have been described in
tumours induced by the ingestion of 2-amino-3 methylimidaz [4,5-f] quinoline
(IQ) and 2-aminodipyrido [1,2-a:3',2'-d] imidazol (Glu-P-2) (Ishikawa et al.,
1985), both of which are heterocyclic amines found in cooked food
(Sugimara, 1986). These compounds are metabolised by cytochrome P450,
are mutagens and induce single strand breaks in double stranded DNA
(Yamazoe et al., 1983; Wakata et al., 1985). This evidence, when added to
the finding of mutagenic heterocyclic amines in the faeces and urine of
human subjects after ingestion of fresh ground beef (Flayatsu et al., 1985)
suggests that these compounds may be the colorectal cancer initiators found
in meat and responsible for the correlation between meat consumption and
colorectal cancer already described (section 1.2.5).
1.2.6 Faecapentaenes
Faecapentaenes are a group of potent faecal mutagens identified at
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increased levels in people at higher risk of colon cancer (Reddy et al., 1980).
These compounds are isomers of fecapentaene-14 and fecapentaene-12,
are bacterially derived polyunsaturated derivatives of glycerol and are more
potent mutagens than A/-methy!-/V-nitrosurea or formaldehyde (Plummer et
al., 1986). The specific mutations caused by faecapentaenes have still to be
identified.
1.2.7 Bile acids and cholesterol
Studies into the involvement of fat and cholesterol consumption in colorectal
cancer have concentrated on bile acids as they are cholesterol derivatives
and they are excreted in response to fat ingestion. High fat diets in both
healthy humans and rats result in elevated levels of faecal bile acid excretion
(Reddy, 1981) and Hill et al., (1975) showed that patients with colorectal
cancer had higher levels of faecal bile acid than healthy matched controls.
As long ago as 1964, Fry and Staffeldt demonstrated that in mice, a diet
containing sodium deoxycholate resulted in loss of mucosal cells and of
goblet cells within 8 days with histological evidence of increased proliferation
thereafter. Studies on perfused rat colon have also demonstrated
ultrastructural alterations in mucosal cells characteristic of cell injury and
exfoliation as well as increased permeability in response to deoxycholate
(Goerg et al., 1982). Bile acids and fats instilled into the colons of rats result
in a marked increase in [3H] thymidine incorporation into the colon
suggestive of active cellular proliferation in response to cell injury and
consistent with the action of a tumour promoter (Bull et al., 1983). Short and
long term dietary cholic acid also result in an expansion of the proliferating
compartment within the rats colonic crypts (Deschner et al., 1981).
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Colon tumours in rats can be initiated by a single dose of N-methyl-N'-nitro-
N-nitrosoguanidine (MNNG). However, subsequent administration of bile
acids results in many more animals developing tumours and many more
tumours, both adenomas and carcinomas (Narisawa et al., 1974). Suzuki
and Bruce (1986) have also been able to show a marked increase in colonic
epithelial nuclear aberrations in mice in response to carcinogens along with
bile acids when compared to the carcinogen alone. The carcinogens used
included substances known to be present in cooked diets including IQ
(section 1.2.5).
The action of bile acids on colonic mucosa may be enhanced in vivo by
metabolism to secondary bile acids by bacterial enzymes in the mammalian
gut. Indeed, studies have shown higher levels of certain degradative
bacterial enzymes in human subjects taking a 'Western type' diet (Goldin et
al., 1980) and in patients suffering from colorectal cancer (Hill et al., 1975).
Bile acids, therefore, cause mucosal damage, increased permeability,
(perhaps permitting carcinogens to reach crypt stem cells), increased
proliferation and tumour promotion after initiation. The evidence of higher
bile acid levels in the colons of colorectal cancer patients (Hill et al., 1975)
and the increased cellular proliferation seen in colorectal cancer patients
(Terpstra et al., 1987) suggest a role for bile acids in human colorectal
carcinogenesis.
1.2.8 Calcium
Calcium has been shown to reduce the damage and compensatory
proliferation of colonic epithelium induced by bile acid administration either
intra-rectally (Wargovich et al., 1983) or orally (Deschner et al., 1981) in rats
22
and in the perfused colon (Rafter et al., 1986). This protective effect is
probably as a result of bile acid precipitation by the calcium, reducing the
concentration of free bile acids in solution (Bruce, 1987). However, the
promoting effect of fat on carcinogen induced tumour in rats was not altered
by oral calcium (Bull et al., 1987). A prospective study of human colorectal
cancer risk found a lower calcium consumption in sufferers (Garland et al.,
1985) and calcium supplementation in patients from families with hereditary
non-polyposis colorectal cancer resulted in reduction of the proliferation of
colonic epithelial cells to normal levels (Lipkin & Newmark, 1985).
1.2.9 Summary
The environmental factors involved in human colorectal
carcinogenesis are mainly dietary. Evidence from epidemiological
studies, case control studies and animal research show that fat
(probably via bile acids) and meat consumption along with total energy
intake are associated with colorectal cancer and that vegetable fibre
and calcium consumption are protective. Cooked meats contain
carcinogens capable of activating oncogenes producing initiated cells
which may be promoted by the action of bile acids. The bile acids may
act along with the initiators by increasing the permeability of the
epithelium and permitting access of carcinogens to the crypt stem
cells. Calcium may act by modulating free bile acid concentration but
the protective influence of certain types of dietary fibre is still
unexplained. Demonstration of the specific genetic changes
responsible for colorectal cancer might ultimately permit the relevant
causative environmental factors to be identified and perhaps removed.
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1.3 The Role of Genetic Factors in colorectal carcinogenesis
1.3.1 Introduction
Hereditary factors involved in human colorectal cancer fall into three broad
groups: Familial Adenomatous Polyposis (FAP) and its variant Gardner's
syndrome (GS); hereditary non-polyposis colorectal cancer (Lynch
Syndromes I and II); and the higher incidence of colorectal cancer in first
degree relatives of patients. The evidence for the role of each of these
factors will be discussed in turn.
1.3.2 Familial Adenomatous Polyposis and Gardner's Syndrome
FAP is a disease characterized by the appearance of multiple adenomas
(often thousands) throughout the colon and rectum usually presenting in the
2nd or 3rd decade of life. If left untreated, by prophylactic colectomy, the
patient will inevitably develop one or more colorectal carcinomas (Asman &
Pierce, 1970). The condition has an estimated frequency of 1 in 8300 births
(Reed & Neal, 1955) and is inherited as an autosomal dominant trait
(McKusick, 1962). Gardner's Syndrome (Gardner, 1951) is a variant of FAP
affecting 1 in 14,000 births (Pierce et al., 1970) also inherited as an
autosomal dominant trait (McKusick, 1962) and characterised by multiple
osteomas (especially of the jaw, orbit or pelvis), exostoses of the skeleton
and soft tissue abnormalities including desmoid tumours, epidermal cysts
and lipomas (Garlin & Choudhry, 1960) in addition to the colonic polyposis.
More recently the clinical sign of congenital hypertrophic retinal pigment
epithelium (CHRPE) has been added to the extracolonic manifestations of
GS (Lewis et al., 1984).
24
The differences between GS and FAP have become less clear as subtle
extracolonic changes are often seen in FAP and subsequent genetic linkage
analysis demonstrated that the same region (chromosome 5q21-22) was
involved in both diseases (Leppert et al., 1987; Bodmer et al., 1987). This
finding was consistent with the described cytogenetic abnormalities seen in
the region 5q 15-22 in patients with GS or FAP and associated mental
retardation (Flerrera et al., 1986; Flockey et al., 1988).
In 1971, Knudson proposed a theory to explain the incidence of familial and
sporadic retinoblastoma. This is a rare childhood tumour which is usually
bilateral in familial cases but unilateral in its sporadic form. Knudson
suggested that two mutational events were necessary to produce this
cancer: in familial cases one was inherited and the other somatic whereas in
sporadic cases both were somatic. The gene inactivated by these 2 events
has been cloned (RB1-Lee et al., 1987) and belongs to a heterogeneous
group of genes known as tumour suppressor genes. Both copies of such
genes must be inactivated to produce a phenotype and consistent loss of
specific alleles in tumours is often taken to indicate the sites of such a genes.
The analogy of Knudson's model for retinoblastoma to FAP and sporadic
colorectal cancer is clear and further studies have shown allele loss closely
linked to 5q21-22 (Solomon et al., 1987; Vogelstein et al., 1988; Ashton-
Rickardt et al., 1989 & 1991) in sporadic colorectal cancer, presumably
marking the site of the second mutational event. Allele loss at 5q21.22 can
also be detected at a comparable frequency in FAP colorectal cancer but not
in FAP adenomas (Solomon et al., 1987; Okamota et al., 1988; Sasaki et al.,
1989). Thus, mutation of only one allele (in the germ-line) is sufficient to
25
produce the phenotype of adenoma formation in the absence of a detectable
second event. Adenomatous Polyposis Coli (APC - the gene for FAP) differs
from RB1 in this important respect and will be discussed in more detail later
in this introduction. Linkage to the locus with colorectal cancer is also seen in
families with smaller numbers of colonic polyps, not normally diagnosed as
FAP (Leppert et al., 1990).
The FAP phenotype can be modulated, however, by environmental factors.
Colonic resection with ileo-rectal anastomosis and regular sigmoidoscopic
review of the rectal stump is now the prophylactic treatment of choice in
FAP. Regression of the polyps has been described following this procedure
(Nicholls et al., 1988) suggesting that a factor normally present in the colonic
lumen is necessary to promote the adenoma growth. It is possible that some
action of bacterial flora (such as metabolism of bile salts to secondary bile
acids - see section 1.2.7) is lost resulting in regression. Therapy with the oral
non-steroidal anti-inflammatory drug (NSAID) Sulindac can also result in
polyp regression (Waddell et al., 1989).
A number of genes in the region 5q21-22 have now been cloned and two of
these, designated MCC and APC, appear to be involved in colorectal cancer.
These will be discussed more fully in section 1.5.4
1.3.3 Hereditary Non-polyposis Colorectal Cancer
This syndrome is divided into 2 sub-groups. Both are characterised by early
onset of predominantly proximal colorectal cancer (sporadic colorectal
cancer is usually distal), increased frequency of multiple primary cancers,
improved 5 year survival when compared to matched controls with sporadic
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colorectal cancer and early age of onset. Lynch syndrome II (Cancer family
syndrome) is associated with extracolonic malignancies most noticeably
endometrial cancer, whereas Lynch syndrome I (hereditary site-specific
colon cancer) is not (Lynch et al., 1985a). The incidence of these particular
cancers is significantly higher in first degree relatives when compared to
non-bloodline relatives which argues strongly for a genetic rather than
environmental aetiology.
Biomarker studies were carried out which demonstrated an increase in the
development of tetraploidy in dermal fibroblasts cultured in vitro from
affected individuals and an increase in tritiated thymidine uptake in the distal
colonic mucosal crypt compartment (Lynch et al., 1985b) suggesting genetic
instability and increased cellular proliferation. Abnormal and elevated
patterns of [3H] thymidine uptake are also seen in the normal mucosa of
patients with colorectal cancer, FAP and also in unaffected individuals over
the age of 60 who are at higher risk of colorectal cancer (Deschner & Lipkin,
1975; Terpstra et al., 1987: Roncucci et al., 1988).
The disease genetics follow a Mendelian dominant inheritance with the
penetrance increasing with age (Lynch et al., 1985b). Co-segregation of the
disease with the Kidd (J^) blood group has been demonstrated (Lynch et al.,
1985b) although 2 families had to be removed from the analysis to make it
significant. The Kidd blood group resides on chromosome 18 as does a gene
implicated by other information in colorectal carcinogenesis called DCC (see
section 1.5.6). No genetic linkage however can be demonstrated between
DCC markers and HNPCC (MG Dunlop, personal communication). Nor is
there any linkage with the MCC-APC gene cluster on chromosome 5q21
(Peltomaki et al., 1992)
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1.3.4 Inheritance and "Sporadic" colorectal cancer
Studies of the families of patients with apparently non-inherited colorectal
cancer has demonstrated an increased risk in first-degree relatives of
approximately 3 fold (Macklin, 1960; Lovett, 1976). This risk becomes even
higher if the index case has multiple primary tumours of the colon, a past
history of previous colon tumours or an early age of onset of colorectal
cancer (Lovett, 1976). The pattern of inheritance is difficult to define and can
only be described as polygenic.
Later studies investigated a number of kindreds in Utah where the index
case had colorectal cancer (Burt et al., 1985; Cannon-Albright et al., 1988).
The relatives were screened by flexible procto-sigmoidoscopy for the
presence of colorectal adenomas or carcinoma. A statistically significant
difference was found in the incidence of adenomas between the first degree
relatives and the spouse controls. Analysis of the pedigree suggested that an
autosomal dominant pattern of inheritance best fitted the data. These
kindreds which do not have polyposis, demonstrate a dominantly inherited
susceptibility to develop colorectal adenomas which can be precursors to
colorectal carcinoma. Recent data from the CRC group in Edinburgh showed
that of 200 index cases of colorectal cancer, approximately 20% have an
affected first degree relative (Cancer Research Campaign, Dunlop et al.,
personal communication) suggesting that many cases of "sporadic"
colorectal cancer have an as yet undefined heritable background.
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1.3.5 Summary
Inheritance, plays an important part in the genesis of a number of
colorectal cancers. Apart from the well defined diseases of FAP and
GS, where the susceptibility gene (APC) has now been isolated, there
are the Lynch syndromes and the adenomatous polyp inheritance
which both follow an autosomal dominant pattern along with the
complex inheritance pattern in so-called "sporadic" colorectal cancer
which in some kindreds at least follows an autosomal dominant mode.
Many of these conditions are defined clinically and significant overlap
may exist between them which will remain until the responsible genes
are identified.
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1.4 Histopathology and DNA Ploidy of Colorectal Neoplasia
1.4.1 Histopathology of colorectal carcinomas
Histopathology involves the macro- and microscopic examination of tissue to
identify morphological features which will permit a diagnosis to be made
giving prognostic information and thus allowing a rational approach to
treatment. In the case of colorectal cancer this centres around the
differentiation of benign and malignant tumours, the subclassification of
adenomas to identify those likely to proceed to malignancy and the
subclassification of carcinomas to permit a more accurate estimate of
prognosis and thus the most appropriate treatment. Essentially it is an
estimate of a tumour's future behaviour based on morphological features
sampled (usually) at a single point in time. Considering the limitations
inherent in such an exercise, this can be done to a reasonable degree of
accuracy and is still the standard method of assessment.
Colorectal tumours are usually assessed by staging (the degree of spread)
and grading (histology). In 1932, Dukes proposed a simple, objective method
to stage rectal cancer. Stage A were cases with spread limited to the rectal
wall, B had spread beyond the rectal wall but did not involve any lymph
nodes and Stage C had lymph node metastasis. Stage A had the best
prognosis and C the worst. His classification has subsequently been shown
to be equally applicable to colon cancer (Grinnell, 1939) and has been
modified to include a D stage with distant metastasis. Dukes himself later
modified the C stage into C1 (regional lymph nodes only involved) and C2
(nodes at the point of ligation involved) to give better prognostic
discrimination (Dukes & Bussey, 1958). The reproducibility and objectivity of
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this system means that it is the standard staging system used today.
Grinnell (1938) also attempted to grade colorectal cancer on the basis of the
histology. He was able to demonstrate that an assessment of glandular
arrangement, invasiveness, loss of nuclear polarity and nature of invasive
margin gave information which correlated with prognosis although the
relative importance and interdependency of these variables was not
assessed. It was not until 1986 (Jass et al.) that multivariate analysis was
applied to this problem to identify independent prognostic variables
concluding that, for rectal cancer, lymphocytic infiltration, lymph node status
and extent of spread (the last two being included in Dukes' staging) gave
independent prognostic information. It was also possible to show a
correlation of prognosis with tubule configuration (differentiation) and growth
pattern (nature of invasive margin). This prompted the proposal of a scoring
system (Jass & Morson, 1987) based on extent of invasion, lymph node
metastasis, growth pattern and lymphocytic infiltrate. However, inter- and
intra- observer agreement for scoring lymphocytic infiltration is poor which
limits its use greatly (Dundas et al., 1988).
An assessment based upon Dukes stage and graded (by a single
experienced pathologist) for differentiation and growth pattern probably
represents the best classification (Dundas et al., 1988) in terms of
reproducibility and objectivity. This is the system recommended by the
United Kingdom Co-ordinating Commitee on Cancer Research (UKCCCR,
1988) and used in this thesis.
31
1.4.2 Histopathology of adenomas
There is good, but largely circumstantial, evidence that colorectal cancers
develop from pre-existing adenomas. Adenomas have the same distribution
within the colon as carcinomas (distal predominance), they occur in the
same population as those at risk of colorectal cancer, carcinomas can be
found containing morphologically adenomatous tissue for which they
probably arose and adenomas with small foci invasion can also be identified.
Thus carcinomas can arise from adenomas but the majority of adenomas will
not become malignant and it is highly likely that many carcinomas do not
have any clearly defined adenomatous intermediate.
The histopathological grading of adenomas depends on size, architecture
and cellular morphology. Adenomas greater than 10 mm in diameter, with
villous architecture and severe dysplasia tend to be found in the distal colon
and rectum and are thus likely to be at higher risk of malignancy (Konishi &
Morson, 1982).
1.4.3 DNA ploidy of colorectal tumours
Karyotype analysis of solid tumours is not easy but a number of groups have
produced data on chromosome analysis (Sonta & Sandberg, 1978;
Reichmann et al., 1981, 1982; Remvikos et al., 1988). In addition to specific
chromosome alterations (which will be discussed later in the introduction),
aneuploidy was a noticeable finding. DNA aneuploidy simply refers to the
fact that cells have a non-diploid DNA content. The processes which bring
this about are still not clear but it has been proposed that it results from
chromosomal non-disjunction and reduplication. The flow cytometric
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estimation of aneuploidy is much simpler, faster, can be applied to archive
material (Hedley, 1988) and gives a result very close to that for karyotyping
(Petersen & Friedrich, 1986; Remvikos et al., 1988). DNA aneuploidy has
been shown to correlate with poor prognosis for colorectal cancer,
independent of Dukes' stage (Wolley et al., 1982; Armitage et al., 1985;
Quirke et al., 1987; Giaretti et al., 1991) although the reason for this
consistent finding is unclear. It is important to sample at multiple sites as
heterogeneity of DNA ploidy is seen in approximately 50% of cases (Quirke
et al., 1985). DNA aneuploidy is also seen in adenomas at a frequency
between 6 and 27% (van den Ingh et al., 1985; Quirke et al., 1986) and
tends to be in the larger (> 10 mm) adenomas of tubulovillous or villous
architecture which are the subgroups at greater risk of malignant change.
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1.5 Molecular Genetic Changes in Colorectal Cancer
1.5.1 Introduction
in 1954, Armitage and Doll carried out an epidemiological study exploring the
relationship between mortality and age for a number of common cancers.
Analysis of log age plotted against log death rate for colon cancer gave a
straight line with a gradient of approximately 5. This was interpreted as
suggesting that 5 discrete events are required for colon carcinogenesis.
Interestingly, at younger ages, the death rate is relatively higher with a
gradient closer to 4 suggesting that fewer (genetic) events are necessary.
This observation could be explained as due to the earlier presentation of
familial cancers seen in FAP patients: such patients already possess one
germ-line mutation. At the time of writing, Armitage and Doll could have had
little idea as to the nature of the 5 "events" they were suggesting but a
number of genetic changes have now been described in colorectal cancer
and these will be discussed.
1.5.2 Clonal Evolution of Colorectal Tumours
Current theories of carcinogenesis suggest that neoplasms develop from a
single cell (Nowell, 1976, 1986). The single cell is altered in some way to
permit at least semi-autonomous growth allowing it to proliferate to a greater
extent than its normal neighbours. Subsequent (genetic) changes to
daughter cells in this clone may be lethal or may confer a growth advantage
permitting overgrowth by this new sub-clone. This selection process can
continue until an invasive or metastatic clone is produced. The data
assessed by Armitage and Doll (1954) suggested that 5 such critical "sub-
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cloning" selection events might be required to produce a colorectal cancer.
However, it is possible that greater or smaller numbers of genetic events are
necessary for colorectal carcinogenesis as an unknown factor affecting the
interpretation of the data is the degree of independence of the critical
carcinogenic events from each other. If certain of the critical events result in
increased genomic instability this would accelerate the rate of acquisition of
the other selectable genetic alterations. Later in this thesis evidence will be
discussed showing that some critical events (notably p53 inactivation) do
indeed influence genomic stability. Long term cultures and transformed cells
in culture do have an increased susceptibility to chromosome damage
(Parshad et al., 1979) and fibroblasts cultured from patients with a germline
p53 mutation immortalise frequently and develop DNA aneuploidy (Bischoff
et al., 1990).
The clonal origin of a number of benign and malignant neoplasms has been
studied. Using glucose-6-phosphate dehydrogenase mosaicism in black
females, Linder and Gartler (1965) were able to demonstrate that
leiomyomas of the myometrium were exclusively monoclonal in origin. Using
a similar technique, Fialkow et al., (1967) obtained the same result in chronic
myelocytic leukaemia and the monoclonality of a number of different
lymphoid neoplasms was demonstrated by Arnold et al., (1983) using
immunoglobulin gene rearrangements as a marker.
In the case of colorectal neoplasms, monoclonal origin has been
demonstrated in both adenomas and carcinomas by the pattern of
methylation induced X chromosome inactivation detected using RFLP
probes with methylation sensitive restriction enzymes (Fearon et al., 1987).
Colonic epithelial dysplasia induced by azoxymethane in chimseric mice has
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also been shown to be monoclonal using H2 antigen as a marker (Ponder et
al., 1986).
Although the monoclonal origin of neoplasms may hold true for these
common sporadic tumours, the rarer, inherited tumours appear different.
Benign tumours from GS (Hsu et al., 1983) and neurofibromatosis (Fialkow
et al., 1971) both appear polyclonal origin by G-6-PD mosaicism. However,
these tumours are in fact all "clonal" for the inherited gene defect in APC or
NF1 which is present in all cells of an affected individual including those
giving rise to the benign proliferation. The reason why some cells form a
tumour while their neighbours do not may involve interaction with
environmental factors, the concentration of which may vary locally.
Thus, in general, sporadic colorectal neoplasms arise from a single cell
which has undergone alterations to permit its dysregulated growth. Nowell
(1976, 1986) proposed that as the neoplastic proliferation proceeds,
additional altered cells are produced. Most of these will be eliminated unless
they have a growth advantage compared to the parent cell. In this case, it
will overgrow the neoplasm and become the predominant ceil type, until
another similar event occurs to take the neoplasm another stage further
along its evolution. Colorectal neoplasia provides a suitable system in which
to study this evolution in a human malignancy. The various stages of: normal
mucosa; benign adenoma; carcinoma and metastasis can all be identified
and separated histopathologically and studied individually to define the
events at each stage in the process.
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1.5.3 Methylation
One of the earliest detectable alterations found in colorectal neoplasia is that
of hypomethylation. Studies using methylation sensitive restriction enzymes
to investigate the Southern blot pattern of DNA from adenomas and
carcinomas compared to normal colonic mucosa when probed with DNA
from diverse genes (mainly these not associated with neoplasia)
demonstrated hypomethylation in almost all the neoplasms studied including
benign adenomas (Goelz et al., 1985). Measurement of 5-methylcytosine
content in paired normal and tumour DNA samples by High Performance
Liquid Chromatography (HPLC) confirmed the hypomethylation, which was
even more marked in carcinomas compared to adenomas (Feinberg et al.,
1988).
DNA methylation is a covalent modification of cytosine occurring at CpG
doublets in vertebrate DNA (Bird, 1978, 1986) which is maintained through
DNA replication (Wigler et al., 1981). Islands of sequence rich in such CpG
motifs (CpG islands) are found in the vicinity of the 5' regions of mammalian
("house-keeping") genes and a reduction in methylation at these sites
correlates with active transcription of these genes (Bird et al., 1985; Bird,
1986). Exposure of cells to 5-azacytidine (a cytosine analogue which cannot
be methylated at the 5' position) results in hypomethylation, opening of
chromatin and transcriptional activation (Groudine et al., 1981). It is
tempting, therefore, to assume that hypomethylation of a normal colonic
mucosal cell (by an undefined stimulus) results in the activation of genes, or
perhaps their exposure to modification by mutagens, leading to proliferation
and adenoma formation. However, the evidence is still lacking to show that
hypomethylation is a primary event in this process and not simply a
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secondary epiphenomenon of cells which are more actively proliferating for
other reasons.
1.5.4 Chromosome 5q21
The APC gene (implicated in FAP) was mapped to the q21-22 region of
chromosome 5 by linkage analysis with restriction fragment length
polymorphic (RFLP) probes (Bodmer et al., 1987; Leppert et al., 1987) after
the identification of a patient with FAP and mental retardation who had a
constitutional deletion of chromosome 5q (Flerrera et al., 1986).
The finding that RFLP probes frequently show allele loss in sporadic and
FAP colorectal cancer in the region 5q21.22 strongly suggested that APC
was a tumour suppressor gene in the RB1 mould (Solomon et al., 1987; Law
et al., 1988; Vogelstein et al., 1988; Okamoto et al., 1988; Sasaki et al.,
1989; Ashton-Rickardt et al., 1989 & 1991). The further demonstration that
returning a normal chromosome 5 to colon cancer cell lines rendered them
non-tumourigenic, although not necessarily demonstrating an effect specific
for APC, added evidence of its probable tumour suppressor function (Tanaka
et al., 1993).
However, 5q allele loss is very rare in early FAP adenomas (Solomon et al.,
1987; Vogelstein et al., 1988; Sasaki et al., 1989; Miyaki et al., 1990)
suggesting that the adenomatous phenotype is expressed when only one
allele is mutated (in the germline). Whether this phenomenon is a result of a
reduced gene dosage (Bodmer et al., 1987), an interaction of the mutated
protein to inactivate the wild type (as is seen with p53, Sturzbecher et al.,
1987) or some other mechanisms (Bourne, 1991) remains to be seen.
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Expression of the phenotype also seems to depend upon colonic lumenal
factors: colectomy and ileo-rectal anastomosis results in regression of
adenomas in the rectal stump (Nicholls et al., 1988) as does therapy with the
non-steroidal anti-inflammatory drug Sulindac (Waddell et al., 1989).
Recent studies by two independent groups have isolated APC (Kinzler et al.,
1991a; Joslyn et al., 1991) in a cluster of 6 genes at 5q21. Another gene in
the cluster, designated MCC, (Kinzler et al., 1991b) also appears to undergo
mutation in sporadic colorectal cancer but not FAP (Kinzler et al., 1991a).
APC was identified from yeast artificial chromosome (YAC) libraries by
hybridisation to polymorphic probes shown to flank APC by linkage analysis.
The gene itself spans approximately 100 kb and has a coding region of 8.5
kb encoding a protein of over 300 kDa. The demonstration that it is mutated
in the germline of FAP patients but not in any normal controls and that the
mutated allele co-segregates with the disease in FAP and GS kindreds
proved that it is the APC gene (Joslyn et al., 1991; Nishisho et al., 1991).
Germ-line mutation of the murine homologue of APC also results in multiple
intestinal neoplasia (Su et al., 1992).
The APC mutations so far described are either mis-sense mutations
(producing stop codons), small (one or two bp) deletions (causing frameshift
and termination) or larger deletions removing much of the coding region
(Joslyn et al., 1991; Nishisho et al., 1991; Miyoshi et al., 1992a). All tend to
cause truncation of the message and therefore a protein with altered or non¬
existent function. Further analysis suggests that mutations between codons
1250 and 1464 result in a clinical sub-type of FAP characterized by profuse
colonic adenomatosis whereas mutations at other sites result in the sparse
sub-type (Nagase et al., 1992). It is tempting to assume that it is the
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spectrum of different mutations that gives rise to the spectrum of phenotypes
seen in FAP, GS and familial colorectal cancer with less marked polyposis.
Other types of interaction (environmental or genetic), are suggested,
however, by the finding of the same mutation in two unrelated patients, one
with extracolonic manifestations (a desmoid tumour) and one without
(Nishisha et al., 1991).
The protein has no significant homology with any other protein so far isolated
but does have heptad repeat regions known to facilitate protein-protein
interaction via extended alpha helices presenting hydrophobic residues
along one side (Bourne, 1991). These hydrophobic regions can stabilise by
interaction with similar alpha helices to form hetero- or homodimers and a
coiled-coil structure. Similar motifs are detected in MCC (Bourne, 1991) and
possible interaction between these two gene products cannot be ruled out.
APC appears to exist in two forms with an alternately spliced exon 9. The full
significance of this is not clear but both forms are expressed together and all
tissues so far examined express APC mRNA (Groden et al., 1991).
Analysis of the APC mutations in sporadic colorectal cancer (Nishisho et al.,
1991; Miyoshi et al., 1992b) demonstrates mis-sense mutations causing
amino acid substitutions, splice donor and acceptor disruption and stop
codons as well as small sequence insertions. However, out of 10 colorectal
cancers with a defined APC mutation only 2 had a 5q allele loss (Nishisho et
al., 1991), suggesting perhaps another departure from the classic tumour
suppressor paradigm, exemplified by retinoblastoma. However, subsequent
work has suggested inactivation of both copies of APC is rather commoner
(Miyoshi et al., 1992b). Fine mapping of the deletions in sporadic colorectal
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cancers has shown that they are centred around the polymorphic probe
L5.71 (Ashton-Rickardt et al., 1991) which is located within MCC and not
APC. Thus, mutation of one copy of APC has the phenotype of colonic
adenomatosis in FAP. Mutation of APC however, can be present without
deletion of the wild-type gene in FAP related colorectal adenomas (Miyaki et
al., 1990) and in sporadic colorectal cancer the 5q deletions are centred over
MCC (Ashton-Rickardt et al., 1991). These data are therefore consistent with
APC mutations acting in a dominant fashion and MCC as a tumour
suppressor and the target for 5q deletions.
MCC is centromeric to APC spanning about 100 kb. Mutations in MCC are
not found constitutively in FAP or GS patients but can be demonstrated in (a
small proportion of) sporadic colorectal cancers although full analysis is still
awaited (Kinzler et al., 1991b). It also contains coiled-coil motifs suggesting
dimerisations and a possible structural function in the cell (Bourne, 1991).
MCC also has an intriguing but short homology to the m3 muscarinic
acetylcholine receptor hinting at a signal transduction function, but the
significance of this is still unclear.
In summary, two genes, closely linked physically, have been isolated
from a region frequently deleted in colorectal cancer and therefore
suggestive of a tumour suppressor locus. One, MCC, is mutated only
in sporadic colorectal cancer (Kinzler et al., 1991a and b) and is at the
centre of mapped deletions (Ashton-Rickardt et al., 1991), whereas the
other, APC, is the heritable genetic lesion in FAP and GS. APC is not a
"simple" tumour suppressor gene, however, in that a single mutated
allele has a phenotype, the phenotype is modulated by unidentified
factors; and although deletion of the wild-type gene copy is commonly
41
seen it may not be the target for such a deletion (Ashton-Rickardt et al.,
1991). It is conceivable that APC and MCC interact at a protein level
and that inactivation of either is responsible for the loss of tumour
suppressor function (Kinzler et al., 1991). Much more work on these
genes will be necessary to define their roles and possible interactions
in colorectal cancer.
1.5.5 K-ras Oncogene
Kirsten ras (K ras) is a cellular proto-oncogene thought to play a central role
in growth control. Kras belongs to a family of ras genes (along with H- and N
ras) which in turn belong to the GTPase superfamily of conserved proteins
involved in "molecular switching" (Bourne et al., 1990). The c-ras genes
encode 21 kd proteins, p21ras, which are located on the inner plasma
membrane and bind guanine nucleotides. p21ras is in the active state when
GTP bound but inactive when GDP bound and it is the change between
these two states which seems to be important for cell proliferation control.
Movement into the active (GTP bound) state is enhanced by guanine
nucleotide release proteins, GNRP (Wolfman & Macara, 1990) and GTP
hydrolysis by p21ras is enhanced by GTPase activating protein, GAP
(Trahey & McCormick, 1987). Transformation by p21ras can be achieved
either by overexpression or by mutations both acting by increasing the
amount of active (GTP bound) protein in the cell (Marshall, 1991). Mutation
at codons 12, 59 and 61 greatly reduce the GTPase activity resulting in the
predominance of active p21ras (Vogel et al., 1988).
Analysis of c-ras gene sequence in human colorectal tumours demonstrated
a high frequency (approximately 40% of carcinomas) of K-ras mutations (and
42
fewer N-ras) at codons 12, 13 and 61 (Forrester et al., 1987; Bos et al.,
1987; Vogelstein et al., 1988). The same mutations are also found at a
similar frequency in colorectal adenomas (Vogelstein et al., 1988) and when
carcinoma and adenoma can be separated in the same lesion, the same
mutation is found in both (Bos et al., 1987; Vogelstein et al., 1988).
Mutations of ras genes are also more frequent in the larger adenomas which
are those more likely to progress to carcinoma (Vogelstein et al., 1988). This
suggests that c-ras mutation is an event occurring early in colorectal
tumourigenesis perhaps during adenoma development.
Thus, activation of c-ras by mutation at specific sites which prevent the
action of GAP to inactivate p21ras by GTP hydrolysis appears to be
responsible for the increased proliferation of the adenomas but not for the
transition to malignancy. Experiments in many in vitro experimental systems
have shown that ras cannot fully transform cells when acting alone but
requires cooperation with another genetic event (Land et al., 1983). This is
likely to be the case in colorectal carcinogenesis although the cooperation
may come from tumour suppressor gene inactivation rather than activation of
another oncogene.
1.5.6 Chromosome 18q and DCC
Chromosome 18 abnormalities in colorectal cancer were first detected
cytogenetically (Muleris et al., 1985) and subsequent studies demonstrated
allele loss on 18q (by RFLP analysis) in 52-71% of cases (Law et al., 1988;
Vogelstein et al., 1988; Vogelstein et al., 1989; Delattre et al., 1989). These
deletions are relatively rare in adenomas (11%) but common in "adenomas"
which have foci of invasion (47%) and even more frequent in frank
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carcinoma (73%) (Vogelstein et al., 1988). This suggests that 18q allele loss
is an event closely concurrent with the evolution of adenoma to carcinoma.
Consistent loss of markers at specific loci in tumours is thought to indicate
the presence of critical tumour suppressor genes and so fine mapping of
these deletions in many tumours was undertaken delimiting the minimum
region of overlap to 18q21.qter (Vogelstein et al., 1988). The identification of
a marker homozygously deleted in a particular tumour permitted cloning of
the gene designated DCC (Fearon et al., 1990).
DCC encodes a 750 amino acid protein which is well conserved through
evolution and which has significant homology to neural cell adhesion
molecules (N-CAM) in that DCC contains 4 immunoglobulin (Ig) like domains
and a fibronectin like domain similar to those in N-CAM and other members
of the cell adhesion molecule family (Fearon et al., 1990). The introduction of
a normal human chromosome 18 into colon carcinoma cell lines renders
them non-tumourigenic and reduces their cloning efficiency in soft agar
(Tanaka et al., 1991). This further suggests a tumour suppressor gene on
chromosome 18. However, the authors did not demonstrate DCC inactivation
in the parental cell line, nor does this result exclude the effect of any other
gene on chromosome 18. However, subsequent studies showed that
expression of DCC antisense RNA in vitro increased growth rate,
tumourigenicity in nude mice and decreased cell adhesion (Narayanan et al.,
1992) suggesting that DCC is indeed a tumour suppressor gene.
The finding that DCC, a gene which is inactivated at or about the time of
adenoma-carcinoma evolution, should be related to molecules involved in
cell-cell interactions is suggestive. One of the hallmarks of carcinomas when
compared to adenomas histologically is the reduction or loss of cellular
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organisation and architecture and it could be speculated that this is due to
the loss (by inactivation of both copies) of a gene, such as DCC, which is
involved in cell to cell adhesion and interaction.
1.5.7 Chromosome 17p and p53
Cytogenetic studies of the karyotypes of human colorectal cancer
demonstrated loss of the short arm of chromosome 17 as a frequent finding
(Muleris et al., 1985). Subsequent RFLP analysis confirmed this result with
17p alleles lost in 40-75% of carcinomas (Lothe et al., 1988; Vogelstein et
al., 1988; Monpezat et al., 1988; Law et al., 1988; Vogelstein et al., 1989;
Delattre et al., 1989). This change is seen rarely in adenomas with foci of
invasive carcinoma (24%) and in only 6% of true benign adenomas
(Vogelstein et al., 1988) suggesting that this is indeed a late change in the
adenoma-carcinoma evolution.
Subsequent mapping of the minimum region of overlap of deletions in a
series of colorectal cancers suggested p53 as a possible genetic target for
such deletions and the finding that the remaining p53 allele was frequentky
mutated seemed to confirm this (Baker et al., 1989). The role of p53 and its
involvement in colorectal carcinogenesis will be discussed in more depth in
chapter 2.
Deletions of chromosome 17p are frequent findings, especially in the
common human malignancies of colorectum (Vogelstein et al., 1988), breast
(Mackay et al., 1988) and non small lung cancer (Chiba et al., 1990). No
similar correlation between allele loss and p53 mutation has been
demonstrated for breast (Varley et al., 1991) or non small cell lung cancer
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(Chiba et al., 1990) and for breast cancer, careful deletion mapping has
shown a locus distinct from p53 which is also a target for 17p allele loss
(Coles et al., 1991). This putative tumour suppressor locus is mapped,
provisionally, to a marker MCT 35.1 which is located within the minimum
region of overlap demonstrated in colorectal cancer (Baker et al., 1989;
Coles et al., 1991). In fact the minimum region of overlap for 17p allele loss in
colorectal cancer is so large (approximately 30mb) that it must contain many
genes each one of which could have some tumour suppressor function.
1.5.8 Other genetic events in colorectal cancer
C-myc is a proto-oncogene whose gene product (p62-c-myc) is normally
located in the cell nucleus (Evan et al., 1985). The normal function of c-myc
is not yet clear but it has been implicated in early development (Muller et al.,
1982), control of cell growth (Kelly et al., 1983), patterns of differentiation
(Lachman & Skoultchi, 1984) and tissue regeneration (Makino et al., 1984).
Elevated levels of c-myc protein are associated with malignancy and
transformation either as a result of transcriptional activation by adjacent
promoter insertion (Hayward et al., 1981), balanced translocation
juxtaposing immunoglobulin sequences with c-myc as seen in Burkitts'
lymphoma (Taub et al., 1982) or gene amplification (Collins & Groudine,
1982).
Overexpression of c-myc at the protein and mRNA level is relatively common
in colorectal cancer detectable in approximately 70% of cases (Erisman et
al., 1985; Rothberg et al., 1985; Sikora et al., 1987). This does not appear to
be as a result of gross rearrangement or amplification (Erisman et al., 1985;
Sikora et al., 1988) suggesting that it is probably due to transcriptional
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activation. Amplification of c-myc has been described in certain aggressive
subtypes of colorectal cancer (Heerdt et al., 1991) but in view of the fact that
the level of amplification is so low (1-3 fold normal) and given the subjectivity
of grading tumours, the significance of this result is unclear. Expression of c-
myc does not correlate with disease recurrence or patient survival (Erisman
et al., 1985).
The precise timing of the c-myc event resulting in overexpression is not yet
clear but a change in the immunohistochemical pattern of staining is
observed with tumour evolution. In normal mucosa, the antibody binding is
predominantly nuclear becoming more cytoplasmic in adenomas (especially
large, dysplastic adenomas) and is predominantly cytoplasmic in all
carcinomas (Williams et al., 1990). This suggests that the up-regulation of
the protein occurs near the point of adenoma-carcinoma evolution.
Cooperation between myc and ras to fully transform cells in vitro is well
described (Land et al., 1983) therefore an in vivo cooperation in colorectal
carcinogenesis is quite possible although, evidence linking the two
oncogenes in colorectal cancer is still lacking.
Loss of alleles can be detected for all the arms of all non-acrocentric
chromosomes in human colorectal cancer in at least 7% and usually 10+%
except in those already described where it is higher (Vogelstein et al., 1989).
It is difficult to imagine that these all indicate the sites of tumour suppressor
loci. It seems more likely that they either represent telomeric shortening
(Hastie et al., 1990) or, more probably, the genomic instability which is seen
in transformed cells resulting in the many chromosomal aberrations detected
cytogenetically (Muleris et al., 1988). Whatever its role or cause, however,
loss of many alleles does correlate with a poorer prognosis (Vogelstein et al.,
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1989; Kern et al., 1989).
Colorectal cancer is, therefore, a multistep process involving a number
of different molecular genetic steps, some of which have been defined
(Fearon & Vogelstein, 1990). Some of these events tend to occur earlier
than others, but this proposed order is not exclusive as development
of the critical events, in whatever order, appears to lead to
carcinogenesis. The most critical event in colorectal tumourigenesis is
clearly the development of malignant potential. Whether this is after
adenoma growth or in its absence, p53 appears to act at this point and
may be central to malignant transformation. The data suggesting this





The 53 kDalton protein p53 was initially isolated by virtue of its binding to
SV40 large T antigen in infected cell lines (Lane & Crawford, 1979; Linzer &
Levine, 1979; Rotter, 1983). The detection of p53 in transformed cell lines in
vitro (De Leo et al., 1979) and in vivo (Rotter et al., 1983) resulted in its
classification as a tumour antigen. Following the isolation of complementary
and genomic clones for p53, it was demonstrated to immortalise both rat
embryo fibroblasts (Rovinski & Benchimol, 1988) and adult rat chondrocytes
(Jenkins et al., 1984) and to co-operate with ras to fully transform rodent
embryo cells in culture (Parada et al., 1984; Elijahu et al., 1984). These
observations led to the classification of p53 as an oncogene.
However, subsequent studies demonstrated that the p53 gene clones used
in these experiments all carried mutations and that true wild type (WT) p53
would suppress transformation in co-transfection assays (Hinds et al., 1989;
Finlay et al., 1989). Further work using cell lines derived from tumours has
confirmed the negative effect on cellular proliferation of transfected WT p53
(Baker et al., 1990a; Mercer et al., 1990). Thus p53 is currently classified as
a tumour suppressor gene product.
In this section, the biochemical and biological properties of p53 and the
alterations detected in human neoplasia will be discussed.
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2.2 The gene for p53
The gene for p53 has been isolated from a wide variety of vertebrate and
invertebrate species covering an evolutionary spectrum including xenopus
laevis (Soussi et al., 1987), rainbow trout (Caron de Fromentel et al., 1992)
chicken (Louis et al., 1988; Soussi et al., 1988), mouse (Oren & Levine 1983;
Bienz et al., 1984), rat (Coulier et al., 1985), monkey (Rigaudy & Eckhart
1989) and human (Matlashewski et al 1984) suggesting an important role for
p53. However, no p53 homologue has thus been detected in yeast despite
extensive screening (JR Jenkins, personal communication).
The human p53 gene is located on the short arm of chromosome 17 in the
region p13 (Isobe et al., 1986) and has been further mapped to the D1 sub-
region (Baker et al., 1989). The murine p53 gene is on chromosome 11
(Czosneck et al., 1984; Rotter et al., 1984) and the murine genome also
contains a processed pseudogene lacking introns on chromosome 14
(Zakut-Houri et al., 1983). Both human and mouse genes consist of 11
exons with a large (6.1-10 kbp) first intron separating the untranslated first
exon from exon 2 (Bienz et al., 1984; Lamb & Crawford 1986). The murine
protein has a predicted length of 390 amino acids (Zakut-Houri et al., 1983;
Pennica et al., 1984) or 387 depending upon which methionine is considered
to be the start codon (Soussi et al., 1987). The human protein consists of
393 amino acids and shows 79% amino acid homology with mouse p53
(Harlow et al., 1985). Many of the differences are conservative suggesting a
high degree of sequence retention through evolution (Harlow et al., 1985).
This hypothesis is strengthened by the finding that p53 from xenopus laevis
shares 57% primary structure with mouse p53. Further analysis reveals five
regions (designated l-V, figure 2.1) in which the homology rises to 91-100%
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(Soussi et al., 1987). Such conservation through evolution argues strongly
for these regions having an important role in the function of the protein.
Human p53 domain I spans residues 13-19; II, 117-142; III, 171-181; IV,
236-258; and V, 270-288 (Soussi et al., 1987; Levine & Momand, 1990).
Interestingly, the binding sites on murine p53 for SV40 large T antigen have
been mapped to residues 165-199(A) and 232-285(B) (Jenkins et al., 1988)
corresponding to 171-205(A) and 238-291 (B) in human p53. These regions
span conserved domains III, IV and V suggesting that T antigen may be
occupying a site important in the normal (tumour suppressor) function of p53
and could be displacing a normal p53 ligand if such exists.
Analysis of the primary structure of p53 from several species for charge
distribution and hydropathic profile provides further evidence of evolutionary
conservation (Soussi et al., 1990). The amino terminus region (100 residues)
is highly acidic, proline rich and hydrophilic and is predicted to form an a
helix; the carboxy terminus is a basic, hydrophilic a helix; and the internal
amino acids (containing domains ll-IV) consist of few charged residues and
are predicted to form a hydrophobic 6 pleated sheet. This arrangement
would suggest a secondary structure with the amino and carboxy terminals
on the external surface and the central residues internal to the folded
protein. This may explain why single mis-sense mutations in domains ll-IV,
which reside in the hydrophobic centre of p53 cause important changes in
protein conformation which have signficiant functional sequelae (see Section
2.3).
Northern blot analysis of p53 mRNA detects a transcript of 2.2 kbp in the
mouse (Oren et al., 1983) and 2.5-2.8 kbp in the human (Matlashewski et al.,
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1984; Harlow et al., 1985). The difference in size is largely due to the greater
3' untranslated region in the human gene (Matlashewski et al., 1984) which
contains Aiu sequences. The gene for p53 does not contain any of the
consensus sequences found in most eukaryote promoters such as a CAAT
box, a TATA box or G/C rich sequences but promoter activity has been
detected in the region 5' to the first exon (Bienz-Tadmor et al., 1985) termed
P1. This activity, however, is down-regulated by inclusion of sequences
between this region and exon 1. A second promoter site (P2) has been
identified downstream of the first exon (Reismann et al., 1988; Reismann &
Rotter 1989) but transcript representing in vivo activity at this site has not
been detected. The relevance of P1 and P2 in vivo remains in doubt.
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Figure 2.1 Diagram showing the conserved domains of human p53
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2.3 p53 Protein Conformation
The p53 protein exists in different conformations which can be detected by
its affinity to a range of monoclonal antibodies. In its wild type or growth
suppression form p53 will bind PAb 246 (mouse) (Yewdell et al., 1986), PAb
607 (human and mouse) and PAb 1620 (human and mouse) (Milner et al.,
1987). Whereas in its mutant form, p53 will bind PAb 240 (Gannon et al.,
1990). The epitopes and binding characteristics are summarised in table 2.1
and figure 2.2. The binding of the PAb 246, PAb 607 and PAb 1620 are
denaturation sensitive indicating their dependence on the p53 protein
conformation. PAb 240 is denaturation insensitive and binds to an epitope
centred on amino acids 213-217 (Stephen & Lane, 1992) which is within the
hydrophobic region of the p53 protein predicted to be internal in the wild-type
(WT) conformation. Thus, mutation exposes a previously hidden epitope for
antibody binding. Mutations at many different sites within p53, especially
those within conserved domains ll-IV, bring about similar conformational and
antibody binding alterations (Gannon et al., 1990). This suggests that
mutation within the conserved domains alters the WT conformation and
diminishes the tumour suppressor activity of the protein. It cannot be
assumed however that all mutants, even if PAb 240 reactive, have the same
conformation and biological properties.
In the case of mouse p53, a temperature sensitive mutant exists, which has
a valine substituted for alanine at codon 135 (p53 val 135) and behaves like
the wild type protein at 32°C but in a mutant fashion at 37°C (Milner &
Medcalf, 1991). With this alteration in behaviour there is a conformational
change from PAb 246+ at 32°C to PAb 246- at 37°C. These data strongly
suggest that it is the conformational change in p53 brought about by
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mutation which alters its behaviour from tumour suppressor to non-tumour
suppressor and possibly oncogene.
However, different conformations of murine and human p53 translated from
WT p53 mRNA in a cell lysate translation system have been detected (Cook
& Milner 1990). The mouse protein is either in a PAb 246+ or PAb 246-
conformation and both mouse and human protein either PAb 1620+ or PAb
240+ depending upon the batch of reticulocyte lysate used for each
experiment. Thus WT p53 can exist in a PAb 246+, PAb 1620+ tumour
suppressor conformation or a PAb 246-, PAb 240+ non tumour suppressor
conformation. It has also been demonstrated that a change in conformation
from PAb 246+ to PAb 246- occurs 1 hour after serum stimulation of cells in
vitro (Milner & Watson 1990). Thus, it would appear that physiological
alterations in WT p53 tertiary structure from PAb 246+, PAb 1620+ to PAb
246-, PAb 240+ (mimicking the alterations seen with p53 mutation) occur in
cells stimulated to replicate and this conformational change may be a signal
to permit proliferation.
Wild-type p53 can also be induced to change to a "mutant" conformation
when co-translated with certain mutant p53 mRNA's. This property appears
to depend upon oligomerization between mutant and WT protein and is lost
when a truncated mutant lacking the carboxy terminal residues responsible
for oligomerization is employed (Milner et al., 1991; Milner & Medcalf 1991).
However, a mutant p53 containing a mutation described in the Li-Fraumeni
syndrome (Malkin et al., 1990; Srivastava et al., 1990) fails to have any
influence upon the co-translated WT protein (Milner & Medcalf 1991). This
demonstrates that different mutants of p53 can have different properties.
55
Table 2.1 Summary of p53 antibody binding.
Antibody Mouse p53 Human p53 Reference
Wild-type Mutant Wild-type Mutant
240 + + Gannon et al., 1990
242 + + - - Yewdell et al., 1986
246 + - - - Yewdell et al., 1986
248 + + - - Yewdell et al., 1986
421 + + + + Harlow et al., 1981
1620 + - + - Milner et al., 1987
1801 - - + + Banks et al., 1986
+ binds antibody
does not bind antibody
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2.4 Subcellular localisation of p53
Analysis of nuclear sub-fractions of normal and transformed cells
demonstrated that p53 is found in the chromatin and in the nucleoplasms
and nuclear matrix factions (Deppert & Haug 1986). In herpes simplex virus
infected cells, p53 co-localises to areas of viral DNA replication within the
nucleus (Wilcock & Lane, 1991). This suggests a role for p53 within the
nucleus and indeed a nuclear location sequence has been detected which
has homology to that described in SV40 large T antigen (Addison et al.,
1990). This sequence is highly conserved for human, mouse and rat p53
(Soussi et al., 1990) and when bound to non-nuclear proteins results in their
relocation in the nucleus (Dang & Lee 1989; Addison et al., 1990). Mutation
of residues within the sequence also result in loss of nuclear localisation
(Addison et al., 1990).
The localisation of p53 within the cell is not constant and varies with the cell
cycle. In synchronised cells stimulated to grow by the addition of serum, p53
first appears in the cytoplasm coinciding with protein synthesis in a
perinuclear location and soon after can be detected in the nucleus during G1
and into early S phase. As S phase proceeds p53 is again found in the
cytoplasm (Shaulsky et al., 1990). The temperature sensitive mutant,
p53val'|35j which adopts a WT configuration at 32°C and a mutant
configuration at 37°C (Milner & Medcalf 1991) is detected within the nucleus
at 32°C and within the cytoplasm at 37°C (Gannon & Lane 1991; Ginsberg
et al., 1991). At 32°C the cells are growth arrested whereas at 37°C they
are actively proliferating. These data suggest that p53 in WT conformation
acts within the nucleus at G1 to arrest further replication events and then
relocates to the cytoplasm possibly coincident with a conformational change
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so allowing replication to proceed.
2.5 Properties and Functions of p53
The major functions of p53 appear to stem from its capacity to bind to other
cellular proteins, to itself and to DNA. Deriving from this are its regulatory
roles in the cell-cycle and as a transcription factor. The ensuing section
attemts to summarise the data supporting these major cellular roles.
p53 was originally isolated by virtue of its ability to bind SV40 large T antigen
(Lane & Crawford 1979; Linzer & Levine, 1979; Rotter, 1983). Subsequent
studies have implicated p53-protein interactions resulting in p53 inactivation
as frequent events in many systems. Complex formation can occur with
other p53 molecules (both WT and mutant), viral proteins and other
endogenous proteins.
2.5.1 Homologous Complexes
p53 will form high molecular weight, homologous complexes involving
interspecies p53 relatively quickly (Kraiss et al., 1988; O'Reilly & Miller
1988). This phenomenon is also detected between WT and mutant p53 from
the same species when they are co-translated but not when simply mixed in
vitro (Milner et al., 1991). In contradistinction to this, p53 from normal cells
(presumably of WT) exists in a low molecular weight monomeric form (Kraiss
et al., 1988). High molecular weight oligomers of p53 are chemically very
stable and require high salt concentration and denaturing detergent to bring
about their disaggregation (Kraiss et al., 1992).
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The formation of homologous p53 complexes can be shown to be dependent
upon the presence of the carboxy terminus of the protein as truncated
variants fail to oligomerize (Milner et al., 1991). This process may explain
how mutant p53 can act as an "oncogene" in the presence of WT p53. By
binding WT p53 into a complex and preventing its normal function, the
mutant protein would be acting in a dominant negative fashion by inactivating
a tumour suppressor whilst having no independent oncogenic function
(Herskovitz et al., 1987).
2.5.2 Heterologous Complexes
Studies have demonstrated that the products of several viruses bind p53
including SV40 large T antigen (Lane & Crawford 1979; Linzer & Levine,
1979; Rotter, 1983), E1b 55kDa protein of adenovirus 5 (Sarnow et al.,
1982), the E6 proteins of the human papillomaviruses HPV 16 and HPV 18
(Werness et al., 1990) and the large tumour antigen of lymphotropic
papovavirus (Symonds et al., 1991). In the case of SV40 T Ag this
complexing will only occur with WT p53 and not mutant p53 (Sturzbecker et
al., 1987; Finlay et al., 1988). It has also been shown that p53 forms high
molecular weight complexes with the constitutive 70kDa protein of the heat
shock protein family (Pinhasi-Kimhi et al., 1986; Hinds et al., 1987;
Sturzbecker et al., 1987) and that this association is confined to mutant p53
(Sturzbecker et al., 1987, Finlay et al., 1988; Romano et al., 1989).
WT p53 has a short half life of 6 minutes in spleen tissue (Rogel et al.,
1985) and 20-30 minutes in cell lines (Gronostajski et al., 1984). The half life
of p53 is greatly extended both in chemically transformed cells, where it is of
the order of 5 hours (Reich et al., 1983) and in SV40 transformed cells
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where it is about 20 hours (Oren et al., 1981). This extended life span of p53
may be due to complex formation with heterologous proteins such as SV40 T
Ag, or adenovirus E1b 55kDa protein (Reihaus et al., 1990) but
uncomplexed and stable p53 can be detected in SV40 transformed rodent
cells (Deppert et al., 1986). This increase in stability results in much higher
levels of p53 protein (Thomas et al., 1983) within transformed cells
(regardless of the method of transformation) when compared to their normal
counterparts.
The degradation of p53 occurs via a non-lysosomal ATP dependent
proteolytic pathway (Gronostajski et al., 1984) and although no specific
recognition sequences for degradation have been identified, loss of
sequences at the amino terminus result in increased p53 half life (Jenkins et
al., 1985; Rovinski et al., 1988). Binding of p53 to the E6 protein of HPV 16
and 18 results in more rapid degradation via an ATP dependent, ubiquitin
pathway (Scheffner et al., 1990).
Thus, viruses of diverse types have all evolved strategies for p53 inactivation
suggesting a critical role for p53 in preventing viral replication and possibly
cellular replication in the presence of such aberrant DNA.
MDM2 is a mammalian protein originally identified as an amplified gene in a
transformed mouse cell line (Fakharzadeh et al., 1991). It has been shown to
complex with both WT and mutant p53 (Oliner et al., 1992; Momand et al.,
1992) and to interfere with its transactivation function (Momand et al., 1992).
Amplification of the MDM2 gene has been detected in a proportion of human
sarcomas suggesting that the endogenous protein MDM2 is inactivating p53
by complexing with it in a fashion analogous to that seen with viral proteins.
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2.5.3 Other Protein-Protein Interactions
p53 is associated in vivo with two protein kinases for which it acts as a
substrate. The first is casein kinase II (CK-II) (Meek et al., 1990) which is
ubiquitous in both nucleus and cytoplasm of eukaryotic cells and is
stimulated by several mitogens. The second is cdc-2 kinase, a 34 kDa
protein which is linked to mitogenic commitment at G1 (Milner et al., 1990;
Bischoff et al., 1990; Sturzbecker et al., 1990). The significance of these two
kinases which are closely associated with p53 is not yet clear but p53 could
be involved in their transport into the nucleus at critical times in the cell cycle.
Phosphorylation of p53 at residues ser 37, ser 310 and/or 312, ser 389 and
one or more of serines 7, 9, 12, 18 and 23 has been described in SV40
transformed cells and NIH 3T3 cells. However, two fold higher levels of
phosphorylation are detected at serines 312 in the SV40 transformed cells
compared to NIH 3T3 raising the possibility that phosphorylation is involved
in cell transformation. However mutation of serines 312 to alanine or aspartic
acid or loss of serine 312 phosphorylation does not appear to alter the
properties of p53 (Meek & Eckhart 1990). Changes in conformation and
properties in the temperature sensitive mutant p53val135 are not associated
with phosphorylation changes suggesting that conformation alterations in WT
p53 are not secondary to phosphorylation (Picksely et al., 1992).
2.5.4 DNA Binding
Wild type p53 binds to DNA (Kern et al., 1991a) and this property is greatly
diminished by p53 mutation. Further analysis of p53 binding to SV40 DNA
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showed this to be sequence specific and also to be diminished in p53
mutants (Bargonetti et al., 1991). More specifically, murine p53 inhibits SV40
origin dependent DNA replication in SV40 transformed monkey cells
(Braithwaite et al., 1987) and human WT p53 has similar properties which
are again lost with p53 mutation (Friedman et al., 1990). To investigate the
specificity of this process more closely the binding of p53 to human genomic
clones in vitro was tested. Mapping of the p53 binding sites within the clones
obtained, revealed 2 copies of the 10 bp sequence 5'-
PnPnPnC(A/T)(A/T)GPyPyPy-3' (Kern et al., 1991b). Both sequences,
separated by up to 13 bp of random sequence were required for binding.
The sequences are symmetrical thus giving four copies in opposing
directions suggesting that p53 may bind in a tetrameric structure. Further
studies screening oligonucleotides for p53 binding produced a 20 bp
sequence very similar to that described above (Funk et al., 1992). It was also
shown that DNA binding is dependent upon the presence of nuclear extracts
when in vitro translated p53 is employed suggesting that post-translational
modification or complex formation with other nuclear proteins is required for
this function.
2.5.5 Intracellular Effects
Mutant p53 expression can immortalise both rat embryo fibroblasts (Rovinski
& Benchimol, 1988) and adult rat chondrocytes (Jenkins et al., 1984) acting
alone and can co-operate with ras to fully transform rodent embryo cells in
culture (Parada et al., 1984; Eliyahu et al., 1984). However, in similar
experiments on rodent cells in culture, WT p53 suppresses transformation
when co transfected with activated ras, E1b 55 kDa protein and mutant p53
(Hinds et al., 1989; Finlay et al., 1989). Expression of human WT p53 cDNA
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will inhibit proliferation of both Sacchromyces cervisiae (Bischoff et al., 1992)
and Schizosacchromyces pombe (Nigro et al., 1992) even though these
yeasts have no known p53 homologue of their own. Growth of cells cultured
from Friend virus-induced murine erythroleukaemia, human colorectal
cancers and human glioblastoma all undergo down-regulation of proliferation
when transfected with either murine or human WT p53 usually with arrest at
the G1/S boundary (Baker et al., 1990; Mercer et al., 1990; Johnson et al.,
1991). Chromosome transfer studies adding a normal human chromosome
17 (containing WT p53) to colorectal cancer cell lines which have lost or
inactivated both copies of p53 show a reduction in proliferation (Goyette et
al., 1992).
WT p53 is, therefore, classified as a tumour suppressor gene but it is still not
clear whether mutant p53 is a true dominant oncogene. A cell line lacking
any functional p53 develops enhanced tumourigenicity in
immunosuppressed mice when it is transfected with mutant p53 suggesting a
true oncogene effect as there can be no dominant negative effect on
endogenous WT p53 (Wolf et al., 1984). In other studies, the transfected
mutant p53 is under the control of a powerful promoter which results in high
levels of expression (Parada et al., 1984; Elijahu et al., 1984). These effects
could well be explained by a dominant negative action of the mutant p53 on
the endogenous WT p53 complexing with it or altering its conformation.
Although mutant p53 may exert its influence via "inactivation" of WT p53, the
possibility of a true oncogenic effect over and above this cannot be
discounted.
Apoptosis (programmed cell death) is a fundamental biological process
involved in tissue remodelling especially during embryogenesis and
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restricting the size of immature progenitor cell pools (Duvall & Wyllie 1986).
Within a tissue or a neoplasm changes in cell number depend upon the
balance between the rate of mitosis and the rate of apoptosis. Thus a
neoplasm can only grow if mitotic rate exceeds apoptotic rate. The
expression of wild type p53 in myeloid leukaemia cells results in rapid loss of
viability which is due to apoptosis (Yanish-Rouach et al., 1991). Stimulation
by interleukin 6 results in "rescue" of the cells from apoptosis. Mutant p53
under the same circumstances does not induce apoptosis. Thus a function of
WT p53 may be to limit certain cell populations by apoptosis at certain times
and then permit their growth when a suitable differentiation or proliferation
signal is received. Clearly, loss of cell population control by apoptosis
consequent upon loss of WT p53 could lead to population expansion and
neoplasia.
Expression of WT p53 in acute phase, chronic myeloid leukaemia cells,
which lack endogenous p53 expression, results in a return of some features
of differentation seen in chronic phase cells (Feinstein et al., 1992). The
mechanism for this effect remains obscure but holding cells in G1 for a
greater length of time may be critical.
The amino terminal 73 residues of p53 have been shown to act as
transcriptional activators both in vivo (Fields & Jang 1990; Raycroft et al.,
1990) and in vitro (Farmer et al., 1992) and this property is greatly
diminished by mutation (Raycroft et al., 1990; Farmer et al., 1992). Further
studies have mapped this activation domain to an area between codons 20
and 42 (Linger et al., 1992).
Sequence specific DNA binding and transcriptional activation suggest that
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p53 may activate the transcription of genes adjacent to its DNA binding site.
The work of Kern et al., 1992 and Funk et al., 1992 confirm this view. Co-
transfection of a p53 expression vector and a p53 binding site upstream of a
reporter gene resulted in high levels of reporter gene expression. This result
has been repeated in a yeast system making it much more likely that p53 is
acting directly and not via specific intermediates as no p53 homologue has
been detected in yeast (Scharer & Iggo 1992; Kern et al., 1992).
Mutation of p53 results in diminished DNA binding (Kern et al., 1991, 1992)
and transcriptional activation (Raycroft et al., 1990; Kern et al., 1992; Farmer
et al., 1992). In addition to this mutant/WT p53 complex formation can
interfere with WT p53 function (Kern et al., 1992, Farmer et al., 1992).
DNA damage caused by y irradiation, UV irradiation or chemical mutagens in
both cultured cells and normal keratinocytes results in a rise in p53 levels
and associated G1 arrest (Maltzman & Czyzyk,, 1984; Kastan et al., 1991;
Hall et al., 1993). These effects can be abolished by preventing p53
production using a protein synthesis inhibitor and are not detected in cell
lines containing either mutant p53 or no p53 (Kastan et al., 1991). These
findings are in complete accord with the other findings of G1 arrest produced
by WT p53 expression previously discussed and the rise in p53 levels in G1
seen in normal cells (Reich & Levine, 1984) and suggest that p53 has a role
in preventing DNA replication until DNA repair has taken place in G1
following DNA damage. This hypothesis could also explain the large
numbers and varied types of tumours developed by patients with a germ-line
p53 mutation (Malkin et al., 1990; Srivastava et al., 1990) and in mice with
no p53 (Donehower et al., 1992) or over-expressing mutant p53 (Lavigueur
et al., 1989) and the instability of cultured fibroblasts from Li-Fraumeni
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syndrome patients (Bischoff et alM 1990). Inactivation by complexing or
enhanced degradation of p53 by the gene products of viruses is also
compatible with this theory as viral infection could well result in G1 arrest by
WT p53 and abolition of this effect would be necessary to permit viral
replication. Wild type p53, therefore, has a central role in protecting the cell
from replicating in the presence of DNA damage. This appears to be brought
about by the transcription of as yet, undiscovered genes. Loss or inactivation
of p53 results in genetic instability with cellular immortalization and the
development of aneuploidy (Bischoff et al., 1990) and neoplastic growth.
2.6 p53 in Carcinogenesis
In keeping with its central role in protecting the genome from replicating in
the presence of DNA sequence errors, p53 appears to be the commonest
genetic target in human carcinogenesis (Hollstein et al., 1991). Chromosome
deletions including the gene for p53 along with p53 mutation, rearrangement
and complexing with amplified endogenous or viral proteins have all been
described. The evidence for and relevance of these processes will be
discussed.
In man, the gene for p53 has been mapped to chromosome 17p13 (Isobe et
al., 1986). Loss of genetic material for the short arm of chromosome 17 is a
frequent event in colorectal cancer, ranging from 0-75% depending upon the
study (Lothe et al., 1988; Vogelstein et al., 1988; Okamato et al., 1988, Law
et al., 1988; Monpezat et al., 1988; Vogelstein et al., 1989; Sasaki et al.,
1989; Delattre et al., 1989) and possibly the care with which samples were
taken to minimize contamination with normal tissue (Vogelstein et al., 1988).
In those studies where tissue microdissection was employed, the frequency
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of 17p allele loss ranges from 56-75% (Law et al., 1988; Vogelstein et al.,
1988; Delattre et al., 1989). Those studies showing less frequent loss of 17p
alleles (0-27%) were conducted in Japan and may represent racial genetic
differences (Okamato et al., 1988; Sasaki et al., 1989).
Loss of 17p alleles is also a frequent finding in many other common human
cancers including small cell and squamous carcinoma of the lung (Yokota et
al., 1987; Weston et al., 1989), breast (Devillee et al., 1988; Mackay et al.,
1988), bladder (Tsai et al., 1990), glioma (James et al., 1988) and ovary
(Eccles et al., 1992).
In order to delineate the minimum region of overlap of chromosome 17p
deletion, a large series of colorectal cancers (Baker et al., 1989) and breast
cancers (Coles et al., 1990) were studied with numerous DNA probes
mapping to 17p. This region, in colorectal cancers lay between probes
EW505 and YNZ22.1 spanning 17p12 to17p13.3 and covering approximately
33cM (sex-averaged distance between markers D17S5 and D17S67: Wright
et al., 1990). This region includes the p53 gene locus at 17p13.1 (Baker et
al., 1989) and as a tumour suppressor gene it was proposed as the target for
such deletions. The finding that the remaining p53 gene copy is frequently
mutated further suggested that p53 was being inactivated in a fashion similar
to RB1 in retinoblastoma (Cavanee et al., 1983). In a similar study on a
much larger series of breast cancers (Coles et al., 1990) the data were
incompatible with a single shortest region of overlap of 17p deletion and
suggested two loci: one centred on probe MCT35.1 and another on
YNZ22.1.
Mutation of the p53 gene also appears to be a common event in human
68
cancers. They have been demonstrated in cancer of the colorectum (Nigro et
al., 1989; Baker et al., 1989, 1990; Rodrigues et al., 1990; Cunningham et
al., 1992), lung (Nigro et al., 1989; Iggo et al., 1990; Chiba et al., 1990;
Henzel et al., 1992), breast (Nigro et al., 1989; Prosser et al., 1990; Varley et
al., 1991; Thompson et al., 1992), bladder (Sidransky et al., 1991),
glioblastoma (Nigro et al., 1989), astrocytoma (Fults et al., 1992), stomach
(Tamura et al., 1991) and hepatocellular carcinoma (Brassac et al., 1991;
Hsu et al., 1991). The majority of the mutations described in these studies
can be found in the highly conserved regions of the p53 gene designated II-
IV (Soussi et al., 1987) (figure 2.1). In a study of non-small cell lung
carcinomas, Chiba et al., 1990, proposed that the distribution of the
mutations detected mapped more closely to the SV40 large T antigen
binding sites (Jenkins et al., 1988) which has been proposed as a binding
site for a putative endogenous ligand.
A review of the current literature shows that the spectrum of mutation varies
depending upon the tissue studied (figure 2.3). Tumours of the colorectum
and brain most frequently contain G to A and C to T mutations, whereas
these are relatively uncommon in lung and hepatocellular carcinoma in Africa
in which G to T transversions predominate. This presumably represents
exposure to a different spectrum of mutagens in cigarette smoke (Chiba et
al., 1990) and aflatoxin B (Brassac et al., 1991; Hsu et al., 1991). The
pattern of base pair substitution in breast cancers is also different with G to T
transversion being the most common (as in lung cancer) but with C to G
mutation also frequent whereas these are very rare in other types of tumour.
Thus, each tumour has a different spectrum of base pair substitution
presumably reflecting the varied exposure to mutagens. Although the
mutations all tend to occur in the conserved regions ll-IV, they clearly differ
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between tissues and this may have important implications for the behaviour
of the different mutant proteins (Halevy et al., 1990).
Mutation of p53 and loss of the remaining (presumably) WT allele tend to
occur together in colorectal tumours (Baker et al., 1989; 1990; Cunningham
et al., 1992). These events are much commoner in colorectal carcinomas
than adenomas. Moreover, where carcinoma and adenoma portions of the
same tumour can be analysed separately, mutation and allele loss are
present in carcinoma but not adenoma, suggesting that the two events are
closely linked and occur at or about the adenoma to carcinoma transition
(Baker et al., 1990). A similar close correlation between p53 mutation and
17p allele loss is seen in bladder cancer (Sidransky et al., 1991). p53 would
therefore appear to be behaving in a similar way to RB1 in retinoblastoma
(Kundson 1971; Cavanee et al., 1983).
However, similar studies on cancers of the lung and breast have failed to
demonstrate a correlation between 17p allele loss and p53 mutation (Chiba
et al., 1990; Varley et al., 1990; Thompson et al., 1992). In the case of breast
cancer, this may be due to another locus on 17p acting as a target for
deletion (Coles et al., 1990). It may also represent the fact that mutated p53
can act as an oncogene even in the presence of a WT copy (possibly in a
dominant negative fashion) although not all mutant p53 proteins are equal in
their abilities either to co-operate with ras, to oligomerize WT p53 or to force
it into a mutant conformation when co-translated (Halevy et al., 1990; Milner
& Medcalf 1991). The different range of mutations seen in tumours arising
from different tissues (figure 2.3) may confer different properties on particular
mutants from particular tissues.
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Inactivation of p53 by gross gene rearrangement has also been described
both in cultured Friend virus enytholeukaemia cells (Mowat et al., 19985)
and in human osteoscaroma (Masuda et al., 1987; Miller et al., 1990)
although not in any other of the common human malignancies. The
functional inactivation of p53 by complexing with viral proteins SV40 T Ag
adenovirus E1b protein and large tumour antigen of lymphotropic
papovavirus, binding to HPV 16 and 18 E6 protein resulting in enhanced p53
degradation and complexing with amplified levels of MDM2 have already
been discussed (section 2.5.3
The importance of p53 in preventing carcinogenesis can be seen in three
systems which have a constitutive, germ-line p53 abnormality: Li-Fraumeni
syndrome; transgenic mice over expressing mutant p53; and the gene
targeted p53 null mouse. Li-Fraumeni syndrome is a rare dominantly
inherited human disease characterised by a spectrum of early onset cancers
including breast carcinoma, soft tissue sarcomas, brain tumours,
osteosarcoma, leukaemia and adrenocortical carcinoma (Li & Fraumeni
1969). Inheritance of the syndrome is linked directly to germ line p53 gene
mutations (Malkin et al., 1990, Srivastava et al., 1990; Borresen et al., 1992).
The affected individuals from 6 families studied proved to possess mutations,
most closely grouped in conserved domain IV (Soussi et al., 1987) whereas
unaffected siblings had WT p53. DNA extracted from 2 tumours from
affected individuals and cell lines derived from patients showed loss of the
remaining WT allele (Malkin et al., 1991; Srivastava et al., 1992) in a fashion
analogous to that seen in familial retinoblastoma (Cavanee et al., 1983).
Transgenic mice which over express the p53 val 135 develop (in 20% of
cases) an excess of lung adenocarcinoma, osteosarcoma and lymphomas
(Lavigueur et al., 1989). There is a long latency however and relatively low
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penetrance suggesting that many other factors are involved in this process.
Over-expression of mutant p53 in this system is likely to be acting in a
dominant negative fashion although formal demonstration of WT allele
retention in tumours was absent. Mice which have lost both copies of p53,
although developmentally normal, develop sarcomas, lymphoma and
osteosarcoma at a very early age (Donehower et al., 1992).
1.6.8 Conclusion
p53 has a central role in the well-being of cells by delaying DNA
replication until DNA repair has been completed. This process is
carried out by transactivation of as yet unidentified genes and its
importance can be gauged from the fact that p53 abnormalities are the
commonest genetic lesions detected in human cancer. This thesis
concerns the study of the role of p53 in colorectal carcinogenesis.
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Over-expression of p53 has been demonstrated immunohistochemically in a
wide range of common human malignancies including colon (van den Bergh
et al., 1989; Rodriguez et al., 1990; Purdie et al., 1991; Scott et al., 1991;
Cunningham et al., 1992; Kikuchi-Yanoshita et al., 1992), breast (Cattoretti
et al., 1988; Bartek et al., 1990; Ostrowski et al., 1991; Varley et al., 1991;
Thompson et al., 1992), lung (Iggo et al., 1990; Bodner et al., 1992), ovary
(Eccles et al., 1992), squamous cell carcinoma of larynx (Maestro et al.,
1992), gastric carcinoma, malignant melanoma, embryonal carcinoma of the
testis, transitional cell carcinoma of the bladder, carcinoma of the uterus and
soft tissue sarcoma (Bartek et al., 1991). In the case of breast cancer, a
correlation between p53 over-expression and certain immunohistochemical
and histopathological indicators of poor prognosis has been demonstrated
(Cattoretti et al.; 1988), suggesting that p53 over-expression may be
associated with enhanced tumour aggression. However, another study
(Ostrowski et al., 1991) using clinical outcome as their end-point, could not
demonstrate a correlation between p53 over-expression and prognosis.
Although the study was relatively small (90 cases as opposed to 200 in the
study of Cattoreti et al., 1988) the expected correlation of lymph node status
and tumour grade with clinical outcome was clearly demonstrated suggesting
that sufficient numbers of patients were included to make the analysis valid.
The reaction product marking antibody binding, in each of these studies was
confined to neoplastic cells. In the majority of tumours studied including
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colon cancer and non-small cell lung cancer the staining was almost
exclusively nuclear (van den Bergh et al., 1989; Rodriguez et al., 1990; Iggo
et al., 1990; Bartek et al., 1991) whereas in breast and small cell lung cancer
cytoplasmic as well as nuclear staining was detected (Cattoretti et al., 1988;
Iggo et al., 1990; Varley et al., 1991). In normal cells, p53 is undetectable by
immunohistochemical methods due to its low levels and short half-life
(Dippold et al., 1981; Rogel et al., 1985). Mutation of p53 can result in
increased protein stability and a greatly extended half-life (Jenkins et al.,
1985) permitting its immunohistochemical detection. Mutation, at many sites
within the p53 gene, also results in a conformation alteration which changes
its immunoreactivity. Wild-type (murine) p53 reacts with PAb246 (Yewdell et
al., 1986) and PAb1620 (Milner et al., 1987) whereas mutant p53 fails to
bind PAb246 or PAb1620 but reacts with PAb240 (Gannon et al., 1990).
Thus, PAb240 binds specifically to mutant p53 (human and murine) and in
immunohistochemistry binds the same cells as the conformation
independent antibodies PAb421 and PAb1801 (Rodriguez et al., Bartek et
al., 1990; 1990, Varley et al., 1991) suggesting that immunohistochemically
detectable p53 is mutated.
Wild-type p53 is usually localised in the cell nucleus (Dippold et al., 1981;
Rotter et al., 1983; Deppert & Haug, 1986) but a cytoplasmic location has
been described in some non-transformed cell lines (Rotter et al., 1983).
Localisation of p53 may be modulated during the cell cycle spending short
periods in the cytoplasm and cell membrane during mitosis (Milner & Cook,
1986) and accumulating in the nucleus in late G1 (Shaulsky et al., 1990).
Mutation of p53 alters its conformation and protein binding characteristics
(Gannon et al., 1990) resulting in loss of SV40 large T antigen binding (Tan
et al., 1986) and acquisition of hsp 72/73 heat-shock-related protein binding
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(Sturzbecher et al., 1987; Hinds et al., 1987). Hsp 72/73 is found in the
nucleus and the cytoplasm, thus binding of mutant p53 to cytoplasmic hsp
72/73 may be responsible for its cytoplasmic distribution in some tumours
(Cattoretti et al., 1988; Iggo et al., 1990). Studies involving the temperature
sensitive mutant p53 val135 have demonstrated that at 37°C (when it
behaves as a mutant protein) it is located within the cytoplasm but at 32°C
(WT) it relocates to the nucleus (Gannon & Lane, 1992; Oren et al., 1992).
This process is reversible and appears to depend upon a short lived
cytoplasmic anchor protein and not upon hsp 72/73 binding (Gannon &
Lane, 1992). Whether these properties are exclusive to p53 val135 or pertain
to other p53 mutatants remains to be seen but another mutant, p53 cys270
does not show this property (Halevy et al., 1990).
Over-expression of p53 has been demonstrated in 55% of sporadic
colorectal carcinomas and 10% of sporadic adenomas using PAb421 on
cryostat sections (van den Bergh et al., 1988). Higher frequencies of over-
expression in FAP associated carcinomas and adenomas were also
demonstrated although the numbers studied were rather small. No
correlation with degree of adenoma dysplasia was found and no association
with prognostic indicators was studied. Rodriguez et al (1990) studied 10
colon cancer cell lines and demonstrated that the 6 which had p53 mutations
on sequence analysis were positive immunohistochemically with PAb1801
and PAb240. In another study of p53 expression in primary colorectal
carcinomas, Scott et al (1991) demonstrated immunoreactivity for PAb421 in
42% of 52 carcinomas. Staining was confined to neoplastic nuclei and was
seen in 70% or more of nuclei in positive cases. In five cases multiple
samples were analysed and no intra-tumour heterogeneity was observed.
No correlation was demonstrated between positive immunostaining and
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markers of tumour aggression or clinical outcome but PAb421 positive cases
were more frequently distal to the splenic flexure than proximal and had (in
those which were DNA diploid) a higher rate of cell proliferation as assessed
by flow cytometry. Fibroblasts cultured from patients with germ-line p53
mutations (Li-Fraumeni syndrome) spontaneously immortalize very readily
and develop aneuploidy at high frequency (Bischoff et al., 1990). DNA
aneuploidy measured by flow cytometry is a common finding in colorectal
cancer which has been shown to correlate with poor prognosis independent
of other prognostic indicators (Quirke et al., 1987). Heterogeneity of DNA
content within different regions of colorectal cancers is also common
indicating the presence of clonal divergence (Quirke et al., 1987).
This chapter concerns the study of a large consecutive series of colorectal
carcinomas and polyps for p53 over-expression. Immunohistochemistry
using PAb1801 (Banks et al., 1986) was carried out on PLPD fixed, paraffin
sections from 86 carcinomas and 62 polyps once it had been established
that the results for positivity were identical for material processed in this
manner when compared to cryostat sections. Previous studies have been
limited to cryostat sections as the PAb1801 epitope is destroyed by
formaldehyde fixation. The use of PLPD and paraffin sections permitted a
much superior morphologic resolution of immune reaction product. A subset
of the carcinoma series was also studied using the mutant p53 specific
antibody PAb240 (Gannon et al., 1990). The correlation of staining with well
recognised indicators of clinical outcome was investigated. Multiple samples
of each tumour were studied for DNA ploidy by flow cytometry to investigate
whether p53 over-expression was related to DNA aneuploidy and clonal
divergence within a single tumour.
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3.2 Results
3.2.1 PAb1801 immunostaining of colorectal carcinomas
Reaction product, marking the binding of PAb1801, was confined to the
nuclei of neoplastic cells (figure.3.1). Normal cells, including colonic mucosa,
never stained in cytoplasm or nucleus. Rarely pale staining was observed in
smooth muscle cells (particularly of blood vessels) at high antibody
concentrations but not at the working dilution. Staining within the tumour
nucleus (figure.3.2) was granular or reticular in nature sometimes with
obvious nucleolar sparing. During mitosis, reaction product was reduced
dramatically (figure.3.2), whereas interphase tumour cells never showed
cytoplasmic staining. The tumours divided unequivocally into two groups on
the basis of PAb1801 immunohistochemistry. Tumours were scored as
positive when staining was visible in any nuclei within the tissue section. In
such cases, positive nuclear staining of identical incidence and distribution
was found even when the concentration of primary antibody was reduced to
1:400 or increased to 1:10.
Similarly cases scored negative remained without staining in any cells even
at concentrations as high as 1:10. A subset of 53 carcinomas were stained
as cryostat sections at a dilution of 1:100. The distribution of PAb1801
staining within cells and within the tissue was identical in PLPD-fixed and
frozen section. No discrepancy in the assignment of PAb1801 positivity
between frozen and paraffin sections was found.
In positive tumours the pattern of immunostaining was not uniform. In a small
number of tumours almost all the nuclei stained positively, but the more
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common pattern was an admixture of tumour acini which showed no staining
with those in which most nuclei were stained. The greatest proportion of
positive cells was found in acini at the invasive margins of carcinomas.
Sometimes the distinction was obvious within a single gland, with strong
staining on the outer (invasive) side of a carcinoma and weak, or none, on
the inner side (figure.3.3).
In total, 87 carcinomas from 87 patients were analysed with PAb1801 and of
these 41 (47%) showed positively stained nuclei. Prognostic indicators
(Dukes' stage, degree of tumour differentiation and nature of invasive
margin) and DNA aneuploidy, showed no significant correlation with
PAb1801 staining (table 3.1). Similarly the proportion of PAb1801 positive
tumours was unrelated to their site within the colon or rectum (table 3.1).
Immunoblots of total protein extracted from SV80 cells (known to express
high levels of p53) and tissue samples (figure. 3.4) demonstrated that
PAb1801 recognises a single 53 kDa protein which could be extracted from
those tumours which were immunohistochemically positive but not from
negative tumours or normal colonic mucosa. In a series of 5 cases on which
both immunohistochemistry and immunoblotting were carried out, the
detection of a 53 kDa protein in immunoblots correlated exactly with positive
staining in frozen or paraffin sections.
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Figure 3.1 PLPD-fixed, paraffin-embedded colorectal carcinoma tissue
immunostained using PAb1801 with a light haematoxylin counter-stain. Low
power view showing positively stained carcinoma nuclei and adjacent
negatively stained normal mucosa (X 40).
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Figure 3.2 PLPD-fixed, paraffin-embedded colorectal carcinoma tissue
immunostained using PAb1801 with a light haematoxylin counter-stain. High
power view showing granular staining pattern confined to nuclei and several
mitotic cells (arrowed) exhibiting reduced intensity of staining compared to
other carcinoma nuclei (X 400).
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Figure 3.3 PLPD-fixed, paraffin-embedded colorectal carcinoma tissue
immunostained using PAb1801 with a light haematoxylin counter-stain.
Heterogeneity of staining with more marked staining at the invasive margin




Table 3.1 Correlation of PAb1801 immunostaining with histopathological
classification, DNA ploidy, and primary tumour site for carcinomas.
Classification PAb1801 - PAb1801 + p value*
Dukes A 2 5
Dukes B 23 18
Dukes C 21 18 NS
Margin: Infiltrating 40 36
: Expanding 7 5 NS
Differentiation: Other# 19 24
: Poor 26 18 NS
DNA Diploid 14 6
DNA Aneuploid 32 35 NS
Distal colon 28 27
Proximal colon 15 13 NS
* Chi-square test with Yates' correction for continuity.
# Well or moderately differentiated.
NS, not significant (p>0.05).
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Figure 3.4 Immunoblot of total protein stained using PAb1801. Lane 1:
SV80 cells. Lane 2: Normal colonic mucosa. Lane 3: Immunohistochemically
positive carcinoma. Lane 4: Immunohistochemically negative carcinoma.
Lanes 5 and 6: Immunohistochemically positive carcinomas. Lane 7: SV80









3.2.2 PAb1801 immunostaining of colorectal adenomas
Fifty-five sporadic polyps from 30 patients were studied with PAb1801
comprising 9 metaplastic (hyperplastic) polyps and 46 adenomas. The
metaplastic polyps were all negative. Of the 46 adenomas, 4 (8.7%) were
positive (table 3.2). The positively staining nuclei were dispersed throughout
the adenoma in one case (figure. 3.5) and in the remaining 3 were restricted
to only a few glands. All 4 showed either moderate or severe dysplasia, but
there is no statistically significant correlation within this series with other
morphologic parameters or tumour size (table 3.2). In one large villous
adenoma which contained foci of infiltrative carcinoma, however, PAb1801
staining was absent in the adenoma but present in the infiltrative glands only.
In addition PLPD-fixed material was available from 9 tubular adenomas (all
less than 4 mm in diameter) from 2 patients undergoing colectomy for FAP:
all were negative for PAb1801 immunostaining. The difference in incidence
of positive staining in adenomas as compared with carcinomas is highly
significant (table 3.2).
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Table 3.2 Correlation of PAb1801 immunostaining with histopathology of
adenomas.
Classification PAb1801 - PAb1801 + p value *
FAP adenomas 9 0
Metaplastic polyps 9 0
Tubular adenomas 1 2
Tubulovillous adenomas 11 2
Villous adenomas 12 0 NS
Maximum diameter of
adenoma #
> 10mm 29 3
< 10mm 13 1 NS
Dysplasia: Mild 5 0
: Moderate 34 2
: Severe 3 2 NS
Sporadic adenomas 42 4
Carcinomas 47 40 p<0.001
* Chi-square test with Yates' correction for continuity.
NS, not significant (p>0.05).
# Sporadic adenomas only.
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Figure 3.5 PLPD-fixed, paraffin-embedded colorectal adenoma tissue
immunostained using PAb1801 with a light haematoxylin counter-stain.




3.2.3 PAb240 immunostaining of colorectal carcinomas
PAb 240 immunostaining was carried out on a subset of 45 carcinomas from
which frozen material of suitable quality was available. The overall pattern
and distribution of immunostaining was almost identical to that described for
PAb1801. Reaction product was confined to the neoplastic cell nuclei, with a
non-uniform distribution within the tumour, although in some cases almost all
the tumour nuclei were stained (figure. 3.6)
Of the 45 carcinomas studied, 22 (48.9%) showed positive staining. No
significant correlation with prognostic indicators (Dukes' stage, nature of
invasive margin and tumour differentiation) or tumour site within colon or
rectum was demonstrated (table 3.3) but PAb240 immunostaining did
correlate with DNA aneuploidy and this finding prompted further analysis.
Comparison of PAb1801and PAb240 immunostaining demonstrated a highly
significant correlation (p<0.001, table 3.3)
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Figure 3.6 Immunostaining of a colorectal carcinoma using PAb240 on
acetone-fixed, cryostat section with a light haematoxylin counterstain (X
200).
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Table 3.3 Correlation of PAb240 immunostaining with histopathological
classification, DNA ploidy, primary tumour site and PAb1801 immunostaining
for carcinomas.
Classification PAb240 - PAb240+ p value*
Dukes A 0 2
Dukes B 9 8
Dukes C 14 12 NS
Margin: Infiltrating 19 20
: Expanding 4 2 NS
Differentiation: Other# 11 12
: Poor 12 10 NS
DNA Diploid 11 2
DNA Aneuploid 12 12 p<0.02
Distal colon 14 14
Proximal colon 7 8 NS
1801 - 22 5
1801 + 1 17 p<0.001
* Chi-square test with Yates' correction for continuity.
# Well or moderately differentiated.
NS, not significant (p>0.05).
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3.2.4 p53 expression and DNA ploidy
Comparison of positive p53 immunostaining (positive with PAb240 and/or
PAb1801) with DNA aneuploidy also demonstrates a significant correlation
(figure 3.7). In a sub-set of 42 cases, the flow cytometry had been carried
out on a minimum of 3 areas of each tumour sampled fresh. These cases
gave the highest quality of DNA histogram (figure 3.8) permitting accurate
identification of different clones within a single tumour. Tumours exhibiting
positive immunostaining were significantly more likely to be aneuploid and
also to contain multiple neoplastic stem lines (table 3.4).
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Figure 3.8 DNA histograms obtained from two samples of a single
carcinoma. The x axis shows the relative DNA content of each nucleus and
the y axis the number of nuclei. The diploid peak (G0/G1) is arbitrarily
assigned a DNA index of 1 and an internal standard (IS) of avian
erythrocytes is included which has a DNA index of 0.35. (a) a diploid area of
carcinoma (histological examination of tissue adjacent to that used for flow
cytometry confirmed the presence of greater than 50% neoplastic nuclei),
(b) an aneuploid region of the same carcinoma showing a small diploid peak
(D) and a larger aneuploid peak (A) with a DNA index of 1.6. The aneuploid




Table 3.4 Correlation of p53 immunostaining with DNA ploidy and the
number of different clones defined by flow cytometry. Diploid cases had
peaks with a DNA index of 1 in all tumour samples. Aneuploid cases were
defined as having one clone if all samples had the same non-diploid DNA
index and more than one clone if samples had DNA indices differing by more
than 0.1.
PAb1801/240 Diploid Aneuploid Aneuploid Totals
immunostaining 1 stem-line >1 stem-line
Positive 4 2 15 21
Negative 10 6 5 21
Totals 14 8 20 42
p < 0.05 (Chi-square test with Yates' correction for continuity).
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3.3 Discussion
The data demonstrate a strong relationship between p53 expression and
malignant transformation in colorectal tumours. In contrast to carcinomas,
very few adenomas showed p53 expression and those which did all
belonged to the more dysplastic categories in which the risk of transition to
invasive carcinoma is higher. In one case of a villous adenoma which had
undergone malignant change, p53 expression was restricted to the frankly
carcinomatous portion sparing the dysplastic epithelium. In the carcinomas,
the advancing edge was the most consistently staining region. Nonetheless,
approximately one half of all colorectal carcinomas did not show p53
expression, and comparison of expressing and non-expressing carcinomas
revealed no differences in terms of the tumour site or established prognostic
indicators such as histologic grade (Jass et al., 1986) and Dukes' stage
(Dukes, 1932). The majority of the tumours studied in this consecutive series
were (as expected) of Dukes' B and C stages, therefore the lack of
correlation with staging is essentially an indicator that p53 expression has no
association with tendency to form lymph node metastasis. It appears,
therefore, that p53 expression is associated with the transition from
adenoma to carcinoma in some colorectal tumours but does not uniquely
determine infiltrative activity or relate to other features of carcinoma
progression.
The monoclonal antibody PAb1801 is specific for human p53, its epitope
being between amino acids 32 and 79 (Banks et al., 1986) at the amino
terminal of this protein. Its epitope is distant from the sites of mutation so far
described (Nigro et al., 1989; Baker et al., 1990; Rodriguez et al 1990) and it
will thus bind wild-type and mutant p53. No immunoreactivity is detected in
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any normal tissue in this study, therefore the positively staining cells are
likely to contain mutated p53, detectable by virtue of the concomitant
increase in half-life (Jenkins et al., 1985). The analysis of a subset of the
carcinomas with PAb240, which is specific for the mutant conformation
(Gannon et al., 1990) confirms that there is a very high concordance
between the two groups (p<0.001, table 3.4) and that the intra-tumour and
intra-cellular distribution is almost identical. The relationship between
mutation and expression is not a simple one and depends at least on the
specific mutation (Bodner et al., 1992). In colorectal cancer, more than 90%
of the p53 mutations are located within exons 5-9 (Rodrigues et al., 1990;
Baker et al., 1992; Cunningham et al., 1992; Kikuchi-Yanoshita et al., 1992)
and these are the mutations which tend to produce immunohistochemically
detectable p53 (Bodner et al., 1992). Thus immunohistochemically
detectable p53 is likely to represent mutated forms of the protein (see also
chapter 5).
The p53 detected immunohistochemically in this series was exclusively
nuclear in distribution, in agreement with published studies (van den Bergh
et al., 1988; Rodriguez et al., 1990, Scott et al., 1991). Studies on breast
cancers and small cell lung cancer (Cattoretti et al., 1988; Iggo et al., 1990;
Varley et al., 1991) have demonstrated a number of cases with cytoplasmic
staining. Whether this is due to complexing of mutant p53 with cytoplasmic
hsp 72/73 (Sturzbecher et al., 1987) or whether the mutation affects the
nuclear localisation signal (Addison et al., 1991) is not yet clear. From the
p53 val135 model it might be predicted that mutant protein would be
localised to the cytoplasm (Mickalovitz et al., 1990; Gannon & Lane, 1992)
but this does not appear to be the case (Rodrigues et al., 1991; Cunningham
et al., 1992) suggesting that this observation may depend upon the particular
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mutation. Differences in the types of mutation detected in different classes of
tumour, as a result of exposure to a different set of environmental
carcinogens, may reflect this differential intracellular localisation.
Breast carcinomas which express p53 tend to be in poorer prognostic groups
(Cattoretti et al., 1988). In this series, p53 immunostaining correlates with
DNA aneuploidy which is a recognized independent prognostic variable
suggesting that p53 positive tumours may give a poorer prognosis (table
3.3). Clinical follow-up, however, is required to discover if this association is
relevant to prognosis.
Within some of the sections showing positive immunostaining there was
marked cell-to-cell heterogeneity; a feature described previously (Scott et al.,
1991). The mutation of p53 is likely to be clonal (Fearon et al., 1987),
therefore this variation in protein level may indicate that mutated p53 is
under similar cell cycle control to that demonstrated in WT p53 with levels
increasing prior to S phase (Reich and Levine, 1984; Shaulsky et al., 1986).
Cell-cycle related changes in protein level are also suggested by the greatly
reduced immunostaining in mitotic cells. The distribution of positively stained
cells around the advancing margins is a novel feature and may indicate
greater replicative activity of invading cells or some form of inductive
interaction with stromal tissues.
In 6 cases of the 45 studied with both PAb1801 and PAb240 there was a
discrepancy in the result. One case was PAb1801 positive but PAb240
negative probably representing a truncating mutation removing the epitope
for PAb240 (amino acids 213-217, Stephen & Lane, 1992) but retaining that
of PAb1801; some of these have been described (Baker et al., 1990). The
106
remaining 5 cases are PAb1801 negative but PAb240 positive probably as a
result of mutations which fail to increase the half-life of the protein sufficiently
to be detected by PAb1801 or else cause a conformational change at the
amino terminal sufficient to prevent PAb1801 binding. Thus, a small number
of cases which are negative for p53 immunostaining may contain mutations
but use of more than one one antibody will minimise this problem.
Aneuploidy is a common finding in human colorectal tumours which is
associated with the malignant phenotype and poor prognosis. Cytogenetic
evidence suggests that aneuploidy may arise from non-disjunctive mitosis in
tetraploid cells (Nowell, 1976; Reichmann et al., 1981) or from chromosome
breakage. Over-expression of p53, (probably representing mutated protein
which has lost its normal tumour suppressor function) is linked to the
presence of DNA aneuploidy and the presence of multiple divergent clones.
The evidence suggests that WT p53 causes cell-cycle arrest in G1 in
response to DNA damage to permit repair prior to DNA replication. The loss
of this vital function could facilitate endoreduplication and the appearance of
aneuploidy with the generation of multiple divergent clones some of which
will possess selective growth advantages. This may be the case in colorectal
cancer.
The data presented here show that the expression of p53 acts at or about
the stage of the acquisition of malignant potential in colorectal
tumourigenesis. Although p53 expression does not appear to have any
influence on the appearance of lymph node metastesis it does relate to the
emergence of aneuploidy and multiple divergent clones consistent with the
current hypothesis that p53 has a "genomic surveillance" role to prevent
replication prematurely in the cell cycle or in the presence of DNA damage.
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When this function is lost, genomic instability will result predisposing to the
emergence of clones with a growth advantage and properties such as
invasion and metastasis which define malignancy.
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Chapter 4
Mapping the Deletion on Chromosome 17
4.1 Introduction
Genetic abnormalities involving chromosome 17 were initially identified in
colorectal cancers by cytogenetic techniques which showed loss of
chromosome 17 as one of the most frequent abnormalities (Reichmann et
al., 1981) . Subsequent studies using RFLP markers have identified loss of
17p alleles in up to 75% of colorectal cancers (Lothe et al., 1988; Vogelstein
et al., 1988; Okomato et al., 1988; Law et al 1988; Monpezat et al., 1988;
Vogelstein et al., 1989; Sasaki et al., 1989; Delattre et al., 1989). Fine
mapping of the region of deletion using a number of RFLP markers for
chromosome 17p was carried out on a series of 58 colorectal carcinomas of
which only 8 were suitable for detailed analysis (Baker et al., 1989). All the
tumours in this series were microdissected to enrich for neoplastic cells by
extracting DNA only from areas containing greater than 70% cancer nuclei
(Fearon et al., 1987; Vogelstein et al., 1988). This in turn introduced an
element of selection bias to the tumour series as certain classes of
carcinoma, such as those eliciting a marked desmoplastic response or
lymphocytic infiltration would have been excluded.
The common region of deletion identified in this study spanned an area
between probes YNZ 22.1 (D17S5) and EW505 (D17S30) which covers
17p12 to 17p13.3 (Baker et al., 1989). This region covers some 33cM of the
chromosome arm (sex averaged genetic distance between markers D17S5
and D17S67 [telomeric to D17S30] Wright et al., 1990). A similar study was
carried out for osteosarcoma (Toguchida et al., 1989) on 37 tumours. The
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region deleted in all cases spanned D17S1 (pHF12-1) to D17S5 (YNZ 22.1)
covering approximately 15cM (sex averaged genetic distance, Nakamura et
al., 1988).
Loss of 17p alleles is a frequent finding in a number of other common
human cancers including breast (Mackay et al., 1988; Devilee et al., 1989),
lung (Yokata et al., 1987; Weston et al., 1989), bladder (Tsai et al., 1990),
glioma (James et al., 1988), astrocytoma (Fults et al., 1992) and ovary
(Eccles et al., 1992). Only in the case of breast cancer has the deletion been
mapped to a similar degree to colorectal cancer (Baker et al., 1989). Coles
et al (1989) studied a series of 168 breast cancers using RFLP probes on
17p. In 26 of these cases there was less that total 17p arm loss which
permitted analysis of the common region of deletion. Two independent,
deleted regions on 17p were identified, one centred on MCT35.1 (D17S31)
and another near YNZ22.1 (D17S5). Interestingly, both these loci could fall
within the region identified in colorectal cancer (Baker et al., 1989) and
osteosarcoma (Toguchida et al., 1989).
The gene for p53 is located on chromosome 17p13.1 placing it within the
deleted region of colorectal cancer (Baker et al., 1989). The remaining p53
allele in cases with 17p deletion is frequently mutated in colorectal cancer
(Baker et al., 1989; Cunningham et al., 1992; Kikuchi-Yanoshita et al., 1992)
suggesting that p53 is indeed the target for such deletions in a fashion
analogous to RB1 inactivation in retinoblastoma (Cavanee et al., 1983).
However, similar studies in breast and lung cancer have failed to
demonstrate any such correlation of p53 mutation with 17p loss (Chiba et
al., 1990; Varley et al., 1991; Thompson et al., 1992). A further study on 17p
loss in breast cancer showed a strong association with the presence of
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lymph node metastasis which was statistically significant at the YNZ22.1
locus but not at the p53 locus. This indicates the presence of two
independent and clinically relevant loci on chromosome 17p in human
cancer.
The common region of deletion on chromosome 17p so far defined in
colorectal cancer is relatively large and encompasses 2 independent regions
identified as targets for allele loss in breast cancer (Baker et al., 1989; Coles
et al., 1989). The biology of p53 suggests that the mutant protein may
inactivate the WT protein by complexing it into high molecular weight
oligomers or altering its conformation during translation (Milner et al., 1991;
Milner & Medcalf, 1991). Thus concomitant WT allele would appear
redundant and without selective growth advantage under such
circumstances.
To study the common region of deletion in an independent series of
colorectal tumours, a consecutive series of 90 colorectal carcinomas and
two large villous adenomas were studied for chromosome 17 allele loss
using 5 primary structure polymorphisms (RFLPs). The cases did not
undergo any pre-selection in terms of relative quantities of tumour and
stroma to avoid bias. Three of the polymorphisms used were located close
to, or within the p53 gene to examine this region in depth as a likely target
for the deletion. To investigate the association between 17p allele loss and
clinical outcome, cases with and without 17p deletions were correlated with




Five RFLPs were used to investigate the loss of alleles on chromosome 17
(table 4.1). Three of them, YNZ22.1, MCT35.1 and THH59 are probes which
detect RFLPs by hybridisation to restriction endonuclease digested, genomic
DNA after Southern transfer (Southern, 1975). The remaining 2, p53 E4 and
p53 16, are detected by PCR amplification of sequence within the gene for
p53 to include primary structure polymorphisms within exon 4 (p53 E4,
Banks et al., 1986) and intron 6 (p53 16, Chumakov, 1989) detected by
restriction endonuclease cleavage (figure 4.1). Genomic DNA for Southern
blotting was extracted from macroscopically dissected fresh tumour material
whereas that for PCR amplification was obtained from microscopic
dissection of formalin fixed, paraffin embedded tumour to enrich for
neoplastic cells.
Loss of alleles from 17p13 was detected in 47-57% of all tumours analysed
whereas only 20% had undergone loss of 17q alleles (table 4.1). The pattern
of bands and the physical site of the RFLP are indicated (figure 4.1 a,b). In
44 of the cases there were data from more than one RFLP on 17p13
permitting more detailed analysis of the extent of the deleted region. Of the
44, 17 had retained all alleles at informative sites, whereas 27 (61%) had
loss of heterozygosity (LOH) of at least one allele (table 4.2). In 11 cases
there was less than total 17p arm loss permitting analysis of the region
deleted. A summary of the 11 cases of sub-arm allele loss shows 3 basic
patterns (figure 4.1 c). The first 4 cases show retention of heterozygosity
telomeric to p53 but loss of alleles within the p53 gene itself. In the next 5,
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there is LOH at the telomere with retention of alleles within p53 suggesting a
breakpoint between p53 and MCT35.1 or YNZ 22.1 consistent with a lesion
involving p53 or a more telomeric locus. The remaining 2 cases show loss of
YNZ 22.1 but retention of MCT35.1; no information from within p53 being
available. Both of these cases show loss of a chromosome 17q allele raising
the possibility that the region spanning MCT35.1 may have become
translocated or isolated with loss of the remainder of chromosome 17
including p53. It is perhaps more likely, however, that both copies of p53
have been retained in these cases. The 17q marker loss may well have
occurred in the other chromosome 17 from that showing 17p deletion again
consistent with p53 locus retention.
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Table 4.1 Summary of restriction fragment length polymorphism analysis of
chromosome 17. LOH - percentage of informative (heterozygous) cases




Site Enzyme LOH (n) Reference
YNZ22.1 D17S5 Taq 1 55% (69) Nakamura et al.,1987
MCT35.1 D17S31 Msp 1 57% (30) Barker et al., 1987
p53 I 6 p53 Msp 1 56% (18) Chumakov, 1989
p53 E 4 p53 BstU 1 47% (34) Matlashewski et al.,
1987
THH59 D17S4 Taq 1 20% (64) Nakamura et al., 1987
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Table 4.2 Analysis of allele loss on 17p in cases where information from
more than one locus is available.











Totals 44 44 (100%)
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4.2.2 17p allele loss and p53 expression
Comparison of 17p allele loss with p53 expression detected
immunohistochemically by PAb240 or PAb1801 (chapter 3) shows a highly
significant correlation (figure 4.2). This correlation is maintained when the
allele status is restricted to loci within or adjacent to the p53 gene (table 4.3).
Loss of 17p alleles is also significantly associated with the presence of DNA
aneuploidy but not with tumour stage, grade or site (table 4.4).
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Table 4.3 Correlation of chromosome 17p allele loss at MCT35.1, p53E4 or
p53l6 with p53 expression (immunohistochemical positivity with PAb240 or
PAb1801).
Immunohistochemistry 17p loss 17p
retention
Total
p53 + 19 9 28
p53 - 6 19 25
Totals 25 28 53
p < 0.01 chi-square test with Yates' correction for continuity.
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Table 4.4 Correlation of chromosome 17p allele loss with tumour stage,
histology, site and DNA ploidy.
Classification 17p loss 17p retention p value*
Dukes A 4 3
Dukes B 20 13
Dukes C 22 17 NS
Margin: Infiltrating 38 29
: Expanding 8 4 NS
Differentiation: Other 25 13
: Poor 20 20 NS
DNA Diploid 7 13
DNA Aneuploid 40 20 p<0.05
Distal colon 33 20
Proximal colon 13 10 NS
p53 + 31 9
p53 - 16 24 p<0.01
* Chi-square test with Yates' correction for continuity.
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4.2.3 17q allele loss and markers of tumour aggression
Similar analysis with 17q allele losses revealed a significant correlation with
the presence of lymph node metastasis (Dukes' stage C) compared to their
absence (Dukes' B) but not with DNA ploidy or tumour histology (table 4.5).
Table 4.5 Correlation of chromosome 17q allele loss with tumour stage,
histology, site and DNA ploidy.
Classification 17q loss 17q retention p value*
Dukes A 2 3
Dukes B 2 29 p<0.05*
Dukes C 8 19 p=0.034#
Margin: Infiltrating 9 45
: Expanding 3 6 NS
Differentiation: Other 4 29
: Poor 8 22 NS
DNA Diploid 3 13
DNA Aneuploid 10 37 NS
Distal colon 11 32
Proximal colon 2 16 NS
* Chi-square test with Yates' correction for continuity.
# Fischer's exact test.
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4.3 Discussion
Allelic loss in colorectal carcinoma was detected in approximately 55% of
cases in this series, which is in accord with previous studies (Vogelstein et
al., 1988; Lothe et al., 1988; Monpezat et al., 1988; Okomato et al., 1988;
Law et al., 1988; Vogelstein et al., 1989; Sasaki et al., 1989; Delattre et al.,
1989). Loss of a 17q marker in 20% is slightly higher than the frequencies of
0-15% previously reported (Lothe et al., 1988; Law et al., 1988; Vogelstein
et al., 1989). One particular group consistently detect higher rates of LOH at
17p (and other loci) which they suggest is due to their tissue fractionation
technique to select and enrich for neoplastic cells (Vogelstein et al., 1988;
1989). They detect 17p LOH in at least 75% of colorectal cancers whereas
only 55% were detected here. However, 17q loss is seen in 20% of this
series but only in 15% in studies using tissue fractionation (Vogelstein et al.,
1989) suggesting that the different frequency of allele loss in this series is a
genuine finding and not simply due to normal tissue contamination masking
allele loss.
In the majority of cases showing loss of one allele on 17p there is total arm
loss (table 4.2) confirming earlier work (Baker et al., 1989). Eleven cases in
this series show less than complete loss of 17p (figure 4.1 c). In 4 of them
there is p53 gene loss with retention of more telomeric markers which
reinforces the need to use more than one RFLP and not simply rely upon
highly informative, sub-telomeric VNTR probes (Cunningham et al., 1992).
The next 5 cases have lost alleles telomeric to p53 but retained alleles within
p53. This pattern suggests a breakpoint between p53 and the telomere. This
could conceivably still involve the p53 gene although gene rearrangements
including truncation appear to be rare in colorectal cancer (Masuda et al.,
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1987). A Southern blot of digested genomic DNA probed with genomic p53
could distinguish whether this is the case but this pattern suggests retention
of both p53 alleles. The final 2 cases (figure 4.1 c) have lost YNZ22.1 but
have retained MCT35.1 (a marker close to and telomeric to p53, Baker et
al., 1989, Solomon & Ledbetter, 1991) suggesting a chromosome lesion
retaining p53.
Therefore, in the majority of cases, the results are consistent with p53 or a
gene in the same region as the target for 17p deletions. However, in 7
cases, the pattern is more suggestive that both copies of the p53 gene are
retained and there is loss of distinct genetic material from chromosome 17p.
One explanation is that there is another tumour suppressor locus which is
the target for deletion in a small number of cases. There is evidence for a
distinct locus in the case of breast cancer at such a site (Coles et al., 1991;
Takita et al., 1992). Another explanation is that in these few cases (7/44,
16%) the loss of alleles is a more "random" event which is conceivable given
that allele loss has been detected on every arm of every chromosome so far
examined in colorectal cancer with a "background" frequency of 10-20%
(Vogelstein et al., 1989).
The allele deletion mapping data, therefore, support the hypothesis that p53
is the tumour suppressor gene target for 17p loss in colorectal cancer. The
overexpression of p53 reported previously (Van den Bergh et al., 1988;
Purdie et al., 1991; Scott et al., 1991) is closely linked to 17p allele loss in
this series (table 4.3). This correlation is maintained when the allele status of
the RFLP markers closest to the p53 gene is used (table 4.3) in the analysis.
Thus, the 2 events are closely linked, which is in agreement with data
presented (chapter 3) for the timing of p53 over expression (at the adenoma
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to carcinoma progression) and other work suggesting a similar timing for 17p
loss (Vogelstein et al., 1988).
As discussed in chapter 3, overexpression of p53 detected
immunohistochemically is most likely to represent mutation of the p53 gene
resulting in a product with a greatly enhanced half-life (Jenkins et al., 1985).
The concordance of 17p allele loss and p53 expression (and probable
mutation) suggests a mechanism of tumour suppressor gene inactivation
analogous to that seen in retinoblastoma (Cavanee et al., 1983). Gene
sequencing to investigate the relationship of mutation to protein expression
in this series is necessary to confirm this finding and is the subject of chapter
5.
Loss of chromosome 17p alleles in colorectal cancer can be shown to
predict clinical outcome (Kern et al., 1989). Cases with 17p allele loss are
statistically more likely to develop and also to die from metastasis. This trend
is independent of Dukes' stage and gives independent prognostic
information. No correlation, in this series, with the established prognostic
indicators of Dukes' stage (Dukes, 1932) or histopathologic grade (Jass et
al., 1986) could be detected but actual clinical follow-up data are required to
investigate this fully. 17p allele loss does however correlate with the
presence of DNA aneuploidy (table 4.4) as does p53 expression (and thus
mutation). This further reinforces the hypothesis that the 17p allele loss is
targeted upon p53 as p53 inactivation appears to permit the development of
aneuploidy (Bischoff et al., 1991) possibly by permitting premature
replication or replication in the presence of damaged DNA.
DNA aneuploidy is also an independent prognostic variable in human
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colorectal cancer (Quirke et al., 1988) and the association with 17p loss
suggests that 17p loss marks more aggressive tumours. This is consistent
with the finding that patients with colorectal cancer showing 17p loss have a
poorer prognosis. Clinical follow-up data are required to investigate this
trend more fully.
The frequency of allele loss on the long arm of chromosome 17 is 20%
which is higher than any previous report (Lothe et al., 1988; Law et al., 1988;
Vogelstein et al., 1989). This is likely to represent targeted loss of a further
tumour suppressor gene rather than merely "background" loss in view of the
association with lymph node metastasis. There are several candidate genes
which have been mapped to this region. The nucleoside diphosphate
kinases NM23-1 and NM23-2 have been localised to chromosome 17q21.3
(Backer et al., 1993). These genes were originally isolated due to their
expression in murine melanoma cell lines of low metastatic potential (Steeg
et al., 1988). Subsequent studies demonstrated that for primary human
breast carcinomas, low NM23 expression correlated with regional lymph
node metastases and decreased disease free survival (Bevilacqua et al.,
1989; Henessy et al., 1991). Allelic deletions of NM23 in colorectal
carcinomas with no evidence of of metastasis at the time of resection
correlate with the development of metastatic disease (Cohn et al., 1991).
However, it is now clear that the NM23 genes are expressed at elevated
levels in colorectal tumours of both high and low metastatic potential and are
not mutated (Myerhoff & Markowitz, 1993; Haut et al., 1993). Thus, NM23
does not appear to be the target for 17q deletions. This study and others
(Cohn et al., 1991) do however indicate the presence of a metastasis
suppressor gene in the region. Early onset familial breast cancer and familial
breast-ovarian cancer are linked to a locus at 17q12-23 (Hall et al., 1990;
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Narod et al., 1991). Recently, mutations in the prohibitin gene (which also
maps to 17q21) have been identified in sporadic breast cancer suggesting
that it may be a tumour suppressor gene involved in breast carcinogenesis
(Sato et al., 1992). Further candidate genes on chromosome 17q include the
truncated epidermal growth factor receptor (ERB B2) oestradiol-176
dehydrogenase (EDHB 17), homeobox 2 (HOX 2), retinoic acid receptor a
(.RARA) and WNT 3 (Solomon & Ledbetter, 1991). Careful mapping of the
deletions of 17q in colorectal cancers and analysis of candidate genes for




The data presented here clearly show that 17p loss in colorectal cancer
involves the gene for p53 (in the majority of cases) and is closely associated
with p53 expression (representing mutation). This suggests that inactivation
of both copies of p53 is an important step in colorectal carcinogenesis. This
hypothesis is further strengthened by the demonstration that 17p loss
correlates with DNA aneuploidy (as does p53 expression) consistent with
p53 inactivation cuasing genomic instability by permitting inaccurate or
premature DNA replication.
DNA aneuploidy is a marker of poor prognosis in colorectal cancer
suggesting that 17p loss in this series may also mark more aggressive
tumours as has been described previously (Kern et al., 1989). The novel
finding that 17q loss is associated with the presence of lymph node
metastasis may indicate a tumour metastasis suppressor gene locus and
further deletion mapping and close study of candidate genes is necessary to





Mutations of the p53 gene have been described in the majority of human
cancers (reviewed in section 2.6). Germ-line mutation of one copy of p53
described in Li-Fraumeni syndrome, predisposes to the early onset of
multiple primary malignancies which show loss of the WT gene copy (Malkin
et al., 1990; Srivastava et al., 1990; 1992). Thus, it has been proposed that
mutation of one copy of the p53 gene is often followed by deletion (or
inactivation by second mutation) of the remaining wild-type copy in a fashion
analogous to that seen in retinoblastoma (Cavanee et al., 1983). Such a
pattern of inactivation of both p53 gene copies has indeed been described in
colorectal cancer (Nigro et al., 1989; Baker et al., 1990; Cunningham et al.,
1992), astrocytoma (Fults et al., 1992) and bladder cancer (Sidransky et al.,
1991). In all these studies, cases with 17p allele loss but without p53
mutation and p53 mutation without allele loss have been identified. In the
case of lung cancer (Chiba et al., 1990) the concordance of 17p allele loss
and p53 mutation is less clear cut and for breast cancer there does not
appear to be any such correlation (Varley et al., 1991; Thompson et al.,
1992).
Overexpression of p53 detected immunohistochemically appears to correlate
well with p53 gene mutations in most studies (Bartek et al., 1990; Iggo et al.,
1990; Rodrigues et al., 1990; Cunningham et al.,1992; Kikuchi-Yanoshita et
al., 1992) employing a variety of antibodies. However, in some studies the
concordance is not as close (Borresen et al., 1991; Thompson et al., 1992)
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In these cases, breast cancer was under investigation, which has marked
heterogeneity of immunostaining making sampling bias a source of error
(Varley et al., 1991; Thompson et al., 1992).
Over expression of p53 is closely associated with the transition from
adenoma to carcinoma, the appearrance of DNA aneuploidy, clonal
divergence and 17p allele loss in colorectal carcinogenesis and appears to
have a key role in this process (chapters 3 and 4). To try to identify the
mechanisms underlying this over expression, 12 cases were selected for p53
gene sequence analysis. Of the 12, 6 exhibited loss of 17p alleles defined by
YNZ22.1 and MCT35.1 and 6 did not. In each sub-set of 6, 3 were
immunohistochemically positive with PAb1801 and 3 negative.
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5.2 Results
Exons 5-9 were amplified by the polymerase chain reaction (PCR) from
genomic p53 extracted from tumour and corresponding normal tissue.
Amplified DNA was ligated into a plasmid vector and a preparation of greater
than 100 clones sequenced by the dideoxy chain termination method. Base-
pair substitutions were detected on sequencing gels in 7 of the 12 cases
studied (figures 5.1, 5.2). Six of the mutations were located within conserved
regions lll-V (Soussi et al., 1987) (table 5.1) of the p53 gene. The
concordance between PAb240 and PAb1801 immunostaining was, as
expected, very good with only one discrepancy. Case number 89-143
contains a mutation, Arg -» STOP at codon 213 and is PAb240 positive but
PAb1801 negative.
The correlation between the presence or absence of a mutation and the
immunostaining was absolute in this small series (p=0.013) (table 5.2). In
every case, p53 gene analysis from the patient's normal DNA gave wild-type
sequence, thus excluding germ-line mutations or PCR artefact as a source of
the base-pair substitutions detected in the cancers.
Comparison of p53 gene status and 17p allele status (at the RFLP closest to
p53) revealed a tendency for cancers with mutated p53 to have lost the
remaining WT gene copy and for heterozygous cancers to have only WT p53
(table 5.3). This pattern does not reach statistical significance but shows the
same bias as tables 4.3 and 4.4.
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Figure 5.1 Sequence from case 89-143. Sequence from the patient's
constitutive DNA (N) and from the tumour DNA (T).showing a CGA->TGA
mutation at codon 213. This tumour has lost the remaining WT gene copy;
but a faint WT sequence is still present from small quantities of normal cells



















Figure 5.2 Sequence from case 88-878. Sequence from the patient's
costitutive DNA (N) and from the tumour DNA (T) showing a CGG->CAG




















































































































































Table 5.2 Correlation of p53 immunohistochemistry (with PAb 240 and/or
PAb1801) with mutation defined by sequencing
Immunohistochemistry Mutant p53 Wild-type p53 Totals
P53 Positive 7 0 7
p53 Negative 0 5 5
Totals 7 5 12
p = 0.0013 (Fischer's Exact Test)
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Figure 5.3 Correlation between p53 mutation defined by sequencing and
17p loss defined at the closest informative locus to p53
17p Status Mutant p53 Wild Type p53 Totals
LOH 5 2 7
HET 2 3 5
Totals 7 5 12
p > 0.05 Not significant.
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5.3 Discussion
The mutations detected in this series of colorectal cancers raise a number of
issues and will be discussed in terms of their relationship to those described
in other studies, p53 immunohistochemistry and 17p allele loss.
5.3.1 p53 mutation
Of the 12 cases studied, 7 had single base-pair substitutions within the
coding region of the p53 gene resulting in amino acid substitutions or STOP
codons in two cases. Six of the mutations are within conserved regions lll-V
of p53 (Soussi et al., 1987) and within the 2 SV40 large T antigen binding
sites (Jenkins et al., 1988) in agreement with previous studies on colorectal
cancer (Baker et al., 1990; Rodrigues et al., 1990; Cunningham et al., 1992)
and other common human cancers (Iggo et al., 1990; Chiba et al., 1990;
Bartek et al., 1990; Thompson et al., 1992).
The mutations detected here show a similar distribution to those described
previously in colorectal cancer (Baker et al., 1990; Rodrigues et al., 1990;
Cunningham et al., 1992; Kikuchi-Yanoshita et al., 1992) with G-A and C-T
transitions predominating and a hot-spot at codon 248. Deamination of
methyl cytosine may be responsible for the C-T transitions (Rideout et al.,
1990) and mutagens such as MNNG and NMS are known to cause GC to AT
transitions (Miyaki et al., 1983) but their relevance to human colorectal
carcinogenesis is unclear. Now that the specific mutations found in human
colorectal cancer have been identified, the search for the environmental
factors specifically responsible for them can begin (section 1.2).
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5.3.2 p53 mutation and immunohistochemistry
In this small series the concordance between the presence of a mutation on
p53 gene sequence analysis and immunostaining with PAb240 and
PAb1801 is absolute. This confirms the property that PAb240 binds to a
conformationally altered p53 brought about by mutations at many sites
(Gannon et al., 1990). PAb1801 will bind both WT and mutant p53 (Banks et
al., 1986) but the marked positive correlation of PAb1801
immunohistochemistry with PAb240 immunostaining and with the presence
of gene mutation is highly suggestive that it is detecting mutated and
stabilised p53.
In some studies, discrepancies between p53 overexpression and p53 gene
mutation have been encountered (Thompson et al., 1992). This may be due
to simple sampling error as already discussed (section 5.1) or to the nature
of mutation encountered in certain tissues. In cell lines from small cell and
non-small cell lung cancers, mis-sense mutations in exons 5-8 of p53 result
in high expression of immunohistochemically detected protein whereas
deletions, splicing mutants and mis-sense mutations outside exons 5-8 result
in low or absent expression (Bodner et al., 1992). As more than 90% of
mutations described in colorectal cancer are base-pair substitutions within
exons 5-8 of p53 (Baker et al., 1989; 1990; Rodrigues et al., 1990;
Cunningham et al., 1992; Kikuchi-Yanoshita et al., 1992)
immunohistochemistry should detect the majority of mutations as appears to
be the case in this study and others (Rodrigues et al., 1990; Cunningham et
al., 1992; Kikuchi-Yanoshita et al., 1992). In other tissues, such as lung
cancer, where mutations other than base pair substitutions in exons 5-8 are
more common, immunohistochemical detection of p53 may be a less reliable
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marker of gene mutation.
Case number 89-143 shows a discrepancy between immunostaining with the
two antibodies, being PAb240 positive but PAb1801 negative. This particular
mutation, Arg to STOP at codon 213 has been described in two other
tumours which were strongly positive for PAb240 but showed weak or
negative staining with PAb1801 (Cunningham et al 1992; Bodner et al.,
1992). As the epitope for PAb1801, amino acids 35-79 (Banks et al., 1986) is
unaltered, this suggests that truncation has resulted in an altered protein
conformation which masks this epitope. The epitope for PAb240 has recently
been mapped to an area centred on codons 213-217 (Stephen & Lane,
1992). The finding of strongly positve PAb240 immunostaining in cases with
STOP codons at position 213 in this study and others (Cunningham et al
1992; Bodner et al., 1992) suggests that the epitope is nearer the amino
terminal than codon 213. Discrepancies between antibodies are infrequent
but do occur and reinforce the need to use more than one antibody in
analysis.
5.3.3 p53 mutation and 17p loss
In 71% of the cases with p53 mutation described here, the remaining WT
allele is lost. However, in some cases, one allele is inactivated by mutation
or deletion whereas an apparently normal WT allele remains. At least 3
possible explanations exist for this: the second event is yet to occur in the
tumour progression; there is a selection advantage in reduction to half gene
dosage; or the mutant gene product is inactivating the WT p53 by a
dominant negative action. Indeed, some mutations can produce
immortalisation and cooperate with ras in transformation assays even in the
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presence of 2 WT alleles (Eliyahu et al., 1984). However, not all mutations
have identical biological properties and some may therefore require WT
allele loss to express the full p53 inactivation phenotype whereas others may
not (Halevy et al., 1990).
Two of the mutants in this series (89-143 and 89-167) produce STOP
codons at amino acids 213 and 180 respectively which would presumably
result in a truncated protein product. Both these cases have lost the WT
gene copy. The formation of heteroligomers between mutant and WT p53
requires amino acids 345-366 (Milner et al., 1991) and the ability of certain
mutant proteins to force a co-translated WT protein into a mutant
conformation also depends upon carboxy terminal amino acids (Milner &
Medcalf, 1991) absent in these cases. Expression vectors encoding a
truncated p53 are unable to immortalise cells containing endogenous WT
p53 whereas full length vectors can (Jenkins et al., 1985) suggesting that the
carboxy terminal amino acids are required for a dominant negative action.
This could explain why there is selective pressure for WT allele loss in cases
89-143 and 89-167 as these truncating mutants would be unable to exert a
dominant negative effect by oligomerising or changing the conformation of
the WT protein. There may still be a phenotype associated with half gene
dosage which would be a factor in these cases even in the presence of the
WT p53.
Mutants which have been described in the Li-Fraumeni syndrome (Malkin et
al., 1991; Srivastava et al., 1991) are also deficient in their ability to alter the
conformation of co-translated WT protein to that of mutant protein (Milner &
Medcalf, 1991). Two cases here have mutations described in Li-Fraumeni
patients (Malkin et al., 1991): Arg-Trp at codon 248. One case, 89-022, as
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might be predicted, has lost the WT allele but the other, 89-037, has not.
Case 89-037 is a relatively early Dukes' B stage carcinoma and it may be
that WT allele loss has yet to occur in its progression. Retention of both
alleles when one has this mutation has been described previously in
colorectal cancer (Kikuchi-Yanoshita et al., 1992).
Two cases 88-632 and 88-805 exhibit LOH without p53 overexpression or
mutation. In both cases there is definite loss of 17p alleles including the p53
gene locus itself (table 5.1). A possible explanation for this is that mutations
are present but are outwith the region sequenced. This appears to be rather
rare, and none has been described outwith exons 5-9 in colorectal cancer
(Baker et al., 1989; 1990; Rodrigues et al., 1990; Cunningham et al., 1992;
Kikuchi-Yanoshita et al., 1992) and in addition, both cases are negative for
PAb240 and PAb1801 immunostaining. Such cases are infrequent but make
up approximately 6-13% in other series (Baker et al., 1990; Cunningham et
al., 1992). A possible explanation is that half gene dosage caused by the
allele loss is sufficient to produce a selective growth advantage or that there
is a mutation in regulatory sequences outwith the gene itself resulting in low
levels of expression.
The correlation between 17p allele loss and p53 expression (tables 4.3 and
4.4) almost certainly represents a correlation between mutation of one p53
allele and loss of the remaining WT allele. This is in agreement with other
studies (Baker et al., 1989; 1990; Cunningham et al., 1992; Kikuchi-
Yanoshita et al., 1992) suggesting that inactivation of p53 in a two step
process is very common in colorectal carcinogenesis. In a minority of cases
there is mutation or overexpression of p53 in the absence of detectable
allele loss. This could be due to mutation of both alleles (Baker et al., 1990);
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certain mutations exerting a dominant negative effect over the WT allele
rendering the second (WT deletion) event unnecessary; the second event
being yet to happen in the progression of the particular tumour studied; or
reduction of gene dosage by half producing a selection advantage. Some
cases show loss of 17p alleles without evidence of mutation or
overexpression perhaps suggesting an effect of half gene dosage or p53
gene regulatory sequence disruption resulting in low or absent expression.
Disruption of p53 detected by over expression, allele loss or mutation was
detected in more than 70% of cancers in this series making it the commonest
genetic defect in colorectal cancer.
146
5.4 Summary
The data presented in chapters 3-5 of this thesis provide information on the
role of p53 in colorectal carcinogenesis. Deletions of chromosome 17p
usually involve the p53 gene locus and are strongly associated with p53
expression which is due in turn to gene mutation. Thus, both copies of p53
are commonly inactivated in human colorectal cancer.
Particular mutations produce p53 molecules with differing properties and it
may be that subsequent inactivation of the WT allele will give no further
growth advantage or else the phenotype may not be expressed fully until the
WT p53 has been removed. This may explain some of the cases with a
mutation which retain both alleles.
Over expression of p53 (representing gene mutation) correlates significantly
with malignant rather than benign colorectal neoplasia, the presence of DNA
aneuploidy and, in particular, clonal divergence. Thus alterations in p53
occur at the time of adenoma-carcinoma transition and may indeed be
responsible for this progression. A possible molecular mechanism for this
has recently been suggested (Lane, 1992). Abnormal, inactive p53 has the
effect of reducing transcription of genes which cause G1 arrest following
DNA damage. Hence, DNA repair may not occur prior to replication and so
allowing premature replication and propogation of sequence errors. This in
turn would predispose to more rapid proliferation and the appearance of
aneuploidy and multiple divergent clones some with the properties of tissue
invasion and the ability to metastasize. Thus p53 has a central role to play in
human colorectal carcinogenesis.
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The correlation of 17p loss and p53 expression with DNA aneuploidy also
suggests that detection of these abnormalities may provide useful prognostic
information. In the future this may permit a more rational approach to
therapy. Identification of the aetiology of the spectrum of mutations identified
in colorectal cancer may also permit appropriate preventive measures to be





Gene targeting is a process by which modifications are introduced into a
region of interest in chromosomal DNA by means of recombination with a
specifically engineered, homologous, exogenous DNA sequence. This
phenomenon depends upon the cells' intrinsic ability to mediate
recombination events between homologous DNA sequences. To introduce
the subject of gene targeting, the mechanisms of homologous recombination
and the features of both extrachromosomal and chromosomal recombination
in mammalian cells will be discussed.
6.1.1 Homologous recombination
Homologous recombination was initially described in bacteria (Smith, 1989)
and yeast (Orr-Weaver et al., 1981) and subsequently demonstrated
between 2 non-replicating exogenous plasmid sequences in mammalian,
somatic cells (Folger et al., 1982). The precise mechanism of homologous
recombination remains obscure but it involves the exchange of genetic
information between homologous DNA sequences and can occur during
meiosis, mitotic cell growth and DNA repair. Two general models have been
proposed to explain homologous recombination in yeast and mammalian
cells. The first is based on the Holliday model (Holliday et al., 1964) modified
by Meselson and Radding (1975) to explain the observation that
heteroduplex DNA usually forms on one chromatid. In this model (figure
6.1a), the 3' end of a single strand nick invades its homologue displacing a
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loop and acting as a primer for DNA synthesis. Ligation produces a Holliday
junction which can migrate and finally resolve by cutting the crossed strands
with or without isomerisation around the crossover.
The alternative model was postulated to account for the finding that
homologous recombination can be greatly enhanced by the introduction of a
double strand break into the DNA and missing sequences can be restored
using information from the chromosome (Orr-Weaver et al., 1981). In this
model (figure 6.1b), recombination is initiated by a double strand break. One
3' end invades the homologous duplex producing a loop which is enlarged
by repair until it reaches and anneals to the remaining strand of the
exogenous DNA. Repair of this strand results in two Holliday junctions which
can migrate and resolve by crossover cutting.
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Figure 6.1 Models of homologous recombination. (A) The Meselson-
Radding model. Recombination is initiated (a) by a single-strand nick on one
of the two interacting duplexes. The 3' end of the nicked strand acts as a
primer for DNA synthesis which displaces the strand ahead of it. The
displaced single strand invades the other duplex at a homologous site,
displacing a D loop (b). The single stranded D loop is degraded, and the
invading strand is ligated in place. The region of heteroduplex DNA is
expanded (c) by DNA synthesis on the first duplex and by degradation of the
second duplex. After the production of the asymmetric heteroduplex DNA
stops, either branch migration or isomerization can bring the 5' and 3' single-
stranded ends together permitting ligation. The resulting Holliday junction (d)
can move along the duplex generating symmetric heteroduplex DNA (e).
Resolution can yield either the crossover (f) or the non-crossover (g)
configuration. (B) The double strand break repair model. A double strand cut
is made in one duplex (a), and a gap flanked by 3' single strands is formed
by exonuclease action. One 3' end invades a homologous duplex, displacing
a D loop (b) which is enlarged by repair synthesis until the other 3' end can
anneal to complementary single stranded sequences (c). Repair synthesis
from the second 3' end completes the process of gap repair, and branch
migration results in 2 Holliday junctions. Resolution of the 2 junctions leads
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6.1.2 Extrachromosomal homologous recombination in mammalian
cells
Although the mechanism of homologous recombination is still not clear, a
great deal of work has been carried out on how to increase the efficiency of
this process. Much of the early work involved the introduction into
mammalian cells of a potential but crippled selectable marker, reconstitution
of which required a homologous recombination event. Thus, two copies of
the neomycin phosphotransferase gene (neo) which confers resistance to
G418, containing seperate, non-overlapping, disabling mutations were
introduced into mammalian cells by nuclear injection or calcium-phosphate
transfection. The survival of cells depended upon homologous
recombination to produce a functional neo conferring survival in selectable
(G418) medium (Kucherlapati et al., 1984; Folger et al., 1985a & b). Such
experiments demonstrated that the frequency of recombination is roughly
\
proportional to the length of homology and although detectable homologous
recombination is seen with only 25bp of homology (Ayares et al., 1986) this
is 2 orders of magnitude less than that seen with 500bp. Linearised DNA is
much more efficient than supercoiled DNA (Folger et al., 1982) and
homologous recombination is further enhanced by cleavage of the
exogenous DNA within the region of homology (Kucherlapati et al., 1984).
Homologous recombination is a relatively rapid process, taking place within
1 hour of coinjection of DNA (Folger et al., 1985a & b).
Timing of the introduction of the exogenous DNA relative to the phase of the
cell cycle also appears to be important, with homologous recombination
peaking during early to mid S-phase (Wong & Capecchi, 1987). The
relatively high frequency of homologous recombination events described in
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these experiments is not simply due to high concentrations of injected DNA
as the process is equally efficient when as few as 5 molecules of each
crippled gene are injected at different nuclear sites (Folger et al., 1985a &
b). Thus, the kinetics of homologous sequences coming together does not
seem to be rate-limiting.
These data demonstrated the feasibility of encouraging homologous
recombination between 2 exogenous DNA sequences and paved the way for
experiments to target into sequences of cellular DNA.
6.1.3 Chromosomal homologous recombination in mammalian cells
Expression of herpes simplex virus thymidine kinase (HSVf/c) confers the
ability to proliferate in HAT medium and neo expression renders cells
resistant to G418. Thomas et al (1986) demonstrated that cells with stably
integrated, but mutationally inactivated, HSW/c or neo could be made
resistant to HAT medium or G418 respectively by the nuclear injection of
another copy of the gene carrying a different mutation. Only homologous
recombination between the two sequences could produce a functional gene
capable of permitting growth in selection media. This process occurred at
high frequency (1 per 103 cells receiving DNA) and was again independent
of the number of molecules injected or the site of the integrated sequence.
Thus, finding the relevant sequences in 3 x 109 bp of cellular DNA does not
appear to be a rate limiting step and the site of the original integration does
not influence the frequency of homologous recombination (although there
may be bias for the original site of integration) suggesting that most of the
genome is accessible to the recombination machinery.
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The frequency of integrations by non-homologous (illegitimate)
recombination exceed by a factor of at least 100 homologous recombination
events (Thomas et al., 1986). Therefore, in the absence of a selectable
phenotype, specifically targeted homologous recombination events can be
difficult to detect. Smithies et al (1985) were the first to demonstrate the
insertion of DNA sequences into an endogenous human gene (8 globin) by
homologous recombination. The targeting was detected by an elegant
screening procedure which involved preparation of DNA from pooled cells,
digestion and packaging into a mutant vector phage which would only grow if
part of the targeting vector was present in the ligated DNA, and screening by
colony hybridisation with appropriate probes from human 8 globin outwith
the sequences used in the vector. The frequency of the homologous
recombination event was between 1 in 300 and 1 in 1100 G418 resistant
colonies.
6.1.4 Gene targeting
Pluripotent stem cells isolated from 31/2 day mouse embryos can be grown
indefinitely in culture (Evans and Kaufman, 1981). These embryonal stem
(ES) cells have a normal karyotype, will form teratocarcinomas if injected
subcutaneously in syngeneic mice and form germline chimaaras if injected
into pre-implantation blastocysts which are then returned to pseudo-pregnant
female mice (Bradley et al., 1984). More importantly, ES cells can be
manipulated in vitro, for example by transfection and integration of a neo
gene and selection in G418, and thereafter will still produce germline
chimaeras (Robertson et al., 1986; Gossler et al., 1986). To produce an
animal lacking a functional gene, a single copy is disrupted in mouse ES
cells and these cells injected into a 31/2 day blastocyst. The blastocyst is re-
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implanted into a pseudo-pregnant female and the resultant chimasras will
produce offspring carrying one disrupted gene copy in the constitutive DNA
(ie, heterozygous) if the cultured ES cells have successfully colonised the
chimeric germ cells. Mating of 2 heterozygotes will result in a conceptus
homozygous for the gene disruption and hence lacking any functional copy
of the targeted gene.
The gene for hypoxanthine phosphoribosyl transferase {hprt) was used as a
model system for manipulation of ES cells as it has two useful properties.
First it is located on the X chromosome thus is represented in only one copy
in male XY ES cells. Second, it is possible to select in culture for its
presence in HAT medium or absence in 6-thioguanine (6-TG). ES cells
cultured in 6-TG produced spontaneous hprt- mutants which produced
germ-line chimseras (Hooper et al., 1987). Further experiments on targeting
hprt in ES cells defined many of the parameters for subsequent targeting
strategies in other genes (Thomas and Cappechi, 1987). The targeting
vectors fell into 2 categories: "insertion" where the entire exogenous
sequence inserts into the endogenous DNA (figure 6.2a); and "replacement"
where the homologous endogenous sequence is replaced by the targeting
vector (figure 6.2b). Both classes of vector contained the neo gene and were
designed to recombine near the 8th exon of hprt thus disabling it. The
number of colonies which were G418 resistant gave the frequency of non¬
homologous and homologous recombination whereas the subset which was
also 6-TG resistant gave the frequency of homologous recombination. Both
types of vector targeted at roughly the same frequency: 1 in 1000 for the
most efficient vectors which were those with the largest regions of homology.
Only single copies of the vector were found in each clone of ES cells.
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In non-selectable genes, the targeted clones can only be detected by
screening many colonies usually by Southern blotting or by the polymerase
chain reaction (PCR). This is very labour intensive and two modification to
vectors can enrich for homologous recombination over non-homologous
recombination. The first modification, only applicable for genes expressed in
ES cells, involves cloning the neogene in-frame with the gene sequences in
the targeting vector. Following introduction of such a vector, only
homologous recombination will juxtapose the targeting vector to the
appropriate promoter or enhancer sequences resulting in expression of the
fusion protein conferring G418 resistance. This technique can give several
hundred-fold enrichment (te Riele et al., 1990). The second strategy is to
place one or two counterselectable markers outlying the region of homology
in addition to the selectable marker within the homology (fig 6.3).
Homologous recombination will result in loss of the conterselectable markers
whereas non-homologous recombination would permit retention of one or
both and these cells would be selected against. Enrichment of 2000 fold has
been demonstrated (Mansour et al., 1988) although other groups have
found enrichment of only 2 fold (Mombaerts et al., 1991).
The insertion vector strategy has also been modified, by the addition of a
counterselectable marker (usually HSVf/c), to permit removal of the inserted
selection genes and duplicated DNA. Clones are obtained which have the
correct insertion event (fig 6.4) and this is confirmed by Southern blotting.
The targeted clones are then back-selected in ganciclovir for loss of the
HSMtk gene. This can occur by homologous recombination between the
duplicated regions of the target gene (fig 6.4). The structure will resolve
leaving either a reconstituted wild-type gene or one containing exogenous
DNA (Hasty et al., 1991; Valancius & Smithies, 1991). Therefore, the target
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gene (in roughly 50% of cases) has the desired alteration and lacks any
exogenous sequence (neo, tk, enhancer or promoter) which might
deregulate neighbouring genes and render the phenotype difficult to
interpret. Concerns that gene targeting might not be feasible for genes not
transcribed in ES cells are unfounded; work to date suggests that they are as
susceptible to homologous recombination as highly expressed genes
(Johnson et al., 1989).
Gene targeting in mouse ES cells, formation of chimaeras and germ-line
transmission of the mutated gene can provide a unique insight into the role
of that gene in embryogenesis and development and its function in the whole
organism. Disruption of the mouse homeobox gene hox 1.5 has
demonstrated is role in the normal development of neck structures (Chisaka
& Capecchi, 1992) and disruption of wnt-1 results in abnormalities confined
to the mid-brain and cerebellum (McMahon & Bradley, 1990). Unexpected
effects can also be detected by these techniques such as the role of the
proto-oncogene c-src in normal bone physiology (Soriano et al., 1991). In
addition, gene targeting can provide an animal model of a human genetic
disease such as Lesch-Nyhan syndrome (Hooper et al., 1987) and may
provide insights into their correction (Thompson et al., 1989).
The normal cellular function of p53 remains obscure (chapter 2) and its
possible role in development (suggested by its expression during
embryogenesis, Schmid et al., 1991) is also unknown. The human genetic
disease, Li-Fraumeni syndrome, is characterised by germ-line p53 gene
mutations which co-segregate to affected individuals. The production of a
p53 null animal should, therefore, provide much information on the
developmental role of p53 (if any) and also on the normal function of p53. An
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animal carrying a subtle mis-sense gene mutation of the sort seen in Li-
Fraumeni syndrome would create an accurate model of human disease
which might provide insight into prevention of tumourigenesis and possible
therapy.
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Figure 6.2 Disruption of the hprt gene by gene targeting. (A) Gene
replacement. Homologous recombination between vector and endogenous
hprt sequences results in vector sequences containing neo replacing the
genomic sequences. (B) Sequence insertion. Pairing of the free,
homologous ends of the vector with the endogenous gene is followed by
recombination at the double strand break and results in the vector being
inserted into the endogenous hprt gene. This produces a duplication of a
portion of the hprt gene as well as its disruption. Open boxes represent
introns; closed boxes, exons; and the cross-hatched box, neo. Modified from
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Figure 6.3 The positive-negative selection vector, (a) Gene targeting. Gene
X replacement vector containing a neo gene within the region of homology
and an HSVf/r gene outwith the homology. Correct targeting into endogenous
gene X results in loss of the HSVf/c sequences rendering the cells G418 and
ganciclovir resistant, (b) Random integration results in inclusion of HSVtk
rendering the cells G418 resistant but ganciclovir sensitive. Thus, inclusion
of a counter-selectable marker outwith the region of homology will enrich for
homologous over non-homologous integration when cells are selected in
medium containing G418 and ganciclovir. Open boxes represent introns;
closed boxes, exons; and cross-hatched boxes, neo and HSVtk. Modified




















Figure 6.4 "Hit and Run" gene targeting. The initial step is an insertion event
into the target gene of a targeting vector which contains a specific mutation
and is linearized within the region of homology with the neo and HSW/c
genes located outwith the homology. This results in duplication of genomic
sequences and renders cells G418 resistant but ganciclovir (GANC)
sensitive. One, both or neither of the duplicates may contain the desired
mutation. G418 colonies are screened for this event, expanded and then
selected for intrachromosomal recombination within the duplication by
selection in ganciclovir. Filled boxes represent homologous DNA in the
vector; open boxes, homologous DNA in endogenous gene; numbered
boxes, exons; thick lines, plasmid DNA; thin lines, non-homologous DNA;
asterisk, mutation; and the arrows represent the plane of resolution within










6.2 Targeting p53 by "Hit and Run"
The Li-Fraumeni syndrome is characterised by germ-line transmission of p53
gene mutations which result in a variety of early onset and multiple primary
tumours including osteosarcoma and lymphoma (Malkin et al., 1990;
Srivastava et al., 1990). Transgenic mice which overexpress mutant p53
develop a range of tumours including: osteosarcoma; lymphoma; adeno¬
carcinoma of the lung; rhabdomyosarcoma; and skin carcinoma (Lavigueur
et al., 1989). In mice over-expressing the transgene containing the Ala-Val
mutation at codon 135 the tumours are confined to the osteosarcoma and
lymphoma groups and have a latency of 3.5 to 8.5 months. Although there
are clear parallels between this mouse model and Li-Fraumeni syndrome,
the transgene is over-expressed 40-50 fold making it less like the human
situation where over- expression is not seen (Malkin et al., 1990).
The introduction of a single base pair mutation into the p53 gene of mouse
ES cells and subsequent production of chimeeras and heterozygous offspring
would provide a true and accurate model of Li-Fraumeni syndrome,
permitting investigation of therapeutic intervention.
The "hit and run" or "in-out" technique (Hasty et al., 1991; Valancius &
Smithies, 1991) provides the means of creating a true animal model of this
syndrome (section 6.1.4, figure 6.4). An animal bearing a single mutation in
an otherwise intact p53 gene would also help explain the mode of action of
WT and mutant p53 in tumorigenesis. Comparison of a mutant/WT
heterozygote with a mutant/null heterozygote (by mating with the WT/null
heterozygote described in chapter 7) would show whether mutant p53 exerts
a dominant negative effect by oligomerising (Milner et al., 1991) or altering
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the conformation (Milner & Medcalf, 1991) of the WT protein or whether it is
simply inactivated by mutation.
Homologous recombination of the insertion type (Thomas & Capecchi, 1987)
in some studies occurs at a frequency almost 100 times greater than with
replacement vectors (Hasty et al., 1991). For this reason it was decided to
attempt to make a mutant p53 gene and a disabled p53 gene in independent
experiments using the "Hit and Run" technique as there appeared a higher
probability of success than with a replacement strategy.
Two targeting vectors were constructed of the "hit and run" type (Thomas &
Capecchi, 1987) each containing a selectable marker (neo) and a
counterselectable marker (HSV-f/c). One contained the ala-val mutation at
codon 135 which is known to cooperate with ras (Findlay et al., 1989), is
temperature sensitive (Michalovitz et al., 1990) and causes tumours in
transgenic mice (Lavigueur et al., 1989). The second construct was a




The p53 gene homology used in this study consisted of the central Hind III
fragment of genomic p53 clone Ch53-7 (Bienz et al., 1984) containing exons
2-9. This was inserted into the Hind III site of pGEM PGK-TK (pGEM II
vector containing HSV-f/c under control of the PGK promoter) to create
pCP11.1 (figure 6.5). In order to employ the BamH1 site between exons 6
and 7 of p53 for linearization the Bam H1 site of pSP PGK-NEO had to be
destroyed. This was carried out by Bam H1 digestion of pSP PGK-NEO
followed by filling in the 5' overhang with the Klenow fragment of DNA
polymerase and subsequent blunt end religation. Loss of the Bam H1 site in
the resulting plasmid was confirmed by BamH1 digestion. The Bgl II
fragment of this modified pSP PGK NEO was excised and ligated into the Bgl
II of pCPI 1.1 to make pCPI 2.1 (figure 6.5). pCPI 2.1 was also modified to
make a disabling deletion. The 2kbp Xho I fragment of the p53 homology
was excised removing the 3' region of intron 1 in addition to the initial 13
codons of exon 2 and the splice acceptor site (figure 6.5). All vectors were
confirmed by restriction mapping (figure 6.6). The orientation of the
homologous DNA to the rest of the vector was not initially checked as the
vector would target with the homology in either orientation. It was assumed
initially that the orientation was reversed compared to the actual orientation
(subsequently confirmed by further restriction mapping) (figure 6.7) and this
influenced some of the screening strategies.
It has been demonstrated that areas of heterology adjacent to the double
strand break can be repaired using the target sequences as template
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(Valancius & Smithies, 1991). Therefore, care was taken that the 2kbp Xhol
deletion was distant from the BamHI linearisation site (2kbp). Unfortunately,
the GTG-GCG mutation in exon 6 (codon 135) is close to the Bam HI site
increasing the likelihood of correction using the endogenous gene as
template. Therefore a screening test had to be developed to detect whether
the mis-sense mutation had been incorporated as intended.
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Figure 6.6 UV transilluminated, ethidium bromide stained agarose gel
cofirming the restriction maps of "hit and run" vectors. M, 1 kb ladder
molecular weight marker (sizes given in kbp) 1. pGEM PGK-TK / Hind III. 2.
pCPI 1.1 / Hind III. 3. pCPI 1.1 / Hind III, BamH I. 4. pCPI 1.1 / Bgl II. 5.pCPI
2.1 / Bgl II. 6. pCPI 2.1 / BamH 1 7. pCPI 2.1 /Xho 1. 8. pCPI 2.1XD/Xho 1.
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6.3.2 Transfection and Culture
Approximately 50 pg of PCP1 2.1XD and 35 pg of pCPI 2.1 were transfected
independently into 108 E14 mouse ES cells (Hooper et al., 1987) by
electroporation under conditions optimised for single copy transfer. Both
vectors were linearised by Bam HI digestion, confirmed by agarose gel
electrophoresis, prior to transfection. After 24 hours G418 selection was
introduced and this was subsequently withdrawn once the individual colonies
had reached a suitable size to be picked.
Of the clones surviving, 254 from pCPI 2.1XD and 245 for pCPI 2.1 were
expanded and the DNA harvested for Southern blot and PCR analysis.
6.3.3 Screening of pCPI 2.1 XD clones
The pCPI 2.1XD clones were screened for the "hit" or insertion event by Bgl
II digestion, Southern transfer and hybridisation to external probe P1. The
predicted recombination events (figure 6.8) and Southern blot pattern are
indicated (table 6.1). The external probe, P1, can only show a band shift if
the endogenous gene is altered as it cannot hybridise to the randomly
integrated vector. Results were obtained from 149 clones and of these 20
showed a pattern consistent with a hit event (fig 6.9a) but 1 showed a larger
band shift (fig 6.9a). As P1 is external to homology contained within this
vector this 2kbp band shift must represent endogenous gene disruption.
Further analysis was carried out using internal probe P3 with other enzyme
digests to confirm that the predicted insertion event had occurred and that
"hit and run" had not (fig 6.9b).
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Table 6.1 Summary of predicted Southern blot band sizes for pCPI 2.1 XD
clones. Probes P1 and P3 defined in figure 6.8. All sizes are in kbp.
Probe P1 P3
Enzyme Bglll Bglll Hind III BamH 1
Wild-type 16 16 7 6
"Hit" event 16/14 16/14/13 7/7/4.5 6/6/12
"Hit and Run" 16/14 16/14 7/4.5 6/4
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Figure 6.9 Autoradiographs of Southern blots of genomic DNA extracted
from pCPi 2.1 XD transfected ES cell clones probed with external probe P1.
(a) Lane 1: clone 82 showing an aberrant pattern with an 8kbp band. Lane 2:
clone 83 showing the wild-type pattern. Lane 3: clone 84 showing a pattern
consistent with insertion ■(b) Further Southern blot analysis of clone 84
probed with internal probe P3. Lane 1: BamH 1. Lane 2: Hind III. Lane 3: Bgl







6.3.4 Screening of pCPI 2.1 clones
These clones were screened in an identical fashion to pCPI 2.1 XD by Bgl II
digestion and hybridisation to probe P1. However, the vector was initially
thought to be pCPI 2.1' (homology in reverse orientation, figure 6.7) which
would have produced a diagnostic band shift from 16kbp to 11 kbp (figure
6.10). With the actual vector used, pCPI 2.1, both the endogenous gene and
the targeted gene give a 16kbp band (figures 6.11 and 6.12a). Screening by
Bgl II digestion but probing with DNA from the region 5' to the homology
used in the vector construction (such as P4, chapter 7) would give the true
frequency of the insertion event. However, not all inserted vectors would
have retained the mutation and so a PCR strategy was developed to screen
for insertion at the correct site by the targeting vector and retention of the
mutation. A PCR primer was designed which had a single base pair
mismatch at the 3' end which would create a new Dra III site if the GTG
mutation were present (figure 6.13) in exon 5. The 3' PCR primer was
located initially within exon 7, across the insertion site of the vector into the
endogenous gene (figure 6.11). Thus, amplification would always take place
for the endogenous gene (at least) but would not digest with Dra III unless
the mutation were both present and integrated at the correct site.
Initial attempts at amplification were unsuccessful due to preferential
amplification of the pseudogene which shares a high degree of homology
with the cDNA of the true gene (Zakut-Houri et al., 1983). To circumvent this
problem the 7th intron was partially sequenced and another PCR primer
designed at its 5' end (figure 6.14). Sequences using these 2 primers were
amplified from each of the 245 clones, digested with Dra III and the
fragments resolved by electrophoresis through a 4% agarose gel (figure
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6.12b). DNA from an OLA/129 mouse was used as a negative control and
pCPI 2.1 itself as a positive control (thus also confirming the presence of the
mutation in the targeting vector). Of the 245 tested, 10 showed a pattern
consistent with the presence of the mutation and integration (figure 6.12b).
However, 4 of these also showed extra, smaller fragments perhaps
suggestive of loss of sequence at the integration site.
The relative frequencies of correct insertion of pCPI 2.1 XD and pCPI 2.1
into the genome are given in table 6.2.
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Figure 6.12 (a) Autoradiograph of Southern blot of DNA extracted from pCPI
2.1 transfected ES cell clones digested with Bgl II and probed with external
probe P1. Lanes 1-6, clones 53-58 showing the wild type band at 16 kbp and
the pseudo-gene at 2 kbp. (b) UV transilluminated, ethidium bromide
stained, 4% agarose gel showing Dra III digested PCR amplified fragments
from pCPI 2.1 ES cell clones. M, molecular weight marker, sizes in bp. Lane
1, PCR amplified fragment from pCPI 2.1 (positive control); Lane 2, wild-type
Ola/129 DNA (negative control); Lanes 3-12, clones 69, 74, 76, 100, 101,
106, 115, 116, 202 and 206 showing the extra (mutant) band.
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Figure 6.13 Sequence of exon 5 from wild-type genomic p53 and clone
Ch53-7. Shown in bold is the sequence of the 5' PCR primer used to detect
the alanine to valine (GCG to GTG) mutation at codon 135 (marked by an
asterisk). Presence of the mutation results in the creation of a novel Dra III
site (CAC NNN GTG) which is not present in the wild-type gene. Following



























































Figure 6.14 Sequence of intron 7 from genomic p53 clone Ch 53-7 showing
the position and sequence of 3' PCR primer MM 7.7 used to screen pCPI 2.1


























Table 6.2 Summary of results for insertion event obtained for targeting using
pCPI 2.1 XD (screened by southern blot) and pCPI 2.1 (screened by PCR for
insertion and retention of mutation).
Vector Clones Clones Targeting
Screened Targeted Frequency
pCPI 2.1 XD 149 20 1 / 7.45
pCPI 2.1 245 10 1 / 24.5
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6.4 Discussion
Targeting with pCPI 2.1XD has resulted in disruption of the endogenous p53
gene judged from the result of the Southern blot probed with sequence
external to that used in the vector construction (figure 6.9a). The pattern
obtained with probe P1 is consistent with both the "hit" event and with "hit
and run" (table 6.1). However, confirmatory southern blots using internal
probe P3 indicate that the vector has integrated as predicted (table 6.1,
figures 6.8 and 6.9b). Confusion over the correct orientation of the gene
homology made the interpretation of the blots impossible thus delaying
further expansion and ganciclovir selection which is now under way.
One clone gave a different southern blot pattern (figure 6.9a, lanel) with a
larger band shift than that predicted for the insertion event. The probe used,
P1, is external to the gene homology used in the vector and so this clearly
represents endogenous gene disruption. It is possible that the vector has
integrated correctly but has lost sequence or that endogenous sequence
(including the region homologous to P1) has been picked up by the vector
which has then integrated elsewhere in the genome (Szostak et al., 1983).
The insertion targeting event is occurring at a frequency of 1 in 7.45 clones
screened; in a system employing a single positve selection marker (Neo).
This is therefore comparable to the replacement vector (pCPR 3.1, chapter
7) which targets at a frequency of 1 in 183. The vectors otherwise differ in
the lengths of homology, 7.5 kbp in pCPR 3.1 and 5 kbp in pCPI 2.1 XD and
the particular sequences involved. Thus, in this series, at one locus, an
insertion vector is targeting approximately 25 fold more efficiently than a
replacement vector. This is despite having less homology which is one of the
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most important determinants of targeting efficiency (Ayares et al., 1986).
There are however, other differences between the homologies employed in
the vectors which makes direct comparison impossible. The finding that an
insertion vector targets more efficiently than a replacement vector is in
keeping with previous work suggesting up to 100 fold enhancement (Hasty et
al., 1991).
Targeting with pCPI 2.1 generated 10 clones which appeared to have
integrated correctly and retained the ala-val mutation at codon 135 (figure
6.12b) from 245 screened. It is possible and likely that a greater number
have integrated the vector DNA at the correct site but the mutation has been
"repaired" using target sequences as template (Valancius & Smithies, 1991)
which would give a negative result on PCR analysis. A further possibility to
explain the 10 apparently targeted clones is that recircularisation of the
vector occurred prior to random integration (Hasty et al., 1991; Moenis et al.,
1992). Both of these problems can be addressed by southern blot screening
using external probe P4 (chapter 7) with a Bgl II digest.
The apparently less efficient targeting of pCPI 2.1 compared to pCPI 2.1 XD
(table 6.2) despite containing greater homology can be explained by the
"repair" of the mutation during or after targeted insertion (Valancius &
Smithies, 1991). A further possible, though less likely explanation, is that
sequences which inhibit homologous recombination are located in the 2 kbp
Xho1 fragment removed to make pCPI 2.1 XD. Southern blot screening of
pCPI 2.1 colonies will answer this question.
Of the 10 pCPI 2.1 clones identified, 4 show extra smaller bands on the PCR
analysis (figure 6.12b). These are suggestive of loss of genetic material
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(between 50 and 200bp) during the targeted insertion. Loss of sequence
especially at the free ends of a vector during targeted insertion has been
described (Hasty et al., 1992) and could account for these findings. In this
case, such sequence loss would result in loss of the BamH1 (vector
linearisation) site. Analysis by southern blotting following BamH1 digestion
with internal probe P3 would detect whether this is indeed the case.
Although the pCPI 2.1 XD insertion event has clearly occurred as predicted
and further selection in ganciclovir should result in cells with one inactive p53
gene copy, inactivation using a replacement vector strategy has been
achieved and passed into the mouse germ-line (chapter 7). In the case of
the 10 candidate pCPI 2.1 targeted clones, further southern blot analysis will
be followed, if the correct pattern is obtained, by ganciclovir selection and it
may be possible to screen the colonies generated by PAb240
immunihistochemistry for mutant p53 expression.
Production of chimeeras and susequently mice heterozygous for p53 val135
will provide unique data on the function of p53. They will give informationon
whether this mutant can act dominantly when expressed at physiological
levels in the presence of WT p53, will produce cells for culture which contain
a temperature sensitive mutant (Mickalovitz et al., 1990) under normal
control and produce a model for Li-Fraumeni syndrome (although this
mutation is not directly analogous). Furthermore, offspring of a mating
between p53 val135 heterozygotes and p53 null heterozygotes will address
the question of whether p53 mutants act by a dominant negative effect on
WT p53 or have an action even in its absence.
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Chapter 7
Targeting p53 by Replacement
7.1 Introduction
During mouse embryogenesis, p53 is expressed at high levels at 8.5-10.5
days gestation and also in embryonal cells (Rogel et al., 1985; Schmid et al.,
1991) suggesting a role in early development. Wild-type p53 appears to
cause G1 cell cycle arrest in the presence of DNA damage via transcriptional
control of, as yet, unidentified genes and its inactivation is seen in many
common malignancies (section 2.6).
In order to address the role of p53 in normal mammalian development and
its function in a complete organism, an attempt was made to inactivate p53
by gene targeting in mouse ES cells. This section discusses the success of
this attempt and gives early data on the pathology of the resulting chimseras
and both heterozygous and homozygous p53 null animals.
Another study, using a similar system (Donehower et al., 1992), showed that
mice with a homozygous p53 inactivation were developmental^ normal but
developed, at high frequency, malignant tumours usually of mesenchyme
and lymphoid tissue. Two heterozygotes out of 96 developed tumours but
only after 5 and 9 months. The strategy used in their study however, did
result in downstream p53 gene transcription including exons 5-11 (amino
acids 158-390), a region involved in p53 oligomerization (Milner et al., 1991)
making the phenotype difficult to interpret. In this study care was taken to





The genomic clone of murine p53, termed Ch53-7 (Bienz et al, 1984) was
used for all vector construction. This clone contains the activating mutation
ala-val at codon 135 (Bienz et al, 1984) which confers transforming ability
when co-transfected with mutated ras (Hinds et al, 1989) and is temperature
sensitive (Michalovitz et al., 1990). The remainder of the sequence is wild-
type and the published restriction map was confirmed prior to
commencement of the vector construction.
In order to ensure that this activating mutation would not interfere with the
phenotype by acting as a dominant oncogene, care was taken to remove
exon 5, which contains it, in the vector construction (figure 7.1). The vector
consisted of 5' homology within the first intron and 3' homology spanning
exons 7-11 (figure 7.1). Exons 1, 2-6 and most of intron 1 were removed and
PGK Neo inserted between the two regions of homology in the same
transcriptional orientation as p53. The neomycin (G418) resistance
(neomycin phosphotransferase) vector pSPGKNeo consists of pMCINeo, a
re-engineered coding sequence for the bacterial transposon of Tn5 (Thomas
& Capecchi, 1987), driven by the promoter of the mouse pgk-1
(phosphoglycerate kinase) gene (Adra et al, 1987) to ensure expression of
neo in ES cells. Maps of the targeting vector, pCPR 3.1 and its intermediates
along with confirmatory restriction digests are shown in figures 7.1 and 7.2.
The vector pCPR3.1 only contains a positive selection marker {neo) and no
negative selection marker outwith the homology to enrich for homologous
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recombination (Mansour et al, 1988) (figure 6.2). To incorporate such a
counter-selectable marker this vector was re-engineered starting with pCPR
2.1. The thymidine kinase gene from herpes simplex virus (HSVf/c Colbere -
Garapin et al; 1979) under the control of the pgk promoter was inserted into
the Bgl ll/EcoRI sites at the 3' end of pCPR 2.1 (figure 7.3) in the reverse
transcriptional orientation to p53 creating pCPR 4.1. Thereafter, PGKNeo
was again inserted between the regions of p53 gene homology creating
pCPR 5.1 (figure 7.3) confirmed by restriction digestion (figure 7.2).
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Figure 7.2 Diagnostic restriction enzyme digests confirming the maps of the
replacement targeting vectors, (a) M, molecular weight marker, sizes in kbp;
1, pUC 19 / Hind III; 2, pCPR 1.1 / Hind III (two fragments of approximately
equal size); 3, pCPR 1.1 / BamH 1; 4, pCPR 1.1 / Hind III and BamH 1 (two
fragments of approximately equal size); 5, pCPR 2.1 / Hind III; 6, pCPR 2.1 /
Hind III and BamH 1.(b) M, molecular weight marker, sizes in kbp; 1, pCPR
2.1 / Hind III; 2, pCPR 2.1 / Hind III and BamH 1; 3, pCPR 3.1 / Hind III and
BamH 1 .(c) M, molecular weight marker, sizes in kbp; 1, pCPR 2.1 / EcoR 1
and Bgl II; 2, pCPR 4.1 / EcoR 1 and Bgl II; 3, pCPR 4.1 / Hind III and BamH
1; 4, pCPR 5.1 / Hind III and BamH 1.
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7.2.2 Transfection and Culture
Both vectors were linearised by Pvu I digestion (2 sites within plasmid only)
and this was confirmed by agarose gel electrophoresis of an aliquot prior to
transfection. Approximately 70 pg of pCPR 3.1 and 50 pg of pCPR 5.1 were
transfected independently (conditions optimised for single copy transfection)
into 108 E14 mouse embryonal stem cells (Hooper et al, 1987). After 24
hours, G418 selection alone (pCPR 3.1) or G418 plus ganciclovir selection
(pCPR 5.1) was introduced.
Of the surviving colonies, 183 from the pCPR 3.1 transfection and 204 from
the pCPR 5.1 transfection were expanded and DNA harvested for Southern
blot analysis. One petri dish from the pCPR 5.1 transfection was maintained
in G418 selection only and this demonstrates an approximately 4:1
enrichment when ganciclovir selection is added (figure 7.4).
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Figure 7.4 ES cell clones transfected with pCPR 5.1 (a) selected in medium





Genomic DNA was extracted, digested with EcoR1 and Southern blotted.
The filters were hybridised to probe P4 which is external to the region of
homology contained within the vector. One clone from the pCPR 3.1
transfection out of 183 gave a pattern suggestive of targeting (figure 7.5a).
The mouse pseudogene (Zakut-Houri et al, 1983) also hybridises to P4
making analysis slightly ambiguous (figure 7.5a). The candidate clone,
R3.72, was therefore digested with Bgl II and hybridised to P4 confirming
that the endogenous gene has indeed been disrupted in the fashion
predicted for homologous recombination between it and the targeting vector
(figures 7.5a and 7.6).
Genomic DNA for the pCPR 5.1 transfection was screened in an identical
fashion. Of the 204 clones, 4 showed the targeted EcoR1 band shift and this
was again confirmed by Bgl II digestion (figures 7.5b and 7.7). Unfortunately,
3' p53 sequence outwith the region of homology was not available to
investigate the HR event at the 3' end. The results of both experiments are
summarised in table 7.1.
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Figure 7.5 Southern blots of DNA extracted from ES cells probed with
external probe P4. (a) 1, clone R3.72 / EcoR 1 showing targetted band at 3.5
kbp; 2, negative control (untransfected ES cell DNA) / EcoR 1 showing
pseudogene at 3.3 kbp; 3, R3.72 / Bgl II showing targetted band at 10 kbp;
4, negative control / EcoR 1. (b) pCPR 5.1 targetted clones digested with Bgl
II: 1, negative control; 2-5, targetted clones showing diagnostic band shift
from 16 to 10 kbp and pseudogene at 2 kbp.
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7.2.4 Germ-line transmission of targeting event
The targeted ES cell clone R3.72 was subsequently expanded and 10-15
cells injected into 3.5 day old blastocysts from F2 (C57/BI6 x CBA) mice.
These were implanted into psuedo-pregnant female mice and chimaeric
offspring produced identified by their coat colour. Chimeric animals were
mated with Ola/129 mice and offspring derived from the targeted cells
identified by their chinchilla coat colour. DNA from tail biopsies was screened
by southern blotting in the same way as the ES cells for the targeted event.
Mating of 2 heterozygotes resulted in mice with homozygous p53
inactivation.
Preliminary analysis suggests that both heterozygous and homozygous mice
were developmentally normal. The homozygotes developed tumours at
between 1 and 4 months of age (mean 2.7 months) and these were mostly
soft tissue sarcomas and lymphomas. The heterozygotes likewise developed
a similar spectrum of tumours usually between ages 3 and 12 months (mean
6.8 months) (table 7.2). These tumours tended to be of a high grade;
indicated by the presence of numerous mitoses, areas of necrosis and
multinucleate cells in the sarcomas (fig. 7.8). Apoptotic figures were also
present in the tumours from both heterozygotes (p53+/-) and homozygotes
(p53-/-) (fig. 7.8).
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Table 7.2 Summary of preliminary analysis of p53 targeted mice. Diagnoses




X 220 Homozygote 1 Lymphoma
X 318 Homozygote 2 Sarcoma
X 195 Homozygote 3 Lymphoma
X 228 Homozygote 3 Sarcoma
X 324 Homozygote 3 Lymphoma
X 329 Homozygote 3 Lymphoma
X 196 Homozygote 4 Lymphoma
XS 137 Heterozygote 3 Lymphoma
X 214 Heterozygote 4 Lymphoma
X 166 Heterozygote 4 Lymphoma
X 142 Heterozygote 4 Lymphoma
RX 3 Heterozygote 5 Sarcoma
X 131 Heterozygote 5 Haemangiosarcoma
X 176 Heterozygote 5 Lymphoma
X 181 Heterozygote 5 Lymphoma
X 182 Heterozygote 5 Lymphoma
X 172 Heterozygote 5 Lymphoma
RX 7 Heterozygote 6 Lymphoma
X 59 Heterozygote 8 Sarcoma
X95 Heterozygote 8 Lymphoma
X 44 Heterozygote 9 Sarcoma
X 317 Heterozygote 9 Lymphoma
X 26 Heterozygote 10 Abdominal tumour
X55 Heterozygote 10 Lymphoma
X 2 Heterozygote 11 Sarcoma
X 61 Heterozygote 11 Lymphoma
X 5 Heterozygote 12 Liver tumour
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Figure 7.8 (a) Photomicrograph of soft tissue sarcoma from mouse X2 (p53
+/-) x200. (b) Photomicrograph of a thymic lymphoma from mouse X195





The targeted disruption of one copy of the p53 gene has been demonstrated
in 5 independent ES cell clones. This was confirmed by showing the
predicted band shift in the p53 gene when hybridised to a probe outwith the
vector homology thus excluding random integration as a possibility. In the
case of the vector pCPR 3.1 this was at a frequency of 1 in 183 using only a
positive selectable marker. Previous studies have found targeting a
frequency at the hprt locus of only 1 in 1000 (Thomas & Capecchi, 1987), 1
in 260 at the En-2 gene (Joyner et al, 1989) and 1 in 30 at the 62
microglobulin gene (Zijlstra et al, 1989), all employing targeting vectors
containing only a positive selection marker. It is clear, therefore, that
targeting frequencies vary greatly. This may be due to the recombinogenic
potential of different loci, the packaging of the chromatin at these sites and
its accessibility for recombination. However, the different amounts of
homology in the vectors, the different methods of transfection, the different
ES cells and different selection and culture protocols makes more detailed
comparison impossible.
By the use of a vector, pCPR 5.1, which differs from pCPR 3.1 by containing
a counter selectable marker (HSV-f/c) the targeting frequency increases from
1 in 183 to 1 in 51 G418^ Ganc^ clones. This approximately 4 fold
enrichment is most probably due to the counterselection as the two vectors
otherwise differ only in that pCPR 5.1 has 200 bp less homology. In the case
of pCPR 5.1 a similar reduction in the number of live clones is seen when
ganciclovir is added to the medium (figure 7.4). This level of enrichment is
rather lower than other groups. For example 2000:1 enrichment was
observed in the int-2 gene (Mansour et al, 1988) but only 2:1 enrichment
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was obtained at the T cell receptor 13 sub-unit gene (Mombaerts et al, 1991).
Again, differences in methodology preclude further speculation on the
underlying causes.
Mice with inactivation of one or both copies of p53 in this study develop
normally in keeping with previous work (Donehower et al., 1992). Despite
being expressed at high levels during embryogenesis (Schmid et al., 1991)
and having a central role in cell cycle control and the onset of apoptosis, p53
inactivation does not influence the development of the mouse. This result
has some similarities with finding that inactivation of pim1 (a gene highly
expressed during mouse embryogenesis) does not influence development,
suggesting a degree of redundancy in the mammalian genome with the
inactivation of seemingly important genes being circumvented without any
obvious problem (te Riele et al., 1991). This again demonstrates how gene
targeting can lead to unique insights into the control of mammalian
development.
The homozygous p53 null mice (p53-/-) develop malignant tumours mainly of
mesenchyme and lymphoid tissue with a short latency (mean, 2.7 months)
showing a similar pattern to that reported previously (Donehower et al.,
1992). This spectrum of neoplasia is strikingly similar to that seen in
transgenic mice over-expressing mutant p53 (Lavigueur et al., 1989)
(although at a much higher frequency and with a shorter latent period) and in
humans with germ-line p53 mutations (Malkin et al., 1991; Srivastava et al.,
1991) suggesting a central role for p53 in these tumours.
If p53 inactivation were sufficient alone for tumourigenesis it would be
anticipated that all p53 -/- animals would develop the same tumours at the
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same site soon after birth which does not happen. The short latency and the
fact that not all homozygous p53 -/- have succumbed to malignancy in the
time course of follow-up argues strongly that the inactivation of both copies
of p53 acting alone is insufficient for carcinogenesis. However, p53
inactivation clearly predisposes to the tumourigenesis possibly by permitting
premature DNA replication or replication in the presence of sequence errors
with resultant genomic instability and the development of aneuploidy; these
processes in turn predisposing to mutation in other genes leading to the
acquisition of malignant properties. Such findings suggest that p53
inactivation rather than oncogenic activation by mutation is permissive for
carcinogenesis, an observation entirely consistent with the situation in Li-
Fraumeni syndrome where the germ-line mutations appear more disabling
than activating (Milner & Medcalf, 1991). This evidence also fits with the
finding that both copies of p53 are frequently disabled in a common human
tumours, such as colorectal cancer (chapters 3-5).
Apoptosis is a fundamental process in normal development and
carcinogenesis (Duvall & Wyllie, 1986) and can be induced by wild-type p53
(Yonish-Rouach et al., 1991). However, tumours which lack any functional
p53 still undergo apoptosis (fig. 7.8) indicating the presence of other
pathways involved in the initiatiation of this process.
Interestingly, Ola/129 mice do tend to develop soft tissue sarcomas and
lymphomas with a long latency of more than 22 months (Smith et al., 1973).
It remains to be seen if p53 inactivation merely accelarates this inherent
tendency or whether there is tissue bias in the emergence of neoplasia. The
latter explanation is the more likely in view of the parallels with human Li-
Fraumeni syndrome.
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In this study, the heterozygous p53 +/- mice succumb to a similar range of
tumours as the p53 -/- mice but with a slightly longer latent period (mean 6.8
months). This finding suggests that inactivation of the remaining WT p53
copy is occurring but that this takes a finite time to come about. Analysis of
the WT allele in these tumours is under way. The difference between the
mean latent periods is relatively short and it might be speculated that
inactivation of one p53 allele in the germ-line acting via reduced gene
dosage might predispose to loss of the remaining allele. In addition to loss of
the WT allele in tumours developed in heterozygous p53+/- mice it would be
predicted that the tumours would be DNA aneuploid with multiple divergent
stem-lines (chapter 3). This analysis is also underway.
In a previous study (Donehower et al., 1992), the heterozygous (p53 +/-)
mice appeared to develop tumours infrequently and with a longer latency
(only 2 out of 96 mice after 9 months follow-up). The targeting strategy used
in that particular study employed the poly-adenylation signal of the
endogenous targetted p53 to act for the neo gene within the vector. The
result of this was an enrichment for homologous recombination events over
random integration. However, it did result in transcription of the 3' end of p53
including exons 5-11 (codons 158-390) which includes the region of p53
responsible for oligomerization. Although p53 could not be detected in
immunoblots, expression of low levels of possibly mutated and biologically
active p53 cannot be excluded making the phenotype difficult to interpret.
This may also explain the slight difference in phenotype of the p53 +/- mice.
The vector used here, pCPR 3.1, contains numerous STOP codons following
the poly-adenylation signal of neo thus preventing any p53 transcription.
However, it is also possible that the observed difference in phenotype is due
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to the use of mice with a different genetic background or varied carcinogen
exposure.
Inactivation of both copies of p53 leads to a developmental^ normal
animal with a predisposition to a spectrum of malignancies. Such
animals and cell lines cultured from them will provide the ideal tool to
investigate and dissect the processes by which p53 acts and an in vivo




It has taken 14 years since its first isolation to identify a role for p53. This
appears to be as a "surveyor" of the genome identifying DNA errors or
damage and then delaying replication until this has been rectified or if this
should prove impossible eliminating the damaged cell by initiating apoptosis.
It is not therefore surprising that its inactivation is implicated in so many
malignancies.
In this thesis, it has been shown that in human colorectal cancer p53
mutation appears to result in p53 over-expression detected
immunohistochemically. The over-expression is closely associated with 17p
allele loss in the same tumours and the region deleted on 17p usually
involves the p53 gene locus. Thus, inactivation of both p53 alleles is
common in colorectal cancer. The timing of this over-expression and
mutation is at the adenoma (benign) to carcinoma (malignant) transition
suggesting a critical role for p53 in the acquisition of malignant potential in
this common human malignancy. Furthermore, both p53 over-expression
and 17p allele loss correlate with the presence pf DNA aneuploidy and
multiple divergent clones within a tumour. This is consistent with the
hypothesis of the effects of loss of p53 genomic surveillance and thus
perhaps accelarated acquisition of the genetic alterations conferring tumour
aggression. This would also explain the poorer prognosis of patients with
tumours showing DNA aneuploidy or 17p allele loss.
Loss of 17q alleles has also been identified as a more frequent event in
human colorectal cancer than previously noted and shown to correlate with
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the presence of lymph node metastasis. This suggests the inactivation of a
gene involved in the suppression of tumour metastasis in human colorectal
cancer on chromosome 17q not hitherto detected. Further deletion mapping
and detailed analysis of candidate genes will be necessary to identify this
important locus.
An attempt to introduce a single activating point mutation into the ES cell p53
gene was partially successful and back-selection of clones containing a
correctly inserted vector is underway. This should create an accurate model
of the human, family cancer syndrome, Li-Fraumeni syndrome. In addition,
cell lines from such animals will contain a single copy of the temperature
sensitive mutant p53 val135 under the control of its own promoter and in its
correct chromosomal site permitting study of cells more similar to the in vivo
situation.
A p53 null mouse was successfully generated by gene targeting in mouse
ES cells. This animal is, perhaps surprisingly, developmentally normal,
suggesting a degree of genetic redundancy in mammalian development.
Flowever, the p53-/- animals succumb to malignancies at an early age,
mostly of lymphoid and mesenchymal origin with similarities to Li-Fraumeni
syndrome. Furthermore, heterozygote p53+/- mice also develop the same
spectrum of malignancies but with a longer latency suggesting that the
difference in timing between p53-/- and p53+/- is the loss of the remaining
p53 allele in heterozygous animals.
These p53 -/- and p53+/- animals provide a tool for the investigation of the
normal function of p53, the commonest target for genetic events in human
malignancy. Comparison of p53-/- mice with p53+/- littermates for rates of
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apoptosis, proliferation, spontaneous mutation, response to carcinogens and
DNA repair, amongst other parameters, will give insight into p53 function in
vivo and in tumourigenesis. Such animals could also be used to investigate
possible environmental carcinogens, cancer prevention measures and





All the tumours studied comprised a consecutive series of surgical resections
from two local hospitals between June 1988 and January 1990. Surgical
colectomy specimens were collected onto ice in the operating theatre
immediately upon resection. They were opened and rinsed in ice-cold
PBS/EDTA (20mM sodium phosphate buffer pH 7.4, 137mM sodium chloride,
0.5mM EDTA) and dissected within 30 minutes of resection. Samples for
DNA extraction, cryostat sectioning and flow cytometry were placed in vials,
snap frozen in liquid nitrogen and subsequently stored at -70°C until required.
Adjacent tissue was placed into PLPD fixative (37.5mM sodium periodate,
7mM lysine, 1% paraformaldehyde, 2.5% potassium dichromate, 18.75mM
sodium phosphate buffer pH 7.4) (Holgate et al., 1986) and fixed overnight at
4°C prior to paraffin embedding. The remainder of the specimen was then
fixed in formalin and processed routinely for histopathological assessment.
Tumours were classified as distal if located in the sigmoid colon or rectum
and proximal if located in the remainder of the colon.
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9.2 Histopathological grading and statistical analysis
Carcinomas were reviewed and graded by a single pathologist (J.Piris) using
criteria recommended by the UKCCCR for Dukes' stage, histological type,
degree of differentiation and nature of invasive margin. Adenomas were
similarly reviewed and graded by a single pathologist (J.T.O'Grady) for
morphologic type and degree of dysplasia.
The statistical tests and tables used in this thesis were applied as
recommended by Siegel & Castellan, 1988.
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9.3 Flow Cytometry
Three or more samples from separate sites in each carcinoma were analysed
using the method of Vindelov (1983a & b). Multiple sites were sampled to
avoid misclassification as DNA diploid in view of the known heterogeneity of
DNA ploidy in colorectal carcinomas (Quirke et al., 1985). Normal colonic
mucosa from each patient was analyzed to control for false aneuploid peaks
caused by autolysis (Alanen et al., 1989). A piece of tissue approximately 5
mm3 was disaggregated under a citrate buffer by cutting with a clean scalpel
blade and 100 pi transferred to a disposable plastic test-tube. 25 pi of avian
erythrocytes were added to act as an internal standard followed by 450 pi of
solution A. The sample was mixed by whirlmixer and incubated for 10
minutes at room temperature. Solution B (325 pi) was added, mixed and
incubated for 10 mins at room temperature and finally 250 pi solution C
added, mixed and incubated on ice for 10 minutes.











Diluted in Stock solution
Solution B
0.5mg/ml Trypsin inhibitor
0.1 mg/ml Ribonuclease A
Diluted in Stock solution
Solution C
0.42mg/ml Propidium iodide
1 mg/ml Spermine tetrahydrochloride
Diluted in Stock solution.
The sample was then filtered through loose nylon wool and analysed on a
Coulter EPICS CS flow cytometer at an excitation wavelength of 488nm. At
least 10,000 nuclei were analysed in each sample and cases were scored as
aneuploid if any of the samples showed a Go/G-i peak distinct from the
normal diploid peak (as assessed from the internal standard). Coefficients of
variation of the diploid peak were typically less than 3.5. DNA index was
calculated by dividing the channel number of the aneuploid peak by that of
the diploid peak.
In cases where only one frozen sample was available, nuclei were extracted
from formalin fixed paraffin embedded tissue taken for routine histology.
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Sections 50 pm thick were cut, dewaxed in xylene and rehydrated through
grade alcohols prior to digestion in 0.5% pepsin in 0.9% NaCI (pH 1.5) at 37
°C for 60 minutes. The cells were washed three times in fresh PBS, filtered
through nylon wool and stained in PBS containing 100 pg/ml propidium iodide




4 pm cyrostat sections of tumour were cut, acetone fixed for 10 minutes then
air-dried. Sections were washed in Tris buffered saline (TBS) for 10 minutes




20mM Tris pH 7.6
Appropriately diluted antibody (PAb 1801 1:100 in NRS/TBS, PAb 240 as
neat hybridoma culture supernatant) was applied for 30 minutes, washed in
TBS and followed by a further 10 minute incubation in NRS/TBS. Bound
antibody was detected by application of rabbit antibodies to mouse
immunoglobulins conjugated to horse radish peroxidase (1:20 in NRS/TBS)
for 30 minutes, washed in TBS then visualised with diaminobenzidene
(1 mg/ml in 0.2M Tris pH 7.6, 0.03% hydrogen peroxide) for 2-5 minutes. After
a brief wash in tap water sections received a light haematoxylin counterstain
followed by another tap water wash, dehydration in graded alcohols and
xylene before mounting under coverslips (in DPX).
Paraffin Sections
3 pm sections of PLPD fixed, paraffin embedded tissue were cut, floated onto
glass slides and allowed to dry. After dewaxing in xylene, rehydration in
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graded alcohols and washing for 5 mins in TBS, NRS/TBS was applied for 20
minutes. This was followed by incubation in PAb 1801 (OSI p53Ab-2) diluted
1:100 in NRS/TBS for 60 mins. Bound antibody was detected by incubation in
biotinylated rabbit antibodies to mouse immunoglobulins (1:400 in NRS/TBS)
for 10 mins followed by avidin-biotin complex linked to horseradish
peroxidase (Dako) for 30 mins. After TBS washing, visualisation with
diaminobenzidene, haematoxylin counterstaining, dehydration and mounting
was identical to that used for frozen sections.
Classification
Cases were scored as antibody positive if any positively staining cells were




SV80 cells were grown to confluence on a 90mm Petri dish. The medium was
aspirated and the cells washed twice in phosphate buffered saline (PBS).
Phosphate buffered saline (Delbuccos)
137mM Sodium Chloride
2.7mM Potassium Chloride
1.5mM Potassium dihydrogen orthophosphate
8.1 mM Disodium hydrogen orthophosphate
The PBS was aspirated and 1 ml 1 x SDS-PAGE loading buffer was then
added.
1 x SDS-PAGE loading buffer
50mM Tris CI (pH 6.8)
100mM Dithiothreitol
2% Sodium dodecyl sulphate
0.1% Bromophenol blue
10% Glycerol
Cells were scraped up, placed into test tubes and incubated for 10 minutes.
After sonication until no longer viscous the sample was spun at 100,000 x g
on an ultracentrifuge at 20°C for 30 minutes. The supernatant was removed
and a 50 pi aliquot boiled for 3 minutes and then loaded on to a 10% SDS-
PAGE gel. The remainder was stored frozen at -70°C. Human colonic tissue
was disaggregated in ice-cold PBS using a clean scalpel blade transferred to
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a microfuge tube and centrifuged at 13,000 rpm for 5 mins at 4°C. The pellet
was resuspended in 500 pi of ice-cold suspension buffer.
Suspension Buffer
100mM NaCI
10mM Tris CI (pH 7.6)
1 mM EDTA (pH 8.0)
1 pg/ml aprotinin
100 pg/ml phenylmethylsulphonyl fluoride (PMSF)
As rapidly as possible thereafter 500 pi of 2 x SDS gel loading buffer was
added.
2 x SDS gel loading buffer





The sample was then boiled for 10 minutes, sonicated for 30 seconds to
shear high molecular weight chromosomal DNA and spun at 13,000 rpm at
room temperature for 10 minutes. The supernatant was transferred to a fresh




The gel mould plates were thoroughly cleaned with distilled water and 100%
ethanol and assembled with 0.75mm spacers. A 10% resolving gel was
poured and allowed to polymerise with an overlay of isobutanol.
10% Resolving Gel
10% Acrylamide : Bisacrylamide (39:1)
375mM Tris CI pH 8.8
0.1% SDS
10 pi 10% APS/ml of gel
0.4 pi TEMED/ml of gel
After 30 minutes the isobutanol was poured off, the gel washed with distilled
water and the stacking gel poured.
5% Stacking gel
5% Acrylamide:Bisacrlamide (39:1)
125mM Tris CI pH 6.8
0.1% SDS
10 pi 10% APS/ml of gel
1 pi TEMED/ml of gel
The comb was inserted, and the gel allowed to polymerise for 30 minutes. On
removing the comb the wells were washed with distilled water and the
apparatus assembled with electrophoresis buffer in both chambers.
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Electrophoresis buffer
25mM Tris pH 8.3
250mM Glycine
0.1% SDS
Samples each containing approximately 50 pg total protein were boiled for 3
minutes in 1 x SDS gel loading buffer and loaded. A molecular weight
standard (MW SDS-70L Sigma) was run along with the tissue sample. The
gel was run at 100-150V until the bromophenol blue had reached the bottom
of the gel. Two identical gels were run at the same time: one was stained with
Kenacid Blue to ensure quality and equal loading of total protein; the other









2 changes, 2 hrs.
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Western Blotting
The proteins were electrostatically transferred to a nitrocellulose filter
(hybond-C) in transfer buffer at 50V overnight at 4°C.
Transfer Buffer
15mM Tris pH 8.3
120mM Glycine
25% Methanol
After transfer the apparatus was dismantled, the filter washed in distilled






Then destained three times in 5% acetic acid. The remainder of the filter was
washed in TBS-A .
TBS-A
137mM NaCI
20mM Tris CI pH 7.6
then blocked overnight in blocking solution.
Blocking Solution
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10% milk protein (Amersham)
0.1%Tween in TBS-A.
Copious washing with 0.1% Tween in TBS-A was carried out between each
stage. The gel was incubated in PAb 1801 diluted 1:200 in blocking solution
for 2 hours, washed, incubated in biotinylated rabbit antimouse antibodies
(1:500 in blocking solution) for 20 mins, washed and exposed to streptavidin-
alkaline phosphotase conjugate (1:3000 in TBS-A) for 20 mins. After further




400mM Nitro blue tetrazolium
10mM Magnesium chloride
137mM Sodium chloride
20mM Tris CI pH 9.5
for about 5 mins until bands appeared then the reaction stopped by washing
in distilled water. The filter was then dried and photographed.
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9.6 Southern Blot Deletion Analysis
DNA Extraction
Tissue was homogenised in 10ml lysis buffer using a glass homogeniser.
Lysis Buffer




Proteinase K was added to a final concentration of 500 pg/ml and the sample
incubated at 48°C for 48 hrs with intermittent mixing. Extraction with equal
volumes of phenol, PC-9 and chloroform isoamyl alcohol (24:1) were carried
out sequentially.
DNA was then precipitated in 0.5 volumes of 7.5M ammonium acetate and 2
volumes of ethanol at -20°C, spun down, dried and resuspended at a
concentration of 1 mg/ml.
Blood samples were lysed in an equal volume of lysis buffer for 30 mins,
extracted with an equal volume of phenol and precipitated in Vfe volume 7.5M
ammonium acetate and 2 volumes of ethanol. The pellet was resuspended in
lysis buffer containing 0.5mg/ml proteinase K and incubated overnight at
48°C. Thereafter the sample was extracted, precipitated and resuspended in
the same way as for colonic tissue.
Southern Blotting
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Paired samples of 10jjg of normal and tumour DNA were restriction enzyme
digested overnight in a total volume of 30 pi in accordance with the
manufacturer's recommendations. 5 pi of loading buffer was added to each
samples and they were loaded onto a 0.8% agarose gel and electrophoresed
overnight at 4°C in 1 x TBE buffer.
Loading Buffer
95% Deionised formamide
20mM EDTA pH 8.0




2mM EDTA pH 8.0
89mM Boric acid
The gel was viewed under UV light to check for complete digestion,
denatured and DNA transferred to a charged nylon membrane (Genescreen-




After overnight blotting the membrane was air dried and then placed in a
sealed plastic bag containing prehybridisation buffer and incubated at 65°C






0.1mg/ml Single stranded human placental DNA
20 x SSC
3M Sodium chloride
0.3M Trisodium citrate pH 7.0
Plasmids containing the DNA probes were cut with the appropriate enzyme to
yield the desired fragment, run on a 1% low melting point (LMP) agarose gel
containing 0.5 pg/ml ethidium bromide and the fragment cut out. The DNA
was extracted from the agarose using the Geneclean II kit (BIO-101) in
accordance with the manufacturer's protocol. The yield of DNA was estimated
by comparison with standard DNA after electrophoresis of an aliquot in an
eithidium bromide agarose gel. Probes were labelled to high specific activity
with 32P a dCTP (Amersham) using the random prime method of Fienberg
and Vogelstein (1983). A commercial kit (Amersham) was employed to label
25 ng of heat denatured probe DNA in accordance with the protocol. Labelled
probe was separated from unincorporated 32P a dCTP by passage over a
G50 Sepharose Column, denatured by boiling for 10 minutes and added to
25ml prehybridisation buffer to preincubate for one hour at 65°C prior to
addition to the filter. Hybridisation proceeded overnight at 65°C and then
filters were washed at different stringencies depending on the probe used:
YNZ 22
2 x SSC, 0.5% SDS at room temperature
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0.1 x SSC, 0.5% SDS at 65°C (2 washes)
0.1 x SSC, 0.1% SDS at room temperature
MCT 35
2 x SSC, 0.5% SDS at room temperature
0.1 x SSC,0.1% SDS at 65°C (2 washes)
0.1 x SSC at room temperature
THH 59
2 x SSC, 0.5% SDS at room temperature
1 x SSC, 0.1% SDS at 65°C (2 washes)
0.1 x SSC at room temperature
After the final wash filters were blotted dry, wrapped in transparent plastic
wrap and exposed to X-ray film (Fuji) with intensifying screens at -70°C for 2-
5 days. X-ray cassettes were warmed to room temperature and the film
developed in Kodak D19 for 5 minutes, washed in tap water, fixed in FX 40
for 5 minutes, washed again and dried. Cases were classified as:
homozygous (HOM) if only one band was visible in normal DNA;
heterozygous (HET) if two bands were resolved in both normal and tumour
DNA; and loss of heterozygosity (LOFI) if there were two bands in the normal
and if one of the bands was either absent or showed marked diminution in the
tumour sample.
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9.7 PCR Deletion Analysis
DNA Preparation
DNA was extracted from formalin fixed, paraffin embedded tumour tissue
which had been taken for routine histopathological assessment. Initially
standard haematoxylin and eosin stained sections were examined and the
area containing the highest proportion of neoplastic cells was demarcated. 10
pm sections from the corresponding paraffin block were cut and floated onto
glass slides from which the chosen area was removed to an 1.5ml microfuge
tube. Four 10 pm sections from each case were resuspended in 200 pi
paraffin tissue lysis buffer (Jackson et al., 1990).




0.5% SDS pH 8.4
Proteinase K was added to a final concentration of 0.1mg/ml and incubated
for 5 days at 37°C. DNA was extracted twice with phenol:chloroform:iso-amyl
alcohol (25:24:1), once with chlorofomrisoamyl alcohol (24:1) and
precipitated with 0.1 volume 3M sodium acetate (pH 5.2) and 2 volumes of
ethanol. After centrifugation and drying the DNA was resuspended in 20 pi TE
for 3 days and 1 or 2 pi used for amplification.
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PCR amplification
Two sets of primers were used to amplify p53 sequences around the 2
polymorphisms in exon 4 and intron 6.
Exon 4 primers
954 5' GAG AGA AGC TTG CAG CAG CCA GAC TGC CTT GCG GGT GAC
T 3'
959 5' GAA GAG AGA TCT GCA GGG GGA TAC GGC CAG GCA TTG AAG
3'
Intron 6 Primers
883 5' GAG AGA AGC TTC ACT TGT GCC CTG ACT TTC AAC TCT G 3'
870 5' AGA GAG GGA TCC GGG AGG TCA AAT AAG CAG CAG GAG 3'
PCR reactions were set up in a Class 2 hood in a laboratory which never
contained amplified products using positive displacement pipettes. Extensive
precautions were taken to avoid cross contamination. The 100 pi PCR mix
contained: 2 pi of paraffin extracted DNA or 500ng of normal genomic DNA;
primers at a final concentration of 1 pM; dNTP's each at 200pM; 0.1 volume
of NBL 10 x PCR buffer; and 2.5 units Taq polymerase.
10 x PCR Buffer




Samples were thoroughly mixed, centrifuged and overlain with 100 pi paraffin
oil. Amplification was carried out on a programmable heating block starting
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with 2 minutes at 94°C followed by 30 cycles of 55°C for 2 minutes, 72°C for
3 minutes, 94°C for 1 minute and a final cycle of 55°C for 2 minutes, and
72°C for 10 minutes to ensure complete extension of all products. 20 pi of
amplified PCR mix was digested with BstU 1 or Msp1 in a 30 pi reaction mix
in accordance with manufacturer's recommendations. The fragments were
analysed by electrophoresis through a 3% agarose gel (3:1, NuSieve GTG:
SeaKem GTG) containing 0.5 pg/ml ethidium bromide, viewed under UV light
and photographed.
Cases for paraffin DNA analysis were chosen as those which give a
heterozygous pattern from amplification and restriction digestion of normal
genomic DNA. Paired normal and tumour samples were run together and the
cases classified as showing a p53 deletion if one of the two bands were
absent or markedly diminished in the tumour sample compared to normal.
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9.8 Sequencing Human Genomic p53
Exons 5 - 9 of human p53 were amplified in two sets of reactions with 2 sets
of primers situated in adjacent introns.
Exons 5 and 6
883 5' GAG AGA AGC TTC ACT TGT GCC CTG ACT TTC AAC TCT G 3'
870 5' AGA GAG GGA TCC GGG AGG TCA AAT AAG CAG CAG GAG 3'
Exons 7, 8 and 9
890 5' GAG AGA AGC TTG CCA CAG GTC TCC CCA AGG CGA A 3'
891 5' AGA GAG GGA TCC ACT TTC CAC TTG ATA AGA GGT CCC AAG 3'
Again, elaborate precautions were taken to avoid cross-contamination of
reactions with reaction products. Negative control (template free) reactions
were run with each batch to check for contamination. 100 pi PCR reactions
were set up containing: 500ng genomic DNA; primers at 2.5 pM final
concentration; 10% DMSO; 1 x Taq polymerase buffer; dNTP's each at a final
concentration of 200 pM; and 5 units Taq polymerase.
10 x Taq Polymerase Buffer




Samples were overlain with paraffin oil and placed in a programmable heating
block for 30 cycles of 96°C for 1.3 minutes, 53°C for 1.6 minutes and 71 °C for
2.5 minutes. On completion, the entire sample was electrophoresed through a
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1% LMP agarose gel (BRL Ultrapure) against a standard marker. The
amplified band was cut out and the DNA was extracted by squeeze-freezing.
Squeeze-Freeze DNA Extraction
The agarose plug was equilibrated with 500mM sodium acetate, 1mM EDTA
for 30 minutes, frozen in liquid nitrogen then spun out through siliconised
glass wool in a microfuge. The DNA was then precipitated twice in the
presence of dextran carrier ( 2 pi of 10 mg/ml dextran) with 0.3 volume 3M
sodium acetate and 3 volumes of ethanol at -70°C for 5 minutes. After
warming to room temperature for 5 minutes and spinning in a microfuge for 5
minutes, the final pellet was air-dried, suspended in 20 pi TE and restriction
digested with BamHI and Hindlll as directed by the enzyme manufacturer.
After one hour at 37°C the DNA was again separated through a 1% LMP
agarose gel and re-extracted by squeeze-freezing. The plasmid vector
(pUC19) was prepared by restriction digestion with Hindlll and BamHI,
electrophoresis through 1% LMP agarose gel and squeeze-freeze extraction.
Ligation
Approximately 100 ng vector and 50 ng insert were ligated in a reaction
containing: 1 mg/ml bovine serum albumin; 1mM ATP, 1 x ligase buffer; and 1
pi T4 DNA ligase.
10 x Ligase Buffer
500mM TrisCI pH 7.6
100mM Magnesium chloride
100mM Dithiothreitol
The reaction was incubated at 16°C overnight and 5 pi used to transform
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competent E.coli. DH5a E.coli were made competent by the calcium chloride
method (Sambrock et al., 1989) and transformed by mixing 100 pi thawed
cells with the ligation mix and incubating on ice for 30 minutes. The cells were
heat shocked to 42°C for 45 seconds then allowed to recover on ice for 2
minutes. 900 pi of SOC was then added, the cells incubated at 37°C for one
hour, gently spun down, resuspended in 100 pi of medium then plated out on
LB agarose plates containing 50 pg/ml ampicillin.
SOB
2% Bacto-tryptone
0.5% Bacto yeast extract
0.005% Sodium chloride
2.5mM Potassium chloride
Magnesium chloride was added to a final concentration of 10mM prior to use.
SOC
SOB containing 20mM glucose
LB Medium
1% Bacto-tryptone
0.5% Bacto yeast extract
1% Sodium chloride
LB agar
LB medium with 15 g/litre agar
Following overnight incubation at 37°C the number of colonies on each plate
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was assessed. Typically the "vector only" ligation produced less than 5
colonies whereas the vector plus insert ligation produced 50-400 colonies.
Only those with >100 colonies proceeded to the next stage. Those with <100
colonies were re-transformed with more ligation mix or the ligation repeated
until sufficient colonies were obtained.
A mass preparation using all the colonies was prepared by washing the
bacteria from each plate into 500ml of LB medium containing 50 pg/ml
ampicillin. This was incubated overnight in a shaking incubator at 37°C. The
bacteria were pelleted at 7000 rpm for 10 minutes at 4°C, resuspended in
10ml solution I and left at room temperature for 5 minutes.
Solution I
50mM Glucose
25mM Tris CI pH 8.0
10mM EDTApH 8.0




placed on ice for 10 minutes and 15ml of solution III added.
Solution III (100ml)
5M potassium Acetate 60ml
Glacial acetic acid 11.5ml
Distilled water 28.5ml
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After thorough mixing, the mixture was placed on ice for 20 minutes then
cleared by centrifugation at 7000 rpm for 10 minutes at 4°C. The supernatant
was transferred to a clean tube and nucleic acid precipitated by the addition
of 27ml (0.6 volumes) isopropanol at room temperature for 15 minutes. After
centrifugation at 8000 rpm for 10 minutes at room temperature, the pellet was
resuspended in 4ml TE (pH 7.5) then 4.8g CsCI and 200 pi ethidium bromide
(10mg/ml) added. Once the CsCI was dissolved the solution was transferred
into an ultracentrifuge tube and spun on a Beckman Ultracentifugre for 4
hours at 63,000 rpm (20°C). The plasmid DNA band was visualised under UV
light, removed with a syringe and needle and the ethidium bromide removed
by 3 extractions with isoamyl alcohol. The plasmid DNA was diluted in 3ml TE
and 12ml ethanol added. DNA was precipitated at -20°C for 4 hours. After
warming to room temperature the DNA was pelleted by centrifugation at
10,000 rpm, air dried, resuspended in TE and again precipitated with 0.1
volume 3M sodium acetate and 3 volumes ethanol. The resulting pellet was
again redissolved in TE and the concentration adjusted to 1 mg/ml.
Sequencing
Plasmid DNA was initially denatured and annealed to specific primers for
each exon.
5D 1038 5' TTC ACT TGT GCC CTG AC 3'
5R 1008 5' GCC CAG GGT CCC CAG GC 3'
7D 1041 5' GCC ACA GGT CTC CCC AA 3'
8R 931 5' GAA TCT GAG GCA TAA CTG 3'
9D 1042 5' GAC CAA GGG TGC AGT TA 31
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Double-stranded DNA was denatured prior to sequencing in one of two ways:
Maxiprep DNA -10 pg double standard plasmid DNA was denatured in 0.2M
NaOH for 10 minutes at room temperature then precipitated with 0.5 volume
7.5M ammonium acetate and 3 volumes of ethanol at -70°C for 5 minutes.
The dried pellet was resuspended in 5 pi distilled water and 1 pi taken and
annealed to 12.5ng primer in 1 x sequencing buffer plus 10% DMSO in a
volume of 10 pi. The mixture was heated to 65°C for 2 minutes and allowed to
cool slowly to <35°C.
Miniprep DNA - Hsiao et al., 1991. DNA was extracted from a 1.5 ml
overnight culture by the method described in section 9.9 except that at the
final stage the pellet was resuspended in 25 pi of TE containing RNAase A. 5
pi was mixed with 2 pi primer (10ng) and denatured with 1 pi 1M hydrochloric
acid at 37°C for 10 minutes. The mixture was neutralized with 1 pi 1M sodium
hydroxide and 2 pi 5 x sequencing buffer added and incubated at 37°C for 5
minutes. Thereafter the sequencing reaction proceeded as described.
5 x Sequencing Buffer
200mM Tris CI pH 7.5
100mM Magnesium chloride
250mM Sodium chloride
Sequencing was carried out using the dideoxy chain termination method
using the Sequenase 2.0 kit (United States Biochemical). The protocol used
was that supplied with the kit with slight modifications: 1 pi DMSO was added
to the annealing step and 0.5pl to the extension step; the tubes containing the
termination mixes were not pre-warmed as this step was found to be
unnecessary; 1 pi Mn buffer was added at the extension step when
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sequences near to the primer were required. Samples were stored at -20°C
until required.
A 0.25mm thick polyacrylamide gel was poured between glass plates and
allowed to polymerise.




1 pi 25% Amonium Persulphate per ml of gel
1 pi TEMED per ml of gel
Prerunning at 40W was carried out until the gel had reached 50°C then the
samples were denatured by heating to 75°C for 2 minutes and 2 pi loaded
onto the gel. Once the gel had run a sufficient distance it was allowed to cool,
the plates separated and the gel fixed in 12% methanol, 10% acetic acid for
20 minutes. Fixative was poured off, and the gel allowed to stick to a piece of
Watmann 3MM filter paper. The gel was covered in clear film, vacuum dried
at 80°C for 1 hour then exposed to X-ray film overnight at -70°C. without
intensifying screens. The sequence was read by eye.
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9.9 Vector Construction
The clone used in all the targeting vectors, pMSVp53-G, was initially
restriction mapped by single and double restriction digestion, electrophoresis
through a 1% agarose gel containing 0.5 pg/ml ethidium bromide and
visualisation under UV light. The gel confirmed the published map (Bienz et
al., 1984).
Fragments were isolated by separation through a 1% LMP agarose gel
following digestion with the appropriate enzyme. The desired band was cut
out using a clean scalpel blade and the DNA extracted using the Geneclean II
kit (Bio 101). The DNA was resuspended in 10 pi distilled water and 1 pi run
into an agarose gel (containing ethidium bromide) along with standard
concentrations of plasmid DNA to estimate the concentration. In cases where
the vector had compatible, cohesive ends 2 units of calf Intestinal Alkaline
Phosphatase was added to the digestion mix (after digestion was complete)
and incubated at 37°C for a further 1 hour. The alkaline phosphatase was
then inactivated by heating to 85°C for 10 minutes and the DNA
electrophoresed and recovered as detailed above.
Ligation were carried out in a total volume of 10 pi containing: 100ng of
liniarised vector; an equimolar quantity of insert DNA; 1mM ATP; and T4 DNA
ligase buffer.
T4 DNA Ligase Buffer




1 pi of T4 DNA ligase was added and allowed to incubate overnight at 16°C.
Vector only controls (containing no insert DNA) were included for each
reaction. The total 10 pi ligation was used to transform competent E.coli
(HB101 Stratagene) and 200 pi plated out on LB agar containing 50 pg/ml
ampicillin. Following overnight incubation at 37°C the colonies were counted
to ensure an enrichment in the number from the vector plus insert ligation.
Single colonies were picked using sterile tooth picks, placed into 2ml LB
ampicillin and allowed to incubate overnight at 37°C in a shaking incubator.
Miniprep
1.5ml of bacteria was transferred to a microfuge tube, pelleted by
centrifugation for 30 seconds and the supernatant aspirated. The pellet was
resuspended in 100 pi ice cold Solution I then lysed by the addition of 200 pi
Solution II and incubated on ice for 5 minutes. Solution III (150 pi) was added,
the sample vortexed and placed on ice for a further 5 minutes. Following
centrifugation for 5 minutes at 4°C the supernatant was removed, extracted
once with phenol:chloroform:iso-amyl alcohol (25:24:1) and precipitated at
room temperature by the addition of 2 volumes of ethanol. The DNA was
pelleted by centrifugation, dried and resuspended in 50 pi TE containing
2pg/ml DNAase free RNAaseA. Plasmid DNA was analysed for the correct
ligation event by restriction digestion and agarose gel electrophoresis.
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9.10 Embryonal Stem Cell Culture
The murine embryonal stem cell line E14 was maintained by culture in: CM (3
LIF medium:
CM B LIF Medium
Glasgow Modification of Eagles medium supplemented with:
Glycine 0.1 mM
L-alanine 0.1 mM
L-aspartic acid 0.1 mM
L-asparagine 0.1 mM




Foetal calf serum 5%
Neonatal calf serum 5%
B-mercaptoethanol 0.1 mM
Leukaemia inhibitory factor (sufficient to prevent
differentiation) (Smith et al., 1988; Williams et al.,
1988).
Cells were grown at 37°C in 4% carbon dioxide on plastic tissue culture
vessels precoated with 0.1% gelatin. The medium was changed as required
and cell passaged as they approached 70% confluence.
Electroporation
50-150 pg of plasmid DNA was linearised with the appropriate enzyme and
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an aliquot run on a gel to check for complete digestion. The remainder was
precipitated, pelleted, dried and resuspended in 200 pi sterile PBS in a class I
hood. Approximately 108 E14 cells, were disaggregated by incubation in 4ml





in phosphate buffer saline (Flow labs).
Cells and DNA were mixed, placed in a BioRad electroporation cuvette and
electroporated at 0.8mA, 3.0 pFa, time constant 0.1 in a BioRad Gene Pulser.
Cells were subsequently placed into 120ml of CM B-LIF medium and plated
out, 8 ml per 100mm pregelled Petri Dish. After 24 hours the medium was
aspirated and replaced by CM B-LIF medium containing 300 pg/ml G418 with
or without 2 pM ganciclovir as appropriate.
The medium was replaced as required until obvious clones were visible
usually after 10-14 days. When clones were 2-3mm in diameter they were
picked by aspiration into a finely drawn glass pipette under a phase contrast
dissecting microscope and transferred into a drop of TVP. Following
incubation at 37°C for 5 minutes the cells in each droplet were disaggregated
by gently pipetting and transferred into a single pre-gelled well of a 24 well
plate. Once they had reached 80+% confluence the medium was aspirated
and 3 drops of TVP added to each well. After 5 minutes at 37°C the trypsin
was inactivated by the addition of 1ml of CM B-LIF medium and cells
disaggregated by gentle pipetting. They were then transferred to 25cm2
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pregelled plastic culture bottles and refed as required until 80+% confluent. At
this stage the medium was aspirated and the cells trypsinised with
approximately 2ml TVP. Once disaggregated, 1 ml was taken for freezing and
1ml for genomic DNA extraction. Cells for freezing were gently pelleted at
"lOOOrpm for 60 seconds in a microfuge then resuspended in 1ml of freezing
medium and transferred to a 1.5ml Nunc cryotube.
Freezing Medium
CM I3-LIF Medium 70%
Foetal calf serum 20%
DMSO 10%
These were placed in a -70°C freezer to slowly cool and freeze overnight and
subsequently stored long-term in liquid nitrogen. For DNA extraction, cells
were pelleted 13,000rpm for 3 minutes, resuspended in 750 pi of lysis buffer
containing 500 pg/ml proteinase K and incubated at 37°C overnight with
shaking.
Stem Cell Lysis Buffer
50mM TrisCI pH 8.0





Samples were extracted twice with phenol, once with chloroform: isoamyl
alcohol (24:1) and precipitated with an equal volume of isopropanol. The DNA
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was spooled on a plastic pipette tip and resuspended in 500 pi TE.
Clones required for further analysis by immunohistochemistry or for
blastocyst injection were thawed quickly in a 37°C water bath with agitation,
resuspended in 5ml CM 8-LIF medium, pelleted at 1000rpm for 5 minutes
then resuspended in 10ml CM 3-LIF and used to inoculate a 25cm2 flask.
Analysis of Clones
Southern Blot
30 pi of DNA was digested overnight in a total volume of 50 pi using the
appropriate restriction enzyme under the recommended conditions. It was
separated by 0.8% agarose gel electrophoresis, transferred to a charged
nylon membrane, prehybridised and hybridised to a radioactively labelled
probe as previously described.
Washing was carried out as follows: 2 x SSC at room temperature; 1% SDS,
0.1 x SSC at 65°C (2 washes, 15 minutes each); then lightly blotted dry and
wrapped in transparent plastic film. Filters were exposed to X-ray film for 1-2
days at -70°C.
PCR
Genomic DNA from each clone was amplified using oligonucleotide primers
MM5.5 and MM7.7
MM5.5 5' CTC AAT AAG CTA TTC TGC CAC CTG 3'
MM7.7 5' CTA ACC TAC CAC GCG CCT TCC TAC 3'
5 pi genomic DNA was amplified in 100 pi reaction mix containing: primers at
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0.5 pM; dNTP's each at 200 |jM; and 2.5 units Taq DNA polymerase in PCR
buffer.
PCR Buffer




The mix was overlain with 100 pi paraffin oil, placed on a programmable
heating block and underwent 30 cycles of: 94°C for 1 minute; 55°C for 1
minute; 72°C for 2 minutes; with a final cycle terminating with 10 minutes at
72°C to ensure complete extension of all products. After amplification, 30 pi of
PCR mix was restriction digested in a 40 pi reaction containing 4 pi of 10 x
Dralll digestion buffer and 8 units Dralll (NBL) for 1 hour at 37°C.
10 x Dralll Digestion Buffer




The digested DNA was analysed by electrophoresis through a 4% agarose
gel (Nusieve GTG:SeaKem GTG 3:1) containing 0.5 pg/ml ethidium bromide
and viewed under UV light. The uncut PCR product was approximately 903bp
in length and when digested with Dralll yielded 2 fragments of 555bp and
348bp from the wild type gene or 555bp, 348bp and 324bp in the case of a
WT and mutant gene (the 24bp fragment not being visible in the analysis).
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9.11 Germ-iine transmission of targeted p53
The targeted ES cell clone R3.72 was susequently expanded and 10-15 cells
injected into 3.5 day old blastocysts from F2 (C57/BI6 x CBA) mice. These
were implanted into psuedo-pregnant females and chimaeric mice produced
identified by their coat colour. Chimaeric animals were mated with Ola/129
mice and offspring derived from the targeted cells identified by their chinchilla
coat colour. DNA from tail biopsies was screened by Southern blotting in the
same way as the ES cells for the targeted event. Mating of 2 heterozygotes
resulted in mice with homozygous p53 inactivation.
Heterozygote (p53 +/-) and homozygote (p53-/-) mice were genotyped and
observed. Animals which had obvious tumours or were unwell were killed by
cervical dislocation and underwent post-mortem examination. Diagnoses
were made mostly on the basis of the gross pathological appearances and
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p53 Expression in Colorectal Tumors
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The expression of the nuclear phosphoprotein p53
was studied immunohistochemically in a series of
150 benign and malignant colorectal tumors. Using
monoclonal antibody PAbl801, tumors divided un¬
equivocally into two groups on the basis of immu-
nohistochemistry. Forty of the carcinomas (46.5%)
showedpositive staining but only 4 of the adenomas
(8.7%) were positive (P < 0.001). The few positive
adenomas always showed moderate or severe dyspla¬
sia Metaplastic polyps (n = 9) and small familial
adenomatous polyposis-related adenomas (n = 9)
were uniformly negative. Carcinomas with p53 ex¬
pression did not differfrom those without in terms of
site, differentiation or the prognostic indicators of
Dukes' stage, DNA ploidy, or tumor histology. The
improved morphologic resolution available in per-
iodate lysine paraformaldehyde dichromate (PLPD)-
fixed, paraffin-embedded tissue permitted several
conclusions to be made: p53 is confined to neoplastic
nuclei; staining in positive tumors is heterogeneous
and often more marked at the infiltrative margins;
and staining intensity is dramatically reduced in mi¬
totic cells. It is concluded that expression of immu¬
nohistochemically detectable p53 (probably repre¬
senting mutatedforms of theprotein) occurs in some
adenomas around the time of transition to carci¬
noma Therefore there is an association with the ap¬
pearance of infiltrative behavior but not with degree
of tumor progression (including metastasis) at the
time of resection. (Am J Pathol 1991, 138:807—813)
Overexpression of p53 has been demonstrated immuno¬
histochemically in a number of common human malig¬
nancies, including carcinomas of colon, breast, and
lung.1^3 In the case of breast carcinoma, this immunore-
activity has been shown to correlate with a number of
clinical and histopathologic indicators of poor prognosis2
and may become useful in the future in determining ther¬
apeutic strategies.
The 53-kd nuclear phosphoprotein p53 is found in all
mammalian cells so far investigated as well as in
xenopus.4 It is usually expressed at low levels and has a
short half-life (only 6 minutes in the spleen)5 Its normal
function remains obscure but it has been implicated in
control of the cell cycle because levels of p53 mRNA and
protein increase in late G1 before the onset of DNA
synthesis6 and cells are prevented from entering S phase
by microinjection of p53 antibodies or by the presence of
anti-sense p53 RNA78
p53 forms stable complexes with the products of
transforming genes of DNA viruses (SV40 large T
antigen9,10 and adenovirus E1b protein11) and can be
oncogenically activated by mutations in certain regions of
the gene.12 Under these circumstances, p53 becomes
much more stable,13 loses the capacity to bind viral
oncogenes,14 immortalizes rodent fibroblasts,15-17 and
cooperates with ras in their transformation.18 The nonmu-
tated, wild-type (WT) p53 gene, however, behaves as a
tumor suppressor and can reverse the transformed
phenotype.19
Interest in p53 in colorectal cancer was stimulated by
the finding that the region on chromosome 17p, which is
consistently deleted in the majority of such tumors (thus
indicating the site of a putative tumor suppressor gene),
contains the gene for P53.20 In cases in which one copy
of p53 is deleted, the remaining copy is frequently mu¬
tated, but mutations also occur in tumors that retain a
normal p53 allele.21
Previous immunohistochemical studies of p53 have
been restricted to frozen sections,1,2 because the
epitope is destroyed by formaldehyde fixation. Here, by
the use of the fixative PLPD,22 we exploited the superior
morphologic resolution of immune reaction product pos-
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sible in paraffin sections. We describe p53 expression in
a series of 86 colorectal carcinomas and 62 polyps, in¬
cluding 9 from patients with familial adenomatous poly¬
posis, and correlate the staining pattern with well-
recognized indicators of clinical outcome.
Materials and Methods
Tissue
Ninety-two consecutive colectomy specimens were re¬
ceived onto ice in the operating theater, opened, and
rinsed in ice-cold phosphate-buffered saline/
ethylenediamine tetraacetic acid (EDTA) (20 mmol/l [mil-
limolar] sodium phosphate buffer pH 7.4,145 mmol/l so¬
dium chloride, 0.5 mmol/l EDTA) within 30 minutes. Sam¬
ples of tumor and adjacent normal mucosa for
immunohistochemistry were placed immediately in per-
iodate lysine paraformaldehyde dichromate (PLPD)
fixative22 (1% paraformaldehyde, 75 mmol/l lysine, 37.5
mmol/l sodium periodate, 2.5% potassium dichromate in
18.75 mmol/l sodium phosphate buffer pH 7.4) fixed for
24 hours at 4°C, washed extensively, and processed into
paraffin blocks. Further samples of tumor and distant nor¬
mal mucosa were snap frozen in liquid nitrogen and then
stored at - 70°C for flow cytometry or cryostat sections.
The rest of the specimen was fixed in formalin and pro¬
cessed routinely for hematoxylin and eosin staining and
histopathologic assessment. For the purposes of numer¬
ical analysis, tumors were defined as right sided if they
lay between cecum and splenic flexure or left sided if
they were more distal.
Histopathologic Grading
Carcinomas were reviewed and graded by a single pa¬
thologist (J Piris) using criteria recommended by the
United Kingdom Coordinating Committee on Cancer Re¬
search for Dukes' stage, histologic type, degree of differ¬
entiation, and nature of invasive margin.23 Adenomas
were similarly reviewed and graded by a single patholo¬
gist (J. O'Grady) for morphologic type and degree of
dysplasia.24
Flow Cytometry
Three or more samples from separate sites in each car¬
cinoma were prepared for assessment of nuclear DNA
content by flow cytometry using the method of
Vindelov.25 The tissue was disaggregated under a citrate
buffer and treated with detergent (0.1% NP-40) and
trypsin (30 (j,g/ml) followed by RNAase A (0.1 mg/ml).
The resulting nuclear suspension was stained with pro-
pidium iodide at a final concentration of 2 mg/ml. Avian
erythrocytes were added as an internal standard and the
samples analysed on a Coulter EPICS CS flow cytometer
(Coulter, Hialeah, FL) at an excitation wavelength of 488
nm. At least 10,000 nuclei were analyzed in each sample
and cases were scored as aneuploid if any of the three
samples showed a Gq/G., peak distinct from the normal
diploid peak (as assessed from the internal standard).
Coefficients of variation of the diploid peak were typically
less than 3.5.
Immunohistochemistry
Three-micrometer sections of PLPD-fixed, paraffin-
embedded tissue were stained using the human p53-
specific mouse monoclonal antibody PAb180126 (p53-
Ab2 Oncogene Science Inc., Manhasset, NY). Sections
were rehydrated in graded alcohols incubated in normal
rabbit serum diluted 1:5 in TRIS-buffered saline (TBS)
(145 mmol/l NaCI, 20 mmol/l TRIS pH 7.6), and exposed
to primary antibody at a dilution of 1:100 for 1 hour.
Bound antibody was detected using biotinylated rabbit
antibody to mouse immunoglobulin (Dakopatts No. E354,
Glostrup, Denmark) and avidin-biotin complex linked to
horseradish peroxidase (Dakopatts No. K335). Copious
washing in TBS between each step was essential. Visu¬
alization was with diaminobenzidine (1 mg/ml) in the
presence of 0.03% hydrogen peroxide. Endogenous
peroxidase was not inhibited. Cases known to stain pos¬
itively were included in each run, receiving either primary
antibody or simply dilution buffer, to monitor consistency
and act as controls. Sections received a light hematoxylin
counterstain and were dehydrated in graded alcohols
and xylene before mounting. The specificity of PAb1801
for human p53 under the conditions used was confirmed
by inclusion in some staining runs of PLPD-fixed SV80
cells (an SV40-transformed, human fibroblast cell line
known to express high levels of p53)27 In addition, 4-^m
cryostat sections from a number of carcinomas in the
series were fixed in acetone for 15 minutes then exposed
to PAb1801 at a dilution of 1:100 (53 cases) or undiluted
culture supernatant from the hybridoma secreting anti¬
body PAb240 (39 cases). PAb240 binds to a different
p53 epitope from PAb1801, revealed by the conforma¬
tional changes induced by mutation.28 Bound antibody
was detected using rabbit antibodies to mouse immuno¬
globulins conjugated with horseradish peroxidase (Dako¬
patts No. P260) at a dilution of 1:20 and visualized in an
identical fashion to that used for PLPD-fixed sections. The
distribution of PAb1801 staining within cells and within the
tissue was identical in PLPD-fixed and frozen section. No
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discrepancy in the assignment of PAb1801 positivity be¬
tween frozen and paraffin sections was found.
Immunoblots
tion in TBS, 10% milk protein, 0.1% Tween-20, then
probed with PAb1801 (1:200) and detected using a
streptavidin, biotin, alkaline-phosphatase system (Amer-
sham, RPN 22) in accordance with the manufacturers'
recommendations.
Total protein was extracted from tumors, normal colonic
mucosa, and SV80 cells. Equal amounts of total protein
(approximately 50 p.g) were separated by electrophore¬
sis through a 10% polyacrylamide gel containing 0.1%
sodium dodecyl sulfate along with molecular-weight
standards (MW-SDS-70L Sigma Chemical Co., St. Louis,
MO) and transferred to nitrocellulose (Hybond-C, Amer-
sham, Arlington Heights, IL) by standard methods.28
Nonspecific binding was inhibited by overnight incuba¬
Results
Reaction product, marking the binding of PAb1801, was
confined to the nuclei of neoplastic cells (Figure 1 a). Nor¬
mal colonic mucosa never stained in cytoplasm or nu¬
cleus. Rarely pale staining was observed in smooth mus¬
cle cells (particularly of blood vessels) at high antibody









, • V, 'iv.'
0$ *
D ■ * v '








' •■•b « *
e,
3#
Figure 1. Immunostaining of colorectal tumors using PAbl801
on PLPD-fixed, paraffin-embedded tissue (A, B, C, and E) or
PAb240 on acetone-fixed cryostat sections (D). All sections received
a light hematoxylin counterstain. A: Low-power view showingpos¬
itively stained carcinoma nuclei and adjacent negatively stained
normal mucosa (X40). B: High-power view showing granular
staining pattern confined to nuclei and several mitotic cells (ar¬
rowed) exhibiting reduced intensity ofstaining compared to other
carcinoma nuclei (X400). C: Heterogeneity ofstaining with more
marked staining at the invasive margin ofthe carcinoma, where it
is advancing beneath the adjacent normal mucosa (x 100). D:
Positive staining of carcinoma nuclei with PAb240 (x.200). E:
Positive staining in nuclei dispersed throughout a moderately dys-
plastic adenoma (X200).
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within the tumor nuclei was granular or reticular in nature
(Figure 1 b) sometimes with obvious nucleolar sparing.
During mitosis, reaction product was reduced dramati¬
cally (Figure 1b), whereas interphase tumor cells never
showed cytoplasmic staining.
The tumors divided unequivocally into two groups on
the basis of PAb1801 immunohistochemistry. Tumors
were scored as positive when staining was visible in any
nuclei within the tissue section. In such cases, positive
nuclear staining of identical incidence and distribution
was found even when the concentration of primary anti¬
body was reduced to 1:400 or increased to 1:10. Similarly
cases scored negative remained without staining in any
cells even at concentrations as high as 1:10.
In positive tumors the pattern of immunostaining was
not uniform. In a small number of tumors almost all the
nuclei stained positively, but the more common pattern
was an admixture of tumor acini that showed no staining
with those in which most nuclei were stained. The great¬
est proportion of positive cells was found in acini at the
invasive margins of carcinomas. Sometimes the distinc¬
tion was obvious within a single gland, with strong stain¬
ing on the outer side and weak or none on the inner side
(Figure 1 c). All these patterns were sustained over a 40-
fold range of dilution of primary antibody (data not
shown). Immunostaining of cryostat sections from a sub¬
set of 39 carcinomas using PAb240 demonstrated a very
similar pattern and overall incidence of antibody binding
(Figure 1 d) and all cases that were scored PAb1801 pos¬
itive were also PAb240 positive by the same criteria.
In total, 86 carcinomas from 86 patients were ana¬
lyzed with PAb1801 and of these 40 (46.5%) showed
positively stained nuclei. Prognostic indicators (Duke's
stage, DNA aneuploidy, degree of tumor differentiation,
and nature of invasive margin) showed no significant cor¬
relation with PAb1801 staining (Table 1). Similarly the pro¬
portion of PAb1801 -positive tumors was unrelated to their
site within the colon or rectum (Table 1).
Table 1. Correlation ofPAbl801 Immunostaining with
Histopathological Classification, DNA Ploidy, and
Primary Tumor Site for Carcinomas












* Chi-square test with Yates1 correction.
NS, not significant (P > 0.05).
Fifty-five sporadic polyps from 30 patients were stud¬
ied with PAb1801 comprising 9 metaplastic polyps and
46 adenomas. The metaplastic polyps were all negative.
Of the 46 adenomas, 4 (8.7%) were positive (Table 2).
The positively staining nuclei were dispersed throughout
the adenoma in one case (Figure 1 e) and in the remain¬
ing three were restricted to only a few glands. All four
showed either moderate or severe dysplasia, but there is
no statistically significant correlation within our series with
other morphologic parameters or tumor size (Table 2). In
one large villous adenoma that contained foci of infiltra¬
tive carcinoma, however, p53 staining was absent in the
adenoma but present in the infiltrative glands only. In ad¬
dition, PLPD-fixed material was available from nine tubu¬
lar adenomas, all less than 4 mm in diameter from two
patients undergoing colectomy for FAP; all were negative
for PAb1801 immunostaining. The difference in incidence
of positive staining in adenomas as compared with car¬
cinomas is very significant (Table 2).
Immunoblots of total protein extracted from tissue
samples (Figure 2) demonstrated that PAb1801 recog¬
nizes a single 53-kd protein that could be extracted from
those tumors that were immunohistochemically positive
but not from negative tumors or normal colonic mucosa.
This detection of p53 in immunoblots correlated exactly
with detection in frozen and paraffin sections.
Discussion
The data demonstrate a strong relationship between p53
expression and malignant transformation in colorectal tu¬
mors. In contrast to carcinomas, very few adenomas
showed p53 expression and those that did all belonged
to the more dysplastic categories in which the risk of tran¬
sition to invasive carcinoma is higher. In one case of a
Table 2. Correlation ofPAbl801 Immunostaining with
Histopathology ofAdenomas















* Chi-square lest with Yates' correction.
NS, not significant (P > 0.05).
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Figure 2. Immunoblot of total protein
stained using PAbl801. Lane 1: SV80 cells.
Lane 2: Normal colonic mucosa. Lane 3: Im-
munohistochemically positive carcinoma.
Lane 4: Immunohistochemically negative car¬
cinoma. Lanes 5 and 6: Immunohistochemi-
cally positive carcinomas. Lane 1: SV80 cells.
Molecular weights are expressed in kilodal-
tons.
villous adenoma that had undergone malignant change,
p53 expression was restricted to the frankly carcinoma¬
tous portion sparing the dysplastic epithelium. In the car¬
cinomas, the advancing edge was the most consistently
staining region. Nonetheless, approximately one half of
all colorectal carcinomas did not show p53 expression,
and comparison of expressing and nonexpressing car¬
cinomas revealed no differences in terms of the tumor
site or established prognostic indicators such as histo¬
logic grade,23 Dukes' stage,30 and DNA ploidy31 Be¬
cause most of the tumors studied in this consecutive se¬
ries were (as expected) of Dukes' B and C stages, the
lack of correlation with staging is essentially an indicator
that p53 expression has no association with the tendency
to form lymph node metastasis. It appears, therefore, that
p53 expression is associated with the transition from ad¬
enoma to carcinoma in some colorectal tumors but does
not uniquely determine infiltrative activity or relate to other
features of carcinoma progression. However, in view of
the short time of clinical follow-up of the patients studied
here, we have no data yet that directly compare postop¬
erative course and p53 staining.
The monoclonal antibody PAb1801 used here is spe¬
cific for human p53, binding near the N terminus.26 It thus
detects both WT and mutated forms of the protein, all the
mutations described being 3' to the antibody binding
site.21 Wild-type p53 has a short half-life and was not
detected immunohistochemically in any of the normal tis¬
sues in this study. By contrast, mutations of p53, which
are common in human colorectal cancer21 result in a
greatly extended protein half-life permitting immunohisto-
chemical detection.32 PAb240, which binds selectively to
mutated p53 28 stains positively cases that are PAb1801
positive in this series and has a very similar distribution of
reaction product. Thus the tumors exhibiting PAb1801
immunostaining almost certainly have p53 mutations; we
are now confirming this by sequencing the gene for p53
in selected tumors (manuscript in preparation).
PAb1801 has the advantage that its epitope is stable
in PLPD-fixed (but not formaldehyde-fixed) tissue, thus
permitting the improved morphologic localization of par¬
affin sections. The discrete nuclear localization of the
PAb1801 epitope observed here contrasts with a previ¬
ous report on p53 expression in breast carcinomas
based on an analysis of frozen sections in which cyto¬
plasmic staining was observed 2 Complex formation be¬
tween mutant p53 and the cytoplasmic heat shock pro¬
tein hsp 72/73 has been demonstrated, which might ex¬
plain its cytoplasmic location in some tissues.14 In a large
subset of the present series, however, we also applied
PAb1801 to frozen sections and found the same pattern
of nuclear staining. Breast carcinomas also differ in that
p53-expressing tumors tend to be in poorer prognostic
groups,2 an association we do not observe for colorectal
carcinomas (Table 1).
Within some of the sections showing positive immu¬
nostaining there was marked cell-to-cell heterogeneity.
Because the mutation of the p53 gene probably is clonal,
this variation in protein level may indicate that mutated
p53 is under similar cell-cycle control to that demon¬
strated in WT p53 with levels increasing before S phase.6
Further evidence for cell-cycle-related changes in pro¬
tein levels comes from the mitotic cells that consistently
showed much-reduced immunostaining. The distribution
of positively stained cells around the advancing margins
of carcinomas has not been reported previously and is
812 Purdie et al
AJP April 1991, Vol. 138, No. 4
more difficult to explain as a cell-cycle-related phenom¬
enon and may represent some form of inductive interac¬
tion with stromal tissues.
In transgenic animals, expression of mutated p53,
even at high levels, does not produce tumors in some
tissues,33 indicating that changes in p53 alone are not
sufficient to cause neoplastic transformation. In human
colorectal carcinogenesis, several other genetic changes
occur at high frequency, such as Ki-ras mutations and
deletions in chromosomes 5q, 18q, and 17p (including
the locus of the p53 gene)34 Accumulation of these
events seems to be important in determining prognosis,
presumably facilitating the rather poorly defined cellular
changes that constitute tumor progression. The data pre¬
sented here show that expression of p53 (probably due
to mutation) is an event occurring around the transition
from adenoma to carcinoma and therefore at the same
stage in tumor progression as 17p deletion.34 The distri¬
bution of the most intensely staining cells also relates to
local infiltrative activity. Therefore p53 may be one factor
permitting malignant transformation but it is unlikely to
account for other features of carcinoma progression such
as metastasis and the tendency to develop DNA aneu-
ploidy.
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High frequency of APC loss in sporadic colorectal carcinoma due to
breaks clustered in 5q21-22
P.G. Ashton-Rickardt1, M.G. Dunlop2, Y. Nakamura3, R.G. Morris1, C.A. Purdie1, C.M. Steel2,
H.J. Evans2, C.C. Bird1 & A.H. Wyllie1
1 Department ofPathology, and University Medical School; 2MRC Human Genetics Unit, Edinburgh, UK; 3Howard Hughes Medi¬
cal Center, University of Utah, Salt Lake City, USA
Familial adenomatous polyposis is transmitted by a gene
(APC) located within 5q21-22. Hemizygous loss of at
least a part of 5q has been reported in 19-36% of spor¬
adic colorectal carcinomas. This suggests that an anti-
oncogene is located on that chromosome arm, but the
probes used previously gave little information on the
status of APC in the tumours. Using DNA probes
homologous to polymorphic sequences flanking and close
to the A PC locus we show that more than half of a large
series of carcinomas had lost at least one flanking allele.
Mapping of allele losses provides data that imply clus¬
tering of breakpoints in a 10-15 megabase region around
APC. The commonest chromosome defect responsible for
APC loss was interstitial deletion. Mitotic recombination
or partial arm loss were less frequent mechanisms. Whole
chromosome loss was rare. This pattern contrasts with
that reported in acquired homozygosity at other anti-
oncogene loci in sporadic tumours and implies that A PC
loss is an early event in colorectal carcinogenesis. This
view is also supported by the observations that 5q21-22
loss occurs with similar frequency in DNA diploid and
DNA aneuploid tumours, and also in tumours at all clini¬
cal stages of progression.
Introduction
Two observations suggest that an anti-oncogene con¬
cerned with the regulation of colorectal mucosal growth
is situated on the long arm of chromosome 5. First,
familial adenomatous polyposis -—a Mendelian domin¬
ant condition characterised by development of large
numbers of colorectal adenomas — is transmitted by a
gene (APC) mapping within 5q21-22 (Bodmer et al.,
1987; Leppert et al., 1987). Second, hemizygous loss of
at least part of 5q has been reported in 19-36% of spor¬
adic colorectal carcinomas (Solomon et al., 1987;
Okamoto et al., 1988; van den Broek et al., 1988;
Vogelstein et al., 1988; Law et al., 1988; Rees et al.,
1989). There is, however, little information on the status
of APC itself in these tumours. At other, better-defined
anti-oncogene loci, such as the genes conferring suscep¬
tibility to Wilms' tumour and retinoblastoma, acquired
allele loss within the tumours commonly involves whole
chromosomes (Dryja et al., 1984; Fearon et al., 1984).
Such losses are probably the result of mitotic non¬
disjunction. In contrast, recent studies in human
colorectal and breast carcinoma have revealed a high
frequency of acquired homozygosity of 17p alleles
(Monpezat et al., 1988; Vogelstein et all, 1988; MacKay
et al., 1988), but here the loss is commonly achieved
Received 22 May 1989; accepted in revised form 21 June 1989
through partial arm deletion or mitotic recombination,
requiring an intrachromosomal breakage event. In this
paper we examine the status of APC in a large series of
sporadic colorectal carcinomas. Using DNA probes
homologous to polymorphic sequences flanking and
close to APC ('closely-flanking markers'), we show that
APC alleles are lost in a much higher proportion of
tumours that hitherto recognised. Whole chromosome
loss is rare, the majority of lesions resulting from
intrachromosomal breakage (interstitial deletions,
mitotic recombinations or partial arm losses). The
results have interesting implications on the status of
APC in colorectal carcinogenesis, and its susceptibility
to nearby chromosome breakage events.
Results
Loss of APC in sporadic tumours
There were 119 tumours, confirmed as carcinomas by
histology in all but 2 cases, the exceptions both being
large villous adenomas. Pairs of closely-flanking
markers lying centromeric and telomeric to APC within
5q21-22 were used to detect tumours exhibiting hemi¬
zygous loss of polymorphic restriction fragment alleles.
To establish the physical extent of allele loss, tumour
DNA was analysed with probes mapping to regions
spanning chromosome 5 at 5p, 5ql2-14 (close to the
centromere) and 5q35 (telomeric). Details of the probes
used are given in Table 1 and examples of allele loss
demonstrated with each are shown in Figure 1. The
Table 1 Probes used in analysis of chromosome 5 alleles
Specification
of target Alleles
Probe sequence Enzyme kb Ref
LI.4 D5 S4 EcoRl 0.7, 0.6 1,2
MLZ 7.5 — EcoRl 2.9, 2.2, 3.2* 1
105-153 Ra D5S39 Mspl 8.0, 5.0 1,2
105-599 Ha D5S76 TaqI 17.0, 14.0, 10.0 1, 2
105-789 Rb D5S78 Mspl 2.3, 1.8 1,2
tt227 D5S37 Bell 3.0, 1.8, 1.2 2, 3, 4, 5, 6
C11P11 D5S710 Taql 4.4, 3.9, 5.0* 3, 7,8
YN5.48 D5S81 Mspl 9.0, 8.0 3, 8
MC5.61 D5S84 Mspl 5.5, 5.0 3,8
X MS8 D5S43 Hinfl 2.4-9.5 2, 9
* Constant allele
References: 1. Leppert et al. (1987)
2. Olaison et al. (1987)
3. Nakamura et al. (1988)
4. Dunlop et al. (1989)
5. Meera Khan et al. (1987)
6. Stewart et al. (1987)
7. Bodmer et al. (1987)
8. Wasmuth & Ferrell (1988)
9. Solomon et al. (1987)
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Figure 1 Location of polymorphic sequences in chromosome 5 detected by the ten probes used in this study (Table 1). The genetic
distances between the APC markers are given in centimorgans (1 cM equivalent to 1 megabase (1 mb) in humans). Distances are
reproduced from a single early study (Nakamura et at., 1988) for the sake of consistency. More recent data, however (M.G. Dun'iop,
Y. Nakamura, unpublished), indicates that the distance between n 221 and CI IP 11 may be as little as 2cM and between C11P11 and
YN5.48, approximately 10 cM
overall frequency of loss observed for any 5q-linked
allele was 48% (Table 2A), substantially higher than
that quoted in previous studies. A similar high fre¬
quency (45%) was found when analysis was restricted to
tumours showing loss of alleles in 5q21-22 (Table 2B).
Of the 65 tumours informative with closely-flanking
markers on both sides of APC, 35 (54%) showed loss of
a flanking allele (Table 2C), and in the great majority of
these (24/35; 69%) the loss was unilateral. The uni¬
lateral loss of closely-flanking markers occurred centro-
merically and telomerically to APC in equal
proportions indicating the existence of a cluster of
breakpoints within a 10-15 mb region either side of
APC.
Nature of defects in chromosome 5
Information from tumours mapped with closely-
flanking markers, when combined with data from
markers mapping to outlying regions of chromosome 5,
allowed a physical interpretation of 5q defects (Table
2D). Of the 32 tumours exhibiting loss of one or more
of the alleles within 5q21-22, the great majority
remained heterozygous for one other chromosome 5
allele at least. This demonstrates that loss of the whole
of chromosome 5 plays a minor role in generating APC
allele loss in sporadic colorectal cancer. The commonest
lesion (20/32; 63%) was interpreted as interstitial dele¬
tion since the tumours remained heterozygous for
markers on both sides of the region showing allele loss.
A qualitative depiction of the data (Figure 2) shows the
large contribution of breakpoints close to APC in these
deletions, of which the smallest observed was about 10-
15 mb long (the distance between YN5.48 and C11P11;
Y. Nakamura unpublished data). The remaining class of
chromosome lesions included fewer breaks close to
APC but showed a striking bias towards the loss of
markers telomeric to APC. Presumably these represent
mitotic recombinations or partial arm losses, which are
not distinguished from each other by this type of
analysis. The mapping of these allele losses reinforces
the view that a specific region, inclusive of the APC
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A. Informative within 5q 117 (100%)
Allele loss within 5q 56 (48%)
B. Informative at 5q.21-22 107 (100%)
Allele loss at 5q.21-22 56 (48%)
C. Informative at closely-flanking
loci on both sides offap 65 (100%)
Loss of at least one flanking 35 (54%) (100%)
allele
Loss of one flanking allele 24 (59%)
Loss of both flanking alleles 11 (31%)
D. Permitting physical interpretation
of 5q defect 68 (100%)
Total with 5q.21-22 allele loss 32 (48%) (100%)
Interstitial deletion 20 (63%)
Partial arm loss/mitotic 11 (34%)
recombination
Whole chromosome loss 1 (3%)
gene, is commonly deleted in sporadic colorectal carcin¬
oma. Of 36 carcinomas showing retention of a pair of
closely-flanking markers in 5q21-22 only 1 showed the
loss of an outlying 5q allele.
Loss ofAPC and tumour progression
In an attempt to ascertain the phase of tumour evolu¬
tion at which APC alleles are most commonly lost, we
studied the frequency of loss in tumours that differed in
stage of progression, or in DNA ploidy. There was no
correlation (P > 0.05) between the degree or occurrence
of DNA aneuploidy (as determined by flow cytometry)
and APC loss (Table 3). Nor did loss of -4PC-flanking
markers correlate with Dukes' staging of the extent of
tumour spread. It thus appears that the loss of APC
takes place independently of (and probably before) the
emergence of features determining the progression of
the carcinoma. This agrees with the observation of
5q21-22 allele loss in both of the villous adenomas in
this study. Such tumours do not show infiltration or
metastasis but carry a high probability of progressing to
carcinoma.
Discussion
The high frequency of 5q21-22 loss recorded in this
study is due entirely to the use of closely-flanking
Table 3 Prognostic indicators and 5q21-22 status
5q21-22 status*
Tumour status Retained Lost
Villous adenoma 0 2 (100%)
Carcinoma — Dukes A 1 8 (89%)
— Dukes B 16 20 (56%)
— Dukes C 14 19 (58%)
DNA diploid 2 6 (75%)
DNA aneuploid 8 11 (58%)
* Tumours were scored as 5q21-22 retained only if an allele within
5q21-22 on each side of the APC locus retained heterozygosity. Loss
of a 5q21-22 allele on either or both sides of APC scored as loss
markers on both sides of APC. Previous studies using
unilateral or distant markers, (Solomon et al., 1987;
Okamoto et al., 1988; van den Broek et al., 1988;
Vogelstein et al., 1988; Law et al., 1988; Rees et al.,
1989) suggested lower frequencies of loss, because they
failed to detect small deletions including APC. This
implies that as one approaches the APC locus the fre¬
quency of observed allele loss may increase still further
and indeed that many of the important lesions may be
within APC itself. A similar situation at 13q 14 occurred
in sporadic retinoblastoma, where small deletions of the
Rb-1 gene, not detected cytogenetically, were revealed
by the use of intra-gene molecular probes (T'Ang et al.,
1988) and closely-flanking markers (Dryja et al., 1986).
The low frequency of whole chromosome 5 loss
argues against mitotic non-disjunction as a major
mechanism for the acquired loss of APC in tumours.
Many reported karyotypes in colorectal cancer cells are
hypotriploid or hypotetrapoid, (Reichmann et al., 1981;
Petersen & Friedrich, 1986) consistent with origin
through non-disjunctive events from a tetraploid parent
(Nowell, 1976). The majority of human colorectal
cancers do show DNA aneuploidy in this range, as
determined by flow cytometry. As the presence of aneu¬
ploidy correlates with poor prognosis (Armitage et al.,
1985; Quirke et al., 1987), it is tempting to suggest that
this mode of chromosome loss contributes to the
genesis of homozygosity at anti-oncogene loci during
tumour progression (Wyllie, 1989). Our data, however,
make it clear that whole chromosome non-disjunction
is a rare cause of acquired homozygosity at the APC
locus. Rather, it appears that the APC gene is lost early
in the evolution of colorectal tumours. This is further
supported by the association of presumptive inherited
molecular defects within the APC gene in familial
adenomatous polyposis where the genetic abnormality
is primarily responsible for formation of multiple
adenomas. Loss of APC early in the adenoma-
carcinoma sequence is also suggested by the work of
other groups (Remvikos et al., 1988; Vogelstein et al.,
1988).
Cytogenetic findings in sporadic colorectal carcinoma
(Muleris et al., 1985; Ferti et al., 1988) confirm the
present findings of a low frequency of whole chromo¬
some 5 loss. However the fact that such lesions (and the
commoner 5q arm losses) are tolerated shows that sur¬
vival is possible in cells which are hemizygous for genes
on 5q outside APC. Thus the observed clustering of
breakpoints around APC is unlikely to be merely the
consequence of positive selection for lesions which
delete APC but conserve important outlying genes.
This clustering of breakpoints is not predicted by a
simple interpretation of the anti-oncogene hypothesis of
Knudson (1983). Other putative anti-oncogenes
involved in colorectal carcinoma, such as those on 17p
12-12.3 (Lothe et al., 1988; Baker et al., 1989), and 18q
(Monpezat et al., 1988; Vogelstein et al., 1988), have not
yet been analysed in sufficient detail to measure the
contribution of different types of chromosomal lesions
to the allele loss. Clustered breakpoints are not
observed, however, in the somatic loss of anti-
oncogenes at 13q 14 in retinoblastoma (Dryja et al.,
1984) or 11 p 13 in Wilms' tumour (Fearon et al., 1984),
where whole chromosome loss, mitotic recombination
and partial chromosome arm loss played a greater role
than in the present study. The finding of molecular
1172 P.G. ASHTON-RICKARDT et al.
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Figure 2 Patterns of allelic loss of chromosome 5 linked markers in 32 tumours in which physical interpretation of the defect was
possible. Thirty were carcinomas, two villous adenomas. Uppermost, schematically shown, is the location of polymorphic DNA
probes on chromosome 5. Aligned below is the allelic loss (open circle) or retention (shaded circle) revealed by these markers. The
number of tumours exhibiting a particular pattern of loss is indicated in brackets on the right-hand side and similar patterns are
grouped together as interstitial deletions (centromeric, bilateral, telomeric) or mitotic recombinations/partial arm loss (centromeric or
telomeric), involving APC
lesions grouped around the APC locus in a high pro¬
portion of sporadic colorectal carcinomas suggests that
this chromosomal region may possess some innate
feature predisposing it to breakage and recombination
events. This, as well as the putative altered properties of
the APC gene product(s), may be a factor influencing
the contribution of the locus to the progression of col¬
orectal cancer. A constitutive 'fragile' site for chromatin
APC LOSS IN COLORECTAL CARCINOMA 1173
breakage has been identified in the vicinity of 5q21.2
(Yunis et al., 1987), although its precise relationship to
APC is unknown. More detailed mapping of the region
in and around APC may clarify the mechanisms under¬




One hundred and nineteen tumours from 117 patients under¬
going operation for colorectal carcinoma were sampled. The
colons were placed on ice immediately after removal, and
within 20min were opened and rinsed in ice-cold phosphate-
buffered saline, supplemented to 0.02% (w/v) with EDTA.
Small portions of tumour, and distant apparently normal
mucosa were snap frozen in liquid nitrogen. Immediately
adjacent tissue was fixed in neutral buffered formalin or
PLPD (Holgate et al., 1986) for histology. The remainder of
the specimen was examined after fixation for depth of tumour
invasion and lymph node infiltration to permit staging in the
Dukes' classification. In all there were 117 carcinomas and
two large villous adenomas.
DNA analysis
DNA of high molecular weight was prepared from tissue
using a method based on SDS-lysis and proteinase In¬
digestion as described by Goelz et al. (1985), digested (10 fig)
with the appropriate restriction enzyme and electrophoresed
through 0.8% (w/v) agarose gel DNA was transferred on to
nylon membranes (Southern, 1975) in 0.5 m NaOH, 1.5 m
NaCl. Prehybridization was performed for at least four hours
at 65°C in 10% (w/v) dextran sulphate, 1% (w/v) SDS, 0.9 m
NaCl-0.09M sodium citrate, lOO^gmP1 denatured salmon
sperm DNA. Hybridization was at 65°C for 16-24 h in the
same solution, together with salmon sperm DNA at
250pg ml ~1 and probe labelled with a-[32P]dCTP (specific
activity 109cpm/rg-1) by the random priming method
(Feinberg & Vogelstein, 1983, 1984). Membranes were washed
as described (Nakamura et al., 1988) and exposed at — 70°C.
Hybridization conditions were altered for probes with high
levels of non-specific binding; human placental DNA was
used instead of salmon sperm DNA, and the probe pre-
incubated with the hybridization solution at 65°C for one
hour before addition to the membrane.
For each probe the target locus specification, preferred
restriction enzyme, and allele sizes are given in Table 1. Allele
losses were accepted only if the differences in band intensity
on the autoradiogram were obvious.
Flow cytometry
Small portions of frozen tissue, taken adjacent to the sites
sampled for histology and DNA analysis, were used to
prepare suspensions of single nuclei by the detergent-trypsin
procedure of Vindelov et al. (1983). Chicken erythrocytes were
mixed with the sample at the beginning of the preparation
procedure to serve as an internal DNA ploidy standard. The
DNA content of these cells is about 35% of that of normal
human diploid cells. Nuclei stained with 0.62 m propidium
iodide were analysed in a Coulter Epics CS flow cytometer at
an excitation wavelength of 488 nm. Coefficients of variation
of Gq/Gj peaks seldom exceeded 3%. Aneuploidy was con¬
sidered present when two distinct G0/G, peaks were visible.
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